



Published in final edited form as:

Clin Nutr. 2019 April ; 38(2): 485–521. doi:10.1016/j.clnu.2018.12.022.

ESPEN Guideline on Clinical Nutrition in Liver Disease

Mathias Plauth^{a,*}, William Bernal^b, Srinivasan Dasarathy^c, Manuela Merli^d, Lindsay D. Plank^e, Tatjana Schütz^f, Stephan C. Bischoff^g

^aDepartment of Internal Medicine, Municipal Hospital of Dessau, Dessau, Germany ^bInstitute of Liver Studies, King's College Hospital, London, United Kingdom ^cDivision of Gastroenterology and Hepatology, Cleveland Clinic, Cleveland, OH, USA ^dGastroenterology and Hepatology Unit, Sapienza University of Rome, Rome, Italy ^eDepartment of Surgery, University of Auckland, Auckland, New Zealand ^fIFB Adiposity Diseases, Leipzig University Medical Centre, Leipzig, Germany ^gDepartment for Clinical Nutrition, University of Hohenheim, Stuttgart, Germany

Abstract

This update of evidence-based guidelines (GL) aims to translate current evidence and expert opinion into recommendations for multidisciplinary teams responsible for the optimal nutritional and metabolic management of adult patients with liver disease. The GL was commissioned and financially supported by ESPEN. Members of the guideline group were selected by ESPEN.

We searched for meta-analyses, systematic reviews and single clinical trials based on clinical questions according to the PICO format. The evidence was evaluated and used to develop clinical recommendations implementing the SIGN method.

A total of 85 recommendations were made for the nutritional and metabolic management of patients with acute liver failure, severe alcoholic steatohepatitis, non-alcoholic fatty liver disease, liver cirrhosis, liver surgery and transplantation as well as nutrition associated liver injury distinct from fatty liver disease. The recommendations are preceded by statements covering current knowledge of the underlying pathophysiology and pathobiochemistry as well as pertinent methods for the assessment of nutritional status and body composition.

*Corresponding author: Mathias Plauth.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Conflict of interest

The expert members of the working group were accredited by the ESPEN Guidelines Group, the ESPEN Education and Clinical Practice Committee, and the ESPEN executive. All expert members have declared their individual conflicts of interest according to the rules of the International Committee of Medical Journal Editors (ICMJE). If potential conflicts were indicated, they were reviewed by the ESPEN guideline officers and, in cases of doubts, by the ESPEN executive. None of the expert panel had to be excluded from the working group or from co-authorship because of serious conflicts. The conflict of interest forms are stored at the ESPEN guideline office and can be reviewed by ESPEN members with legitimate interest upon request to the ESPEN executive.

Keywords

Malnutrition; sarcopenia; acute liver failure; fatty liver disease; alcoholic steatohepatitis; cirrhosis; transplantation; surgery

Introduction

The prognostic and therapeutic role of nutritional issues in the management of patients with liver disease has been known for long (1) and therefore, nutritional status was one of the variables in the original prognostic score devised by Child and Turcotte (2). Since publication of the first ESPEN guidelines (GL) on nutrition in liver disease (3) and the subsequent updates (4, 5) a considerable body of new evidence has accumulated necessitating an update of the GL. In the past twenty years new methods for the assessment of nutritional status and the recognition of the prognostic role of sarcopenia are just two among many other major achievements which are covered in the updated ESPEN GL that is based on the current ESPEN guideline methodology (6). In recognition of the increasing disease burden from non-alcoholic fatty liver (NAFL) and non-alcoholic steatohepatitis (NASH) the current GL hold a new chapter addressing the nutritional management of NAFL / NASH patients. Furthermore, a second new chapter addresses clinical questions arising from nutrition associated liver injury (NALI) distinct from NAFL / NASH. In the current guidelines' working group experts from three global regions (Europe, America, Australasia) could base their work on the current GL of the German Society for Nutritional Medicine (7) implementing the identical methodology. The aim of the current GL is to translate current evidence and expert opinion into recommendations for multidisciplinary teams responsible for the optimal metabolic management of patients with liver disease.

Target population

This GL is aimed to address clinically relevant issues in the nutritional and metabolic management of adult patients with liver disease.

Target users

This GL is intended to be used by health care providers involved in the care of patients with liver disease, e.g. medical specialists involved in the management of liver disease, family physicians, pharmacists, nurses, dieticians, nutritionists, as well as by medical leaders and administrators of liver units.

Methodology

General methodology

This guideline was developed in accordance with the standard operating procedure for ESPEN guidelines and consensus papers (6). It based in part on the German guideline "Clinical Nutrition in the Gastroenterology (Part 1) – Liver" (7), which was updated and extended by an international expert group consisting of five physicians (MP, WB, SD, MM, SCB), one physicist (LP) and one nutrition scientist (TS).

Based on the standard operating procedures for ESPEN guidelines and consensus papers, the first development step of this guideline was the formulation of so-called PICO questions to address specific **p**atient groups or **p**roblems, **i**nterventions, **c**ompare different therapies and be **o**utcome-related (6). Originally, 59 PICO were created and split into seven main chapters “General”, “Acute Liver Failure”, “Alcoholic Steatohepatitis”, “Non-alcoholic Steatohepatitis”, “Cirrhosis”, “Transplantation and Surgery” and “Nutrition Associated Liver Injury”. To answer these PICO questions, a literature search was performed to identify suitable meta-analyses, systematic reviews and primary studies (for details see below, “search strategy”). The PICO questions were allocated to subgroups/experts for further working. The group met 2016 in Ljubljana, Slovenia, for one meeting on November 24 and 25, on occasion of the EASL Monothematic Conference Nutrition in Liver Disease on November 25 and 26, 2016. Finally, 106 recommendations and statements were created. To grade the literature, the grading system of the Scottish Intercollegiate Guidelines Network (SIGN) (8) was used. The allocation of studies to the different levels of evidence is shown in Table 1. The working group added commentaries to the recommendations to explain and support the basis of the recommendations.

The grades of recommendation were decided according to the levels of evidence assigned (Table 2). In some cases, a downgrading from the recommendation grades generated based on the levels of evidence according to Table 1 and 2 was necessary, e. g. due to the lack of quality of primary studies included into a meta-analysis. Such cases are described in the commentaries accompanying the respective recommendations. The wording of the recommendations reflects the grades of recommendations: Level A is indicated by “shall”, level B by “should” and level 0 by “can/may”. The good practice points (GPP) are based on experts’ opinions due to the lack of studies. For the GPP recommendations, the wording can be chosen deliberately.

If applicable, the recommendations were assigned to the outcome models according to Koller et al. 2013 (9), see Table 3.

Between 17th February and 23rd March 2017, an online voting on the recommendations was performed using the guideline-services.com platform. Members of ESPEN guideline projects and of the ESPEN council (country representatives) were invited to vote and to provide comments. 64 recommendations reached an agreement >90%, 40 recommendations reached an agreement of >75–90% and three recommendation an agreement 75%. Recommendations with strong consensus (indicated by an agreement higher than 90 %, see Table 4) were directly passed. All others were voted on again during a consensus conference which took place on 24th April 2017 in Frankfurt/Main, Germany. During this consensus conference, 17 recommendations were changed into statements. 22 of the recommendations/statements achieved an agreement of >90 %, 13 an agreement of >75 – 90 % and two an agreement of >50 – 75 %. Six recommendations were rejected due to low agreement or by decision of the group and two additional recommendations were voted on. In total, the guidelines now comprise 85 recommendations and 17 statements. In support of the recommendations and the assigned grade of recommendations, the ESPEN guideline office created evidence tables of relevant meta-analyses, systematic reviews and (R)CTs. These evidence tables are available online as Supplemental Materials to this guideline.

Search strategy

The updated German S3-Guideline on Nutrition in Liver Disease (7) was produced according to almost the same rules as the current ESPEN guidelines, and therefore, the Guideline Editorial Office decided to use them as a base for the updated ESPEN guidelines. Accordingly, a new comprehensive literature search was performed for the period 01–08-2011 through 22–11-2016 extending the literature search of the German guideline which covered the period 01–01-2006 until 31–07-2011. The search was done for systematic reviews and (randomized) controlled clinical trials with the keywords and filters presented in Table 5. After removal of duplicates and abstracts, 830 articles remained from originally 957 hits and were assigned to topics (1) acute liver failure, (2) alcoholic steatohepatitis, (3) non-alcoholic steatohepatitis, (4) liver cirrhosis, (5) transplantation & surgery, or (6) nutrition associated liver disease.

Titles and abstracts were screened using the following predefined inclusion/exclusion criteria:

- paper is written in English
- paper is a controlled trial or a systematic review
- paper is a meta-analysis

After the screening described above, 122 relevant articles were detected. Additional references from studies cited in guidelines, SLRs or (R)CTs were also included, if they did not appear in the original list. After 18 months 49 relevant new articles were retrieved. Articles were allocated to PICO questions by the group member in charge of the appropriate chapter: acute liver failure (WB), alcoholic steatohepatitis (JK, SD), non-alcoholic steatohepatitis (MP, TS), liver cirrhosis (MM), transplantation and surgery (LP), nutrition associated liver disease (MP).

1 General

1.1 In adults, what is the effect of liver disease on a. nutritional status, b. energy metabolism, c. substrate metabolism?

Statement 1—In patients with cirrhosis, a high prevalence of malnutrition, protein depletion and trace element deficiency should be anticipated. (BM)

Strong consensus (100 % agreement)

Commentary: In liver cirrhosis (LC), the prevalence and severity of mixed type protein energy malnutrition are related to the clinical stage of chronic liver disease, increasing from 20 % in patients with well compensated disease to more than 60 % in patients with advanced cirrhosis (11–13)

Etiology of liver disease per se does not seem to influence the prevalence and degree of malnutrition and protein depletion (11, 13, 14) and the higher prevalence and more profound degree of malnutrition in alcoholics likely result from additional factors including unhealthy life style and socio-economic deprivation.

Body composition of cirrhotics is altered profoundly and characterized by protein depletion and accumulation of total body water which may be manifest even in patients with Child-Pugh class A early-stage disease (14–16). This is paralleled by sodium retention and is thus seldom associated with hyper-natremia. Depletion of potassium, magnesium, phosphate and other intracellular minerals frequently occurs. Deficiency in water soluble vitamins, mainly group B vitamins, is common in cirrhosis, especially that of alcoholic origin (17, 18). Deficiency in fat soluble vitamins has been observed in cholestasis-related steatorrhea, bile salt deficiency, and in alcoholics (19, 20).

In LC, malnutrition is associated with a higher prevalence of ascites and hepatorenal syndrome, a greater length of stay and hospital costs (21) as well as higher mortality (16, 21–23). In several descriptive studies, higher rates of morbidity (24–29) and mortality (27, 29–34) are reported in patients with preoperative malnutrition and/or sarcopenia who undergo transplantation for end-stage chronic liver disease.

Statement 2—In acute liver failure (ALF), due to subtotal loss of hepatocellular function and ensuing multi-organ failure, a severe derangement of carbohydrate, protein and lipid metabolism should be anticipated characterized by impaired hepatic glucose production and lactate clearance as well as protein catabolism associated with hyper-aminoacidemia and hyper-ammonemia. (BM)

Strong consensus (100 % agreement)

Commentary: The plasma levels of amino acids are raised 3- to 4-fold in ALF. The amino acid pattern is characterized by a decrease in branched chain amino acids (BCAA) and an increase in tryptophan and aromatic as well as sulphur-containing amino acids (35–37). In ALF, the splanchnic organs do not take up amino acids whereas in healthy humans and those with severe sepsis there is splanchnic bed uptake (35). Hypoglycemia is an ominous feature of ALF and is thought to result from (a) a depletion in hepatic glycogen, (b) impaired gluconeogenesis due to loss of hepatocytes, and (c) hyper-insulinemia due to increased secretion and reduced degradation (38–40). In ALF, the splanchnic tissues show alteration from net glucose release to net glucose uptake (35). These changes are accompanied by impaired glucose tolerance, characterized by a 50 % decrease in whole body glucose elimination rate, severely decreased (to 15 % of controls) insulin sensitivity, and increased glucagon blood levels (40). In contrast to observations in patients with sepsis, in ALF the splanchnic tissues do not extract but rather release free fatty acids and ketogenesis is reduced (41).

Statement 3—In LC, a stage dependent progressive impairment of carbohydrate, protein and lipid metabolism characterized by hepatic glycogen depletion, impaired non-oxidative glucose metabolism and reduced albumin synthetic rate should be anticipated (BM).

Strong consensus (100 % agreement)

Commentary: In LC in the post absorptive state, glucose oxidation rate is reduced and hepatic glucose production rate is low despite increased gluconeogenesis due to a depletion

of hepatic glycogen (42). Thus, after an overnight fast metabolic conditions are similar to that in prolonged starvation in healthy individuals (43). Insulin resistance affects skeletal muscle metabolism: glucose uptake and non-oxidative glucose disposal such as glycogen synthesis are reduced, while glucose oxidation and lactate production are normal after glucose provision (44, 45). The extent to which glucose deposition as glycogen is impaired just in skeletal muscle or in both muscle and liver is not known (46, 47). Some 15–37 % of patients develop overt diabetes which is associated with an unfavorable prognosis (48, 49).

The utilization of oxidative fuels is characterized by an increased rate of lipid oxidation in the fasting state and the frequent occurrence of insulin resistance (even in Child-Pugh class A patients) (43, 50–53). After a meal, the suppression of lipid oxidation is not uniformly impaired (54, 55). Plasma clearance and lipid oxidation rates are not reduced and thus, the net capacity to utilize exogenous fat does not seem to be impaired (56, 57). Plasma levels of essential and polyunsaturated fatty acids are decreased in cirrhosis and this reduction correlates with nutritional status and severity of liver disease (58, 59).

In overweight or obese patients with NAFLD both hepatic and whole-body fat oxidation rates were found reduced under basal conditions and following exercise compared to lean controls (NAFLD 34.1 kg/m²; controls 23.4 kg/m²) (60). The ability to oxidize fat in basal conditions was inversely related to histological findings including severity of steatosis and disease activity.

In LC, normal or increased protein turnover due to increased protein breakdown and/or reduced protein synthesis have been observed (61). Non-abstinent LC patients have higher leucine flux and non-oxidative disposal than abstinent LC patients or controls indicating a catabolic effect of alcohol (62). Albumin but not fibrinogen synthesis rates correlate with quantitative liver function tests and clinical stages of cirrhosis (63, 64). Nevertheless, stable cirrhotics are apparently capable of efficient nitrogen retention and significant formation of lean body mass from increased protein intake during oral refeeding (65).

Statement 4—In ALF, alcoholic hepatitis (ASH) and cirrhosis, resting energy expenditure (REE) is usually increased; patients with nonalcoholic fatty liver disease (NAFLD) have a normal REE (BM).

Consensus (90 % agreement)

Commentary: In ALF patients, measurement of energy expenditure is not performed as a standard procedure (66). However, studies using indirect calorimetry showed an increase in REE by 18 % or 30 %, respectively, in comparison with healthy controls (67, 68). Therefore, in terms of REE, patients with ALF are not different from critically ill patients with other etiologies.

In ASH patients, the relationship between measured and predicted REE was not different from healthy individuals (69, 70) or patients with LC (71). However, when related to their reduced muscle mass REE in ASH patients was up to 55 % higher than that in healthy controls (69, 70). In alcoholics without biochemical evidence of liver disease but not in patients with alcoholic LC an increased REE (25.8 vs 20.8 kcal×kg⁻¹×d⁻¹) was observed

(72). Likewise, in alcoholics with fatty liver, ASH or LC excessive alcohol consumption was associated with increased REE (26 %); a decrease in REE consistently occurred four days after abstinence from alcohol (73). After adjustment for body mass, REE was higher by 11 % in alcoholics with or without liver disease compared to healthy social drinkers (74).

In NAFLD/NASH, it is difficult to draw a clear picture, because patient populations studied vary according to the presence or absence of overweight/obesity, chronic inflammation, or the metabolic syndrome. In severely obese men with NAFLD and metabolic syndrome, REE was higher by 17 % than in those without metabolic syndrome (75). Comparing individuals with less difference in BMI (NAFLD 27.7 kg/m²; controls 25.3 kg/m²) Kotronen et al. (76) found no difference in REE (77.4±1.4 vs 75.6±1.0 J/kg FFM/min) after adjustment for fat-free mass (76).

Measurement of REE in LC and in controls showed no difference when REE was related to body surface area (43, 54, 67, 72) or body mass (LC: 22–27 kcal×kg⁻¹×d⁻¹) (52, 54, 62, 77). REE showed increased values in LC when REE was related to lean body mass in terms of urinary creatinine excretion (54, 67, 78) or in terms of body cell mass (54).

1.2 In adults with liver disease, what is the energy requirement in a. ALF, b. ASH, c. NASH, d. LC?

Recommendation 1—Due to considerable inter-individual variability, REE should be measured using indirect calorimetry, if available. (BM)

Grade of recommendation GPP – Strong consensus (100 % agreement)

Commentary: Whenever available, indirect calorimetry should be used to measure REE, since in an individual patient measured REE may differ considerably from estimated values (79). Measured REE is higher than predicted in up to 35 % of cirrhotic patients (hyper-metabolism), and below the predicted value in 18 % of the patients (53, 80, 81). In LC hyper-metabolism was associated with reduced event-free survival and unfavorable outcome after transplantation (31, 80) and seems to regress with improvement of body composition (82). As a less expensive, valid and rapid method hand-held calorimetry has been proposed (83). Hand-held calorimeters only measuring oxygen consumption and calculating energy expenditure assuming a respiratory quotient of 0.85 are more accurate than predictive equations for determining REE (84).

Recommendation 2—Patients with chronic liver disease and a sedentary lifestyle should receive a total energy supply of 1.3 x REE. (BM)

Grade of recommendation B - Consensus (81 % agreement)

Commentary: Estimates of total energy expenditure (32 kcal×kg⁻¹×d⁻¹) indicate that the 24 hours energy requirement of LC patients amounts to about 1.3 x measured REE (24 kcal×kg⁻¹×d⁻¹) (65, 85). Diet-induced thermogenesis (55, 86) and the energy cost of defined physical activity in stable cirrhosis patients (86–88) also show no deviation from values obtained in healthy individuals. However, the level of spontaneous physical activity is

considerably lower in patients with LC. It is likely that the increased energy requirement in advanced illness is balanced by diminished physical activity reflecting the poor physical condition (88, 89).

In cirrhotics without ascites, the actual body weight should be used for the calculation of the basal metabolic rate. In patients with ascites the ideal weight according to body height should be used, despite the report from a series of ten patients with LC of whom only four were completely evaluated (90) in which it was suggested that ascites mass should not be omitted when calculating energy expenditure.

Liver transplant patients on average have similar energy requirements as the majority of patients undergoing major abdominal surgery (91). In general, non-protein energy provision of 1.3 x REE is sufficient (92, 93). In a longitudinal study, postoperative hyper-metabolism peaked on day 10 after the transplantation at 124 % of the predicted basal metabolic rate (94). By six to twelve months after transplantation there was no longer a difference between the measured and predicted basal metabolic rate (77, 94).

1.3 In adults with liver disease, what is the effect of liver transplantation (LT) on a. nutritional status, b. energy metabolism, c. substrate metabolism?

Statement 5—After LT for LC, prolonged incomplete recovery of total body nitrogen status should be anticipated. (BM)

Strong consensus (100 % agreement)

Commentary: Plank and coworkers reported a loss of 1.0 kg of total body protein (equivalent to 5.0 kg of skeletal muscle) mainly from skeletal muscle immediately after surgery and this loss was not replenished twelve months thereafter (94). In a study using total body potassium counting with follow-up for 24 months after LT, an initial postoperative loss but no subsequent gain in body cell mass was observed (95). As a functional equivalent, Selberg and coworkers (45, 96) demonstrated that glucose uptake and non-oxidative glucose disposal by skeletal muscle had not normalized up to twelve months and longer after LT. Unsurprisingly, respiratory muscle function had not returned to normal up to one year after transplantation (94).

Statement 6—After LT, the risk of developing sarcopenic obesity and metabolic syndrome should be taken into account and nutritional rehabilitation should aim for an earlier and faster recovery of total body protein and muscle function (BM).

Strong consensus (100 % agreement)

Commentary: After transplantation, many patients become obese and develop metabolic syndrome (97). Body composition analyses 50 and 93 months after liver or kidney transplantation respectively, show that despite good graft function, there is a disproportionate increase in fat mass and a persistence of sarcopenia (94, 98, 99) and impaired glucose disposal by skeletal muscle (45, 96). These findings show that organ transplantation alone does not normalize the metabolic dysfunction in these patients (99).

Whilst on the transplant wait list LC patients suffer from fatigue (100), a stage dependent loss of quality of life and exercise capacity (101), and exhibit a very low activity level (102) and a progressive loss of muscle mass (see recommendation 5). Participants in a structured 12-week exercise protocol had an improvement in 6-min walk distance and quality of life (103). After transplantation, activity level, quality of life and exercise capacity in general do not improve to a normal level (100, 104, 105). However, transplant recipients participating in a structured exercise and nutrition protocol had a significantly better gain in VO₂max and quality of life (106).

1.4 In adults with liver disease what is the effect of nutritional status on the prognosis of a. ALF, b. alcoholic steatohepatitis, c. NASH, d. LC, e. transplantation & surgery?

Statement 7—In ALF patients, obesity is associated with an increased risk of death or need for transplantation and an increased mortality after transplantation. (BM)

Strong consensus (96 % agreement)

Commentary: In ALF, there is only very limited data available regarding the effect of nutritional status on its course and prognosis. Rutherford and colleagues (107) analyzed 782 adult ALF patients prospectively enrolled from 1998–2004. They found the same prevalence of obesity (30 %) in ALF patients as in the general population and between BMI categories the proportion of patients being listed for transplantation was not different. Obese and severely obese had a 1.6- and 1.9-times higher risk of transplantation or death from ALF. Obese patients had a 3.4 times higher risk of dying after transplantation. In a small retrospective series, overweight patients were found more susceptible to ALF (108). In severely undernourished anorexia nervosa patients an ALF-like condition has been described (109) without morphologic evidence of hepatocyte necrosis (110). Patients recovered completely upon adequate re-feeding.

Statement 8—In the management of severely malnourished ASH and cirrhosis patients, a poorer survival compared to non-malnourished patients shall be expected. (BM)

Strong consensus (100 % agreement)

Commentary: Undernourished ASH patients had a higher rate of morbidity and mortality in the reports of the combined data from the American Veteran Affairs (VA) study (111–113). The VA study data show a clear association between low intake of normal food and high mortality (111) and this finding has been confirmed recently (114).

In severely malnourished LC patients a number of studies reported higher morbidity and mortality (16, 22, 115, 116) as well as a higher mortality following LT (22, 25–28, 31, 53, 115–117). Data are controversial regarding a higher prevalence of hepatic encephalopathy (HE) in malnourished LC patients (50, 118, 119).

Statement 9—In assessing the prognosis of patients in whom NAFL / NASH is an integral component of the metabolic syndrome the effect of non-hepatic comorbidity should be considered. (BM)

Strong consensus (100 % agreement)

Commentary: NAFLD is defined by the presence of hepatic steatosis when causes for secondary fat accumulation in the liver such as alcohol consumption, HCV infection, drug-induced or hereditary liver disease have been excluded (44, 120, 121). NAFLD is histologically further categorized into NAFL characterized by steatosis alone without hepatocellular injury and NASH which is characterized by the combination of steatosis and inflammation and hepatocyte injury that may progress to fibrosis, cirrhosis and hepatocellular carcinoma (HCC) (44, 120, 121). The definition of significant alcohol consumption has been inconsistent and ranges from $> 10\text{--}40 \text{ g}\times\text{d}^{-1}$ have been reported (44, 120, 121).

In NAFLD, overall and cardiovascular mortality are increased compared to the general population (122–124). NAFLD is associated with an increased standardized mortality ratio compared with the general population (125) and liver disease now ranks after cardiovascular disease and cancer as cause of death. Severe obesity prior to LT is associated with a higher prevalence of comorbidities (diabetes, hypertension), cryptogenic cirrhosis and increased mortality from infectious complications, cardiovascular disease and cancer (126, 127).

Diabetes risk and overt type 2 diabetes are associated with more severe NAFLD, progression to NASH, advanced fibrosis and the development of HCC (128, 129) independent of serum transaminases (130). NAFLD patients also have an increased risk (up to 5-fold) of developing type 2 diabetes after adjustment for several lifestyle and metabolic confounders (131). Therefore, European guidelines recommend that individuals with NAFLD should be screened for diabetes and that patients with type 2 diabetes should be evaluated for the presence of NAFLD irrespective of serum transaminases (120).

1.5 In adults with liver disease, which methods should be used to a. identify patients at nutritional risk and b. assess nutritional status?

Recommendation 3—Liver disease patients should be screened for malnutrition using a validated tool. Grade of recommendation B – Strong consensus (93 % agreement)

Commentary: NRS-2002 and MUST are validated tools to screen hospitalized patients for risk of malnutrition (132, 133) and are recommended by ESPEN (134). The Royal Free Hospital Nutrition Prioritizing Tool (RFH-NPT) has been developed as a screening tool for malnutrition in liver disease patients (135, 136). In a head-to-head comparison, the RFH-NPT was more sensitive than the NRS-2002 to identify liver patients at risk for malnutrition (137). NRS-2002 was considered helpful in identifying malnourished LC patients with HCC (138). According to a recent review, none of the available screening tools has been validated rigorously in LC patients leaving RFH-NPT as the best option currently available (139).

Statement 10—Phase angle (measured by bioelectrical impedance analysis) or handgrip strength allow assessment of mortality risk. (BM)

Strong consensus (93 % agreement)

Commentary: The accurate quantitative measurement of nutritional status is difficult in chronic liver disease patients with fluid overload (140, 141) and/or impaired hepatic protein synthesis (e.g. albumin) (63, 64). Sophisticated methods are required such as total body potassium count (16, 142) or in vivo neutron activation analysis (14, 15) or isotope dilution (140).

For the nutritional assessment of ASH patients in the VA trials a composite scoring system was used (111–113). This scoring system has been modified repeatedly; one of the later publications of this series also reported the prognostic significance of the absolute CD8+ count and hand grip strength (143). The authors observed a close association between low food intake and high mortality (111).

In LC, nutritional status can be assessed using bedside methods, such as the Subjective Global Assessment (SGA) (117, 140, 144) or the modified Royal-Free-Hospital SGA (RFH-SGA) combining SGA and anthropometry (145). The RFH-SGA is a strong predictor of morbidity and mortality, but it is time consuming and requires a trained dietician (29, 145, 146). Anthropometry of midarm circumference and triceps skinfold thickness are non-invasive bed-side methods (115, 116) but suffer from high inter-observer variability.

Handgrip strength is lower in protein depleted LC patients (14, 147) and is a good predictor of the rate of complications within the next year (28, 148, 149) but is an insensitive measure of fatigue (150). Handgrip strength is better preserved in LC of viral as opposed to alcoholic or cholestatic etiology (14). Handgrip strength appears a valuable tool to measure efficacy of nutritional intervention (151).

In LC patients, reactance and resistance readouts from BIA can be used to calculate phase angle or body cell mass as a measure of cell mass and cell function for the nutritional assessment (23, 142, 152, 153). In LC, low phase angle is associated with increased mortality as in many other disease entities (23, 144, 154, 155).

Recommendation 4—In NASH, cirrhosis and LT, the presence or absence of sarcopenia should be assessed since sarcopenia is a strong predictor of mortality and morbidity. (BM)

Grade of recommendation B – Strong consensus (100 % agreement)

Recommendation 5—Radiologic methods (DXA or when CT/MRT images are available for other reasons) should be used to diagnose sarcopenia. (BM)

Grade of recommendation B – Strong consensus (100 % agreement)

Commentary to recommendations 4 and 5: Sarcopenia is the key feature of malnutrition in LC patients and can be assessed by radiologic methods (DXA, CT) to detect loss of muscle mass or by tests of muscle function such as exercise test or 6-min walk distance. Sarcopenia can be diagnosed when there is loss of muscle mass or muscle function (156). On CT images at the level of lumbar vertebra 3 (157) or lumbar vertebra 4 (158) skeletal muscle area can be measured and normalized for stature (159). The skeletal muscle area at L3 has been shown to be linearly correlated with whole body muscle mass (159). Loss of

skeletal muscle mass on CT has been associated with increased mortality in LC patients (157, 160, 161), obese LC patients (162), LC patients wait listed for transplantation (163) and in orthotopic liver transplant (OLT) recipients (24, 34, 164). After TIPS, failure to reverse sarcopenia was associated with worse survival (158) and after transplantation, new-onset sarcopenia was associated with a trend for higher mortality (165). In NASH patients a progressive loss of muscle mass has been observed (166).

A French group showed that transverse psoas muscle thickness measured at the level of the umbilicus was inversely correlated with death on the wait list (163). Low psoas muscle area at lumbar vertebra 3 level was associated with increased mortality and morbidity (29). A systematic comparison of the analysis of psoas muscle alone vs total skeletal muscle area at L3 level has raised concerns about use of the psoas muscle alone to define sarcopenia or measure muscle loss (167, 168).

In order to obviate costly and invasive radiologic imaging ultrasound-based protocols for the assessment of muscle mass have been proposed (169) and await further validation.

In LC patients on the transplant wait list, impaired muscle function in terms of 6-min walk distance, grip strength and the short physical performance battery but not loss of muscle mass in terms of CT derived skeletal muscle index was associated with increased mortality (170, 171). In LC patients, frailty experienced as a functional decline in grip strength, gait speed, chair stands or short physical performance battery has been shown associated with increased risk for complications requiring hospitalization (172) or death on the wait list or delisting (173, 174).

In LC patients, there is a profound reduction in exercise capacity and this reduction is only moderately ameliorated after transplantation as reviewed in detail by Williams & McKenna (105). LC patients with a $VO_{2max} < 60\%$ of normal had a 50% one-year survival when transplanted (30, 32). Actively exercising transplant recipients, however, can restore their VO_{2max} to normal (175).

2 Acute Liver Failure

Preliminary Remarks:

ALF typically affects young adults and develops in the absence of pre-existing chronic liver disease. Its rapidity of development is such that most patients will not have evidence of malnutrition at time of illness onset, though nutritional compromise may develop during the period of acute illness severity, resolution and recovery. Its rarity, severity and rapid trajectory is such that few clinical trials of any sort – including those of nutritional interventions – have occurred. Therapeutic interventions are thus mainly based upon clinical observation in patients with ALF, and extrapolation from other critical illness. Despite this lack of an evidence base, outcome for patients with ALF have improved markedly over recent years suggesting that the approaches adopted do have clinical merit (176).

Two European surveys of nutritional practice have been published and suggest a general commonality of approach, though detail may vary (66, 177). Measures to stabilize

metabolism and vital functions, support hepatic regeneration and prevent or treat brain edema are taken as of central importance. Nutritional therapy has three principal objectives:

- Ensuring the adequate provision of energy, by giving glucose, lipid, vitamins and trace elements.
- Ensuring optimal rates of protein synthesis by providing an adequate intake of protein or amino acids, respectively.
- Avoiding metabolic complications of nutritional therapy though ensuring euglycemia and prevention of hyper-ammonemia and hyper-triglyceridemia.

2.1 In ALF patients, when is nutritional therapy indicated / contraindicated to support recovery from ALF?

Recommendation 6—In malnourished ALF patients enteral nutrition (EN) and/or parenteral nutrition (PN) should be initiated promptly, as in other critically ill patients.

Grade of Recommendation GPP – Strong consensus (96 % agreement)

Recommendation 7—ALF patients without malnutrition should be provided with nutritional support (preferentially EN) when they are considered unlikely to resume normal oral nutrition within the next five to seven days, as in other critical illness.

Grade of Recommendation GPP – Strong consensus (96 % agreement)

Recommendation 8—In patients with severe hyper-acute disease with hepatic encephalopathy and highly elevated arterial ammonia who are at risk of cerebral edema, nutritional protein support can be deferred for 24–48 hours until hyper-ammonemia is controlled. When protein administration is commenced, arterial ammonia should be monitored to ensure no pathological elevation occurs. (BM)

Grade of Recommendation GPP – Consensus (90 % agreement)

Commentary to recommendations 6–8: In general, decisions on when to initiate nutrition support and which route to use are made in accordance with the recommendations for nutrition support in other intensive care unit (ICU) patient groups. Three subtypes of ALF can be classified according to their clinical course. In ‘hyper-acute’ liver failure the onset of hepatic encephalopathy (HE) occurs within seven days of the onset of jaundice and patients most often recover promptly with medical therapy alone or after transplantation or die soon after illness onset. Due to the short duration of illness in most patients nutrition support is thought to play a relatively minor role: prognosis is more favorable in this subtype. In ‘acute’ liver failure the interval between onset of HE after the patient became jaundiced is eight days to 28 days and in ‘sub-acute’ liver failure this interval is between 29 to 72 days. In these latter two subtypes of ALF early nutrition support is more often necessary.

There are no data on the optimal methods to assess nutritional status in patients with ALF. It seems likely that as in critical illness, cirrhosis or acute alcoholic steatohepatitis, simple

bedside tools such as SGA or anthropometry are adequate for identifying patients with malnutrition (5).

Patients with hyper-acute ALF and elevated and sustained arterial ammonia levels (>150 $\mu\text{Mol/l}$) may be at increased risk of cerebral edema and development of intracranial hypertension (178, 179). In this specific setting where there may be short-lived but profound impairment of hepatic function, protein administration may further elevate ammonia levels and increase risk of cerebral edema. Its delivery may be deferred for a short period only (24–48 hours) as liver function improves and when begun, arterial ammonia should be monitored.

2.2 In ALF patients, which are the conditions to safely use oral nutrition to achieve adequate nutrient supply?

Recommendation 9—Patients suffering from only mild HE can be fed orally as long as cough and swallow reflexes are intact.

Grade of Recommendation GPP – Strong consensus (100 % agreement)

Recommendation 10—In patients with mild HE oral nutritional supplements (ONS) should be used when feeding goals cannot be attained by oral nutrition alone.

Grade of Recommendation GPP – Consensus (85 % agreement)

Commentary to recommendations 9 and 10: There are no data from controlled clinical trials in ALF to inform these recommendations. They are based on clinical practice to use normal physiologic modes of feeding as long as they are functional and to resort to EN and/or PN only as second- or third-line options. Close monitoring of oral intake is required to ensure that patients are able to maintain adequate volitional intake. In all sub-types of ALF risk of HE progression with loss of airway control and aspiration exists, and close clinical monitoring of HE level is required.

2.3 In ALF patients who cannot be fed orally, what is the evidence to prefer EN over PN to achieve better survival and/or less complications?

Statement 11—Current clinical practice adopted in many European liver units demonstrates the safety and feasibility of EN in ALF patients.

Strong consensus (100 % agreement)

Recommendation 11—ALF patients who cannot be fed orally should receive EN via nasogastric / nasojejunal tube.

Grade of Recommendation GPP – Strong consensus (100 % agreement)

Recommendation 12—EN should be performed by starting with low doses independent of the grade of HE. Grade of Recommendation GPP – Consensus (80 % agreement)

Commentary to statement 11, recommendations 11 and 12: According to ESICM guidelines (180) low dose EN should be started when acute, immediately life-threatening metabolic derangements are controlled with or without liver support strategies, independent on grade of encephalopathy. Arterial ammonia levels should be monitored.

Recommendation 13—PN should be used as second line treatment in patients who cannot be fed adequately by oral and/or EN

Grade of Recommendation GPP – Consensus (90 % agreement)

Commentary: There is no trial evidence in patients with ALF to inform these recommendations, and the practice adopted mirrors that in other forms of liver disease and critical illness. In the majority of patients with ALF it is practical and safe to use EN, and formulas can be delivered in amounts comparable to other critical illness. As documented above (Recommendation 8 and comments) a small subgroup of hyper-acute patients may be at transient risk of worsening hyper-ammonemia at high protein loads and thus may be intolerant of full dose EN in the early phase of their illness. In other critically ill patients who require nutrition support therapy, PN carries no clear advantage over EN and may increase infectious complications: the same may be the case in ALF (181).

2.4 In ALF patients on EN, what is the evidence to use specialized formula compared to standard formula to achieve a. better survival, b. less complications, c. improve metabolism?

Recommendation 14—Standard enteral formulas can be given, as there are no data regarding the value of a disease specific composition.

Grade of Recommendation GPP – Strong consensus (100 % agreement)

Commentary: There are no published studies comparing enteral formulas in patients with ALF. In other critically ill patients, avoidance of the use of all specialty formulas is advised in those in a medical ICU setting, and disease specific formulas in the surgical ICU. There is no evidence that the use of EN enriched with BCAA improves patient outcomes compared to standard whole-protein formulations in other critically ill patients with liver disease, and they are seldom used in the care of ALF patients (177, 181).

3 Alcoholic Steatohepatitis

3.1 In patients with severe ASH, when is nutrition therapy indicated in order to a. reduce the risk for comorbidity (e.g. infection, HE, multi-organ failure), b. improve liver function, c. improve ASH histology, d. slow progression to cirrhosis, e. reduce mortality?

Recommendation 15—Nutrition therapy should be offered to all patients with severe ASH who cannot meet requirements by spontaneous food intake in order to improve survival, infection rate, liver function and resolution of encephalopathy. (BM)

Grade of recommendation B – Strong consensus (100% agreement)

Commentary: Consistent data have shown that malnutrition, defined by a number of measurement tools, is prevalent in the majority (50–100%) of patients with severe ASH (111, 112, 143, 182). Presence of malnutrition is an independent predictor of mortality and adversely affects response to corticosteroids and oxandrolone only in moderate but not severe ASH (111, 183, 184). In severe ASH, reduced caloric intake is associated with higher mortality and higher complication rates. Oral intake is decreased in these patients and therefore supplementation is necessary to maintain adequate calorie and protein intake. Nutritional supplementation in multiple randomized studies to maintain required caloric intake lowers the incidence of infection and facilitates more rapid resolution of HE and improvement in liver function. Overall survival advantage of nutritional supplementation has been reported in some studies, but systematic reviews/meta-analyses have not shown a survival benefit. In the most recent multicenter study, irrespective of treatment, lower caloric intake ($21.5 \text{ kcal}\cdot\text{kg}^{-1}\cdot\text{d}^{-1}$) was associated with worse clinical outcomes (114, 185). Calorie intake is significantly reduced even in the abstinent ASH patients, and increased caloric intake improves outcomes (111, 186), but there are no randomized controlled trials directly comparing supplemental nutrition alone and ad lib oral intake only that support improved survival for additional nutrition. Whether the reduced caloric intake results in or contributes to the higher mortality in those patients achieving only a lower caloric intake or whether the reduction in spontaneous intake is an outcome of underlying necroinflammatory responses that contribute to higher mortality is not known and should be part of future evaluations.

3.2 In patients with severe ASH, can nutrition therapy by means of ONS with/without nutrition counselling when compared to spontaneous ad lib eating a. reduce the risk of comorbidity (e.g. infection, HE, multi-organ failure), b. improve liver function, c. improve ASH histology, d. slow progression to cirrhosis, e. reduce mortality?

Recommendation 16—ONS should be used when patients with severe ASH cannot meet their caloric requirements through normal food in order to improve survival (BM)

Grade of recommendation B – Strong consensus (100% agreement)

Commentary: In patients with severe alcoholic hepatitis, oral intake is consistently reduced (111, 112, 143, 182). When the treatments are consistent in the groups, supplemental nutrition does improve infection and acute mortality, specifically in hospital deaths over ad lib oral dietary intake (187–189). Enteral or supplemental feeding has been evaluated in severe alcoholic hepatitis, but no mortality benefit has been consistently reported. In the VA studies, a survival advantage to supplemental nutrition was reported in patients with malnutrition. In a meta-analysis of 13 randomized controlled trials, that included both ASH and patients with jaundiced alcoholic cirrhosis who may have had ASH, random effects analysis showed a reduction in mortality with supplemental nutrition. However, whether specifically, oral nutritional support will provide such a benefit cannot be stated with certainty. It must also be noted that in the same meta-analysis, a sequential analysis of the same data did not validate the improvement in mortality. A Cochrane review that included alcoholic and non-alcoholic liver disease concluded that any supplemental nutritional intervention did not influence mortality. Interestingly, there did not seem to be a benefit in alcoholic liver disease compared to other forms of liver disease. The confounding effects of

including non-alcoholic patients and those with cirrhosis on the interpretation need to be taken into consideration. Finally, another meta-analysis of hospitalized patients with alcoholic liver disease, the majority of whom had ASH, showed no mortality benefit on pooled analysis. However, these data are to be tempered by consistent reports that caloric intake $<21.5 \text{ kcal}\cdot\text{kg}^{-1}\cdot\text{d}^{-1}$ was associated with higher mortality (114), there is strong consensus among experts that nutritional supplementation in those patients with poor oral intake should be offered and may provide a survival advantage(189).

Recommendation 17—Patients should be fed orally as long as cough and swallow reflexes are intact, and energy and protein goal intakes can be achieved.

Grade of recommendation GPP – Strong consensus (100% agreement)

Commentary: Supplemental feeding in patients with severe ASH is based on nearly universal data that these patients have poor oral intake, lower calorie and protein intake that contribute to mortality and morbidity (111, 112, 143, 182). Therefore, there is compelling rationale to provide sufficient nutrition. However, when adequate oral intake was achieved, there seems to be no specific advantage to the route of administration. In fact, PN was associated with higher risk of complications including infection (190). There are also advantages to oral feeding of regular diet over EN or PN on gut mucosal integrity and more recent data on maintenance of protective gut microbiome, both of which provide benefits in terms of infection rates that may affect mortality.

3.3 In patients with severe ASH, can nutrition therapy by means of EN when compared to spontaneous ad lib eating a. reduce the risk of comorbidity (e.g. infection, HE, multi-organ failure), b. improve liver function, c. improve ASH histology, d. slow progression to cirrhosis, e. reduce mortality?

Recommendation 18—EN should be used when patients with severe ASH cannot meet their caloric requirements through normal food and/or ONS in order to improve survival and infectious morbidity. (BM)

Grade of recommendation B – Strong consensus (100% agreement)

Commentary: When caloric intake is reduced, mortality is higher in severe ASH (114). Supplementing extra calories does not improve survival in most randomized studies but in patients with malnutrition, a survival advantage was reported in the VA studies. Similarly, in one meta-analysis, random effects analysis showed a survival advantage and lower infection rates (189). Despite a number of negative studies, the consensus among experts is that in patients with severe ASH who cannot take adequate calories orally, supplemental nutrition may provide a survival advantage, especially in the group with moderate malnutrition (111). Infection resolution was better with supplemental nutrition, but it is not known if occurrence of new infection is lower. Given that in the non-alcoholic patients with liver disease, poor oral intake and malnutrition are associated with greater risk of infection, one may consider that improved oral intake may lower the risk of infection in severe ASH even though data supporting this contention have not been published. Progression to cirrhosis has not been

evaluated but a histological study on nutritional supplementation showed that abstinence was the major factor that resulted in histological improvement in ASH.

3.4 In patients with severe ASH, can nutrition therapy by means of PN when compared to spontaneous ad lib eating a. reduce the risk of comorbidity (e.g. infection, HE, multi-organ failure), b. improve liver function, c. improve ASH histology, d. slow progression to cirrhosis, e. reduce mortality?

Recommendation 19—PN shall be commenced immediately in moderately or severely malnourished patients with severe ASH who cannot be nourished sufficiently by oral and/or enteral route.

Grade of recommendation GPP - Strong consensus (100% agreement)

Commentary: Malnourished patients with severe ASH have worse clinical outcomes in terms of one- and six-month survival, infection rates, HE and laboratory parameters (111, 143, 182). Lower calorie intake is associated with increased rates of liver related complications including infection, ascites, HE and jaundice. A number of publications including randomized controlled trials show that nutritional supplementation with amino acid mixtures or calories lowers infection rates and resolution of HE but the beneficial effects on survival was only reported in patients with moderate ASH but not in severe ASH (183, 184, 186, 188, 189, 191). In severe ASH, malnutrition, specifically measures of muscle loss, are associated with increased mortality, infection and HE (187–189).

PN can include amino acids and/or glucose infusion, peripheral or central PN to support dietary intakes in patients whose oral intake is insufficient. Eight studies have evaluated different parenteral supplements, mostly amino acid or glucose infusion, seven of which were randomized in ASH (183, 184, 186, 192–197). One study showed a survival advantage of intravenous amino acids but this has never been reproduced in any other study (186). There is limited data on the impact of nutritional intervention alone on hepatic histology in severe ASH. No studies have evaluated progression to cirrhosis, but intravenous amino acids alone or together with glucose were associated with a greater resolution of fatty infiltration (188) or of Mallory hyaline (196). The improvement or reversal of Mallory hyaline may predict a lower rate of progression.

Systematic reviews and meta-analyses also suggest that nutritional supplementation improves rates of resolution of HE (188, 189). Spontaneous ad lib eating was associated with reduced intake in both the US VA studies and non-VA studies (111, 112, 143, 182, 185, 194). As discussed earlier and based on published literature, poor oral intake is associated with adverse outcomes. Additionally, patients with moderate and severe ASH are hyper-metabolic when REE is corrected for urinary creatinine as a measure of lean body mass (198). To overcome the hyper-metabolic state, if patients do not achieve an adequate caloric and protein intake orally, PN needs to be started as soon as possible. A previous report has also shown better survival with supplemental EN, but such stratified results have not been reported with PN (111). Hence, there is sufficient rationale to start PN in patients with severe ASH who do not take adequate intake orally.

Recommendation 20—PN should be considered in patients with unprotected airways and HE when cough and swallow reflexes are compromised or EN is contraindicated or impracticable.

Grade of recommendation GPP – Majority agreement (72% agreement)

Commentary: There is no direct evidence evaluating the role of PN in the subgroup of patients with HE and/or unprotected airways with impaired protective reflexes (4, 187–190, 199, 200). Even though the use of PN in encephalopathic or critically ill patients with impaired cough or gag reflex is recommended by some(4), there are others who do not believe in the use of PN for ASH (199).

3.5 In patients with severe ASH, can disease specific nutrition protocols regarding quantity and/or composition of protein/amino acids when compared to no such protocols a. reduce the risk of comorbidity (e.g. infection, HE, multi-organ failure), b. improve liver function, c. improve ASH histology, d. slow progression to cirrhosis, e. reduce mortality?

Recommendation 21—For ONS or EN in patients with severe ASH standard formulas should be used, preferably formulas with high energy density (1.5 kcal·ml⁻¹).

Grade of recommendation GPP – Strong consensus (92% agreement)

Commentary: There are no direct studies evaluating specific nutrition protocols in randomized trials in severe ASH. Such protocols include the use of BCAA mixtures, vegetable protein diets, immunonutrition with arginine supplementation. Published data only evaluate intravenous amino acids, commercial parenteral solutions, or intravenous glucose that do not show a mortality benefit in critically ill patients (201). Immunonutrition was reported to provide no specific therapeutic advantage in a randomized controlled trial in patients undergoing LT (202). In severe ASH, there are no controlled trials showing a benefit of specially composed formula over a standard formula (195, 203, 204). Use of high calorie density supplements can lower fluid administration in patients on fluid restriction. These supplements also lower the duration over which they are administered.

3.6 In patients with severe ASH, can disease specific nutrition protocols regarding quantity and/or composition of micronutrients when compared to no such protocols a. reduce the risk of comorbidity (e.g. infection, HE, multi-organ failure), b. improve liver function, c. improve ASH histology, d. slow progression to cirrhosis, e. reduce mortality?

Statement 12—In patients with severe ASH trace element and vitamin deficiency should be anticipated.

Strong consensus (100% agreement)

Commentary: There are a number of observational studies that show micronutrient deficiencies in patients with alcohol use disorders and alcoholic liver disease and very limited studies in ASH (135, 183, 184, 201, 205–210). Due to poor oral intake preceding the acute illness, micronutrient deficiency should be expected and replaced in patients with severe ASH. Whether all patients should have malnutrition risk screening or whether there

should be universal replacement of micronutrients cannot be answered based on evidence. Based on the frequency of deficiency in B vitamins, zinc and vitamin D, replacement of these may be beneficial. It is not known if correcting deficiency can prevent infection or mortality but given the strong evidence for adverse consequences of micronutrient deficiency, one should consider replacement if deficiency is known or determined. However, micronutrient deficiencies are frequent in patients with alcohol use disorders and thiamine supplementation is used routinely in clinical practice to prevent Wernicke's encephalopathy and Korsakoff psychosis. There are very limited randomized trials in patients with alcoholic liver disease but none in severe ASH. Since patients with severe ASH have poor dietary intake and micronutrient deficiency can affect immune and gut mucosal function, it is reasonable to replace micronutrients. Oral administration of multivitamin and zinc preparations is reasonable in severe ASH because deficiency is frequent and empiric oral supplementation is less expensive than laboratory measurements to establish deficiency before replacing individual micronutrients. A recent study suggested that in patients at risk for Wernicke's encephalopathy, thiamin rather than a mixed formulary of micronutrients be administered (208). Similar data do not exist for other vitamin or zinc deficiencies in human ASH. The cost of measuring micronutrient deficiencies vs. that of the replacement should be considered in making this decision. Some micronutrient and vitamin excesses may be injurious when administered in the long-term. If long-term supplementation is planned, then consideration for measuring serum concentrations may be of value.

Recommendation 22—Water soluble and fat-soluble vitamins as well as electrolytes and trace elements shall be administered daily from the beginning of PN in order to cover requirements.

Grade of recommendation GPP – Strong consensus (100% agreement)

Commentary: In patients with severe ASH, given the nearly universal reduction in dietary intake, there is a high prevalence of micronutrient deficiency that have adverse effects on physiological responses to stress and infection. Hence, vitamins and trace elements shall be given to provide at least the recommended daily amounts. In this high-risk patient group, it seems prudent to administer a first dose of thiamine before commencing PN in order to prevent Wernicke's encephalopathy or refeeding syndrome. Replacement should be considered in all patients on PN even though deficiency may not have been documented. Since PN is likely to be short term, the risk of adverse events due to long term vitamin and micronutrient replacement is low even without quantifying serum concentrations (211–213). Specific vitamins, including vitamin A, D and K should be administered along with thiamine, folate and pyridoxine to correct deficiency.

3.7 In patients with severe ASH, how should nutrition therapy by means of ONS with/without nutritional counselling be delivered in order to a. reduce the risk of comorbidity

(e.g. infection, HE, multi-organ failure), b. improve liver function, c. improve ASH histology, d. slow progression to cirrhosis, e. reduce mortality?

Recommendation 23—Individualized nutrition counselling should be used in order to improve food intake. Grade of recommendation GPP – Strong consensus (100% agreement)
Commentary

There are no studies to evaluate the benefit for individualized nutritional therapy compared to ad lib feeding or nutritional supplementation with 30–35 kcal·kg⁻¹·d⁻¹ and 1.2–1.5 g·kg⁻¹·d⁻¹ of protein. However, given the suggestions for restriction of sodium, fluid and other substrates depending on comorbid conditions like renal failure or diabetes mellitus, an individualized, structured nutritional program is likely to be of greater benefit than ad lib feeding.

Recommendation 24—ONS shall be used as first line therapy when feeding goals cannot be attained by oral nutrition alone and should be given as a late evening or nocturnal supplement.

Grade of recommendation GPP – Strong consensus (100% agreement)

Commentary: Reduced oral intake is associated with higher mortality and nutritional supplementation is likely to result in more rapid resolution of HE and elevated serum bilirubin and lower infection risk, and severe ASH is also a hyper-metabolic state. These data support the use of adequate calorie and protein intake by supplementation. Whether alcoholic hepatitis is a state of accelerated starvation akin to cirrhosis has not been directly reported, metabolomic studies and metabolic cart studies suggest hyper-metabolism, accelerated lipolysis and accelerated starvation physiology in ASH (198, 214, 215). Since compelling data for a late evening snack have been reported in LC including alcoholic cirrhosis (216), it is reasonable to extend these data to support the use of a late evening or nocturnal supplements to reduce the duration of starvation.

3.8 In patients with severe ASH, how should nutrition therapy by means of EN be delivered in order to a. reduce the risk of comorbidity (e.g. infection, HE, multi-organ failure), b. improve liver function, c. improve ASH histology, d. slow progression to cirrhosis, e. reduce mortality?

Recommendation 25—EN can be used in severe ASH to ensure adequate energy and protein intake without increasing the risk of HE. (BM)

Grade of recommendation 0 – Strong consensus (92% agreement)

Commentary: EN has proved successful in providing patients with alcoholic cirrhosis (191) or cirrhosis with HE grade I-III (217) with adequate nutrition. In one study ten patients received a BCAA-enriched solution amounting to 70 g protein per day and their mental state improved (217). In another study 16 patients were given 1.5 g·kg⁻¹·d⁻¹ protein using a casein based enteral formula (191). Likewise, in 136 patients of the VA trials low protein intake was associated with worsening HE while patients with a higher protein intake showed improved mental state (218).

Recommendation 26—EN should be used in severe ASH, because EN has been shown to be as effective as steroids alone and, in survivors of the first four weeks, to be associated with a lower mortality rate in the following year (BM).

Grade of recommendation B – Consensus (85% agreement)

Commentary: An initial randomized study comparing steroids alone with total EN showed no difference in mortality on an intention to treat analysis but earlier mortality in steroid treated subjects (185). Even though mortality in the patients with HE was similar in the EN and steroid treated arms, whether the resolution of HE was different was not reported (185). Other studies on EN also reported no survival benefit but EN resulted in greater improvement in HE and reduction in bilirubin (191). A more recent study compared EN or conventional nutrition in patients with severe ASH all of whom received steroids. No difference in mortality was observed at six months. Daily caloric intake of $<21.5 \text{ kcal}\cdot\text{kg}^{-1}\cdot\text{d}^{-1}$ was associated with higher mortality at one and six months and higher risk of infection and a trend towards higher risk of hepatorenal syndrome without a significant impact on HE (114).

Even though the benefit of steroids in severe ASH has been questioned (219), a randomized controlled trial showed that mortality in severe ASH with total EN was similar to that of severe ASH treated with steroids during 28 days. However, patients on EN died sooner and those on steroids died later during treatment for 28 days. Longer-term follow up showed a greater mortality in the steroid treated group related to infection (185). The authors concluded that a synergistic effect of steroids and EN in severe ASH needed to be evaluated. In a recent study, specifically comparing EN with steroids and conventional nutrition with steroids showed no survival benefit of EN over steroids (114). However, lower caloric intake did increase mortality in both groups suggesting that EN may provide a survival advantage early in ASH (114, 185).

3.9 In patients with severe ASH, how should nutrition therapy by means of PN be delivered in order to a. reduce the risk of comorbidity (e.g. infection, HE, multi-organ failure), b. improve liver function, c. improve ASH histology, d. slow progression to cirrhosis, e. reduce mortality?

Recommendation 27—Patients with severe ASH who can be fed sufficiently either by oral or enteral route but who have to abstain from food temporarily (including nocturnal fasting!) for more than twelve hours, should be given i. v. glucose at $2\text{--}3 \text{ g}\cdot\text{kg}^{-1}\cdot\text{d}^{-1}$. When this fasting period lasts longer than 72 hours total PN is required.

Grade of recommendation GPP – Strong consensus (100% agreement)

Commentary: In cirrhotics after an overnight fast, glycogen stores are depleted, and metabolic conditions are similar to prolonged starvation in healthy individuals. It has been shown that a late evening carbohydrate snack or nocturnal feeding of ONS was associated with improved protein metabolism in cirrhotic patients (220–223). There is no corresponding data in patients with severe ASH, but it seems safe to assume that there is a similar depletion in glycogen with all its consequences on protein metabolism in severe

ASH patients as well. Therefore, we recommend avoiding fasting patients with severe ASH for more than twelve hours and timely institute the infusion of glucose or peripheral hypocaloric PN.

There is no data to determine the type or rate of administration of PN in patients with severe ASH. Parenteral amino acids have been shown to result in more rapid resolution of fatty infiltration (194) and alcoholic hyaline (196). Standard PN in patients who need such an intervention is recommended but mortality is not likely to be improved based on the majority of published data.

Recommendation 28—In patients with severe ASH, PN should be delivered like in other critically ill patients. Grade of recommendation GPP – Strong consensus (100% agreement)

Commentary: Even though there are no randomized trials comparing different formulas, rates or components via PN, one can draw some conclusions from the use of PN in critically ill patients. A multidisciplinary team approach is likely to provide benefit and there is no evidence to support a beneficial role for specific nutrient formula in severe ASH. There are no advantages to the type of parenteral solutions used and hence standard practice for PN is recommended in patients with severe ASH.

4 Non-alcoholic fatty liver disease

4.1 In overweight / obese patients with NAFL / NASH, what are the aims of nutritional therapy?

Recommendation 29—In overweight / obese NAFL / NASH patients a 7–10 % weight loss shall be aimed for to improve steatosis and liver biochemistry; a weight loss of > 10 % shall be aimed for in order to improve fibrosis. (BM)

Grade of recommendation A – Strong consensus (96 % agreement)

Commentary: Weight loss generally reduces hepatic steatosis, irrespective of how it is achieved (120, 121, 224). However, longitudinal studies of patients with NAFLD clearly show that fibrosis stage, but no other histologic features of steatohepatitis, is associated independently with long-term overall mortality, liver transplantation, and liver-related events (225). Results from the evaluation of paired biopsies in NASH patients achieving weight loss indicate that only substantial weight loss (> 9–10 % is accompanied by improvement in fibrosis and even full resolution of NASH (226–234). A less pronounced weight loss is associated with improvement in steatosis, inflammation and liver enzymes, but not in fibrosis (234–238).

A meta-analysis of total of 15 studies reporting findings from 766 paired liver biopsies of patients losing weight after bariatric surgery shows improvement or resolution in steatosis in 91.6% (95% CI, 82.4–97.6%), in steatohepatitis in 81.3% (95% CI, 61.9–94.9%), in fibrosis in 65.5% (95% CI, 38.2–88.1%) (239). NASH resolved completely in 69.5% (95% CI, 42.4–90.8%). In this pooled sample mean BMI reduction ranged from 19.1 to 41.7 %. The potential of bariatric surgery to improve fibrosis of NASH is underscored by another meta-

analysis (240). A less invasive procedure, endoscopic placement of a duodeno-jejunal bypass liner for six months, resulted in 10.9% weight loss accompanied by a decrease in liver enzymes (241).

Recommendation 30—In overweight / obese NASH patients, intensive life style intervention leading to weight loss in conjunction with increased physical activity shall be used as first-line treatment. (BM)

Grade of recommendation A – Strong consensus (100 % agreement)

Commentary: Life style change resulting in moderate weight loss (<5 %) was shown to improve hepatic fat accumulation as detected by 1H-MRS only when hypocaloric diet and exercise but not when hypocaloric diet alone were implemented (242, 243). Life style change resulting in weight loss of 5–10 % was shown to improve histology when hypocaloric diet and exercise were implemented (229, 234, 237, 244, 245). Subgroup analyses indicate that the extent of weight loss seems to be correlated with the extent of histological improvement. Profound improvement of steatosis, inflammation and ballooning was observed already when weight loss > 7–9 % was achieved (229, 237, 245) while only a weight loss > 10% was associated with improvement in fibrosis (234). In a systematic trial, shifting energy balance to the same degree by either reduced intake alone or a lesser caloric restriction combined with increased energy expenditure (exercise) yielded the same weight loss (–10 %) and the same improvement in hepatic fat, ALT and insulin sensitivity (246).

Available data indicate also, that each of the two interventions alone is effective when the other variable - either weight or daily physical activity - is kept constant. Non-invasive measurements using 1H-MR-spectroscopy convincingly demonstrate a reduction of intrahepatic and visceral triglycerides in subjects just exercising without losing weight (247–249) or following intensive lifestyle intervention by moderate caloric restriction and exercise (250). Conversely, weight loss by either a low carb or a low-fat diet in subjects maintaining their sedentary lifestyle was associated with a substantial loss of intrahepatic lipid (235).

NAFLD patients have a low level of physical activity and, when they have diabetes mellitus, they perform at the lowest quartile of physical activity and moderate-vigorous physical activity (251). Readiness for behavior changes, however, is low in overweight/obese patients with NAFLD with only 10% actively working on or preparing to change (252).

4.2 In normal weight patients with NAFL / NASH, what are the aims of nutritional therapy?

Recommendation 31—In normal weight NAFL / NASH patients, increased physical activity to improve insulin resistance and steatosis can be recommended. (BM)

Grade of recommendation GPP – Strong consensus (100 % agreement)

Commentary: For the small proportion of normal weight NAFL / NASH patients no recommendations can be made on the basis of intervention trials. Since exercise alone has been shown to improve hepatic fat content and insulin resistance in overweight / obese NAFL /NASH patients (247–249, 253) it seems plausible to recommend exercise in normal

weight individuals for the improvement of steatosis and insulin resistance. Likewise, a reduction in the consumption of fructose sweetened soft drinks should be considered.

4.3 For overweight / obese patients with NAFL / NASH, which oral diet (low energy, low carb, low fat) when compared to a normal oral diet can be recommended to a. reduce the risk for comorbidity (e.g. cardiovascular, diabetes), b. improve liver enzymes, c. improve NASH histology, d. slow progression to cirrhosis, e. reduce incidence of HCC, f. reduce mortality?

Recommendation 32—Overweight and obese NAFL / NASH patients shall follow a weight reducing diet to reduce the risk of comorbidity and to improve liver enzymes and histology (necroinflammation). (BM)

Grade of recommendation A – Strong consensus (100 % agreement)

Recommendation 33—In order to achieve weight loss, a hypocaloric diet shall be followed according to current obesity guidelines irrespective of the macronutrient composition. (BM)

Grade of recommendation A – Strong consensus (93 % agreement)

Commentary to recommendations 32 and 33: In general, nutrition counseling of overweight and obese NAFLD patients should be done in accordance with current guidelines for the dietary management of obesity (254–256). As outlined above, weight reduction and lifestyle interventions reduce hepatic steatosis and liver injury. As yet, there is no robust evidence supporting a particular composition of hypocaloric diet unique for use in NAFL / NASH patients. Coffee consumption, however, seems more likely to benefit health than harm, with summary estimates indicating the largest risk reduction for various health outcomes at three to four cups a day. Patients with chronic liver disease seem to benefit most (257). The authors of this umbrella review of meta-analyses correctly point out that robust randomized controlled trials are needed to understand whether the observed associations are causal (257).

In a multi-center randomized study, very-low-calorie diets were effective and safe in reducing body weight and improving NAFLD within twelve weeks (258). Likewise, a low-calorie diet was effective in achieving weight loss of at least 5 % and improvement of NAFLD (246, 250, 259). Data from two trials suggest that the restriction of dietary carbohydrate was more effective than overall caloric restriction in short-term weight loss (two weeks) and in hepatic triglyceride reduction (260, 261) while Kirk et al. reported the same decrease in intrahepatic lipid after 11 weeks on either a low or a high carbohydrate diet (262). Moreover, another trial showed the same beneficial effects regardless of whether the diet was low fat or a low carb (235). Two trials report beneficial effects of a diet low in saturated fat (263, 264). In a prospective study in obese diabetics comparing isocaloric diets high in animal or plant protein a decrease in intrahepatic fat (by MR spectroscopy) and insulin resistance (by hyper-insulinemic euglycemic clamp) was observed after 6 weeks (265); in the study period BMI decreased significantly, too.

It has been hypothesized that the rising prevalence of obesity in the last four decades was related to an increased consumption of dietary fructose and high-fructose corn syrup as a sweetener in soft drinks and other foods (266, 267). Increased fructose consumption as well as hepatic fructokinase and fatty acid synthase mRNA have been observed in NAFLD patients when compared to controls (268). High fructose consumption may increase the risk of NASH and advanced fibrosis, although the association may be confounded by excess calorie intake or by unhealthy lifestyles and sedentary behavior, which are more common in NAFLD (120, 269). The authors of recent meta-analyses summarize, however, that the available evidence was not sufficiently robust to draw conclusions regarding NAFLD promoting effects specific to fructose when consumed as ingredient of a normocaloric diet (270, 271). Likewise, in a double-blind trial, a hyper-caloric diet but not fructose when compared to isocaloric glucose was associated with an increase in hepatic lipid and ALT levels in overweight men (272).

4.4 For patients with NAFL / NASH, can a Mediterranean diet when compared to a western type diet be recommended to a. reduce the risk for comorbidity (e.g. cardiovascular, diabetes), b. improve liver enzymes, c. improve NASH histology, d. slow progression to cirrhosis, e. reduce incidence of HCC, f. reduce mortality?

Recommendation 34—A Mediterranean diet should be advised to improve steatosis and insulin sensitivity. (BM)

Grade of recommendation B – Strong consensus (100 % agreement)

Commentary: Seven interventional (273–279) and five observational (280–284) studies are available suggesting that a Mediterranean diet (MEDD) has beneficial effects on body weight, insulin sensitivity and hepatic steatosis and fibrosis, but without clear evidence in respect of preventing the appearance of NAFLD (120, 285, 286). There is, however, a solid body of clinical evidence supporting the beneficial effect of MEDD in terms of lowering the risk of cardiovascular disease and the development of diabetes, conditions that share common etiological factors with NAFLD, like insulin resistance and obesity (287). Higher adherence to the MEDD is not associated with lower likelihood of having NAFLD, but it is associated with less degree of insulin resistance and less severe liver disease among patients with NAFLD (282).

Even without weight loss, MEDD reduces liver steatosis and improves insulin sensitivity in an insulin-resistant population with NAFLD, compared to current dietary advice (277). Using whole-body MRI, the investigators of the CENTRAL trial (288) found that the MEDD, rich in unsaturated fats and low in carbohydrates, is superior to the low-fat diet in mobilizing specific ectopic fat depots as hepatic, cardiac, and pancreatic fats. In an analysis of participants in the Framingham Heart Study, increasing diet quality as assessed by Mediterranean Diet Score is associated with less liver fat accumulation and reduced risk for new-onset NAFLD (289). In addition, the authors found that an improved diet is particularly important for individuals with a high genetic risk for NAFLD. The investigators of the MEDINA trial demonstrated in a cohort of patients with NAFLD that MEDD independent of

weight loss can result in significant benefits in liver fat and insulin sensitivity and that these changes are sustained at twelve months (290).

4.5 For patients with NAFL / NASH, can life style intervention by physical exercise and/or reduced/cut alcohol consumption when compared to no life style intervention be recommended to a. reduce the risk for comorbidity (e.g. cardiovascular, diabetes), b. improve liver enzymes, c. improve NASH histology, d. slow progression to cirrhosis, e. reduce incidence of HCC, f. reduce mortality?

Recommendation 35—NAFL / NASH patients shall be advised to exercise in order to reduce hepatic fat content, but there are no data regarding the efficacy of exercise in improving necroinflammation. (BM)

Grade of recommendation A – Strong consensus (100 % agreement)

Commentary: Non-invasive measurements using 1H-MR-spectroscopy convincingly demonstrate a reduction of intrahepatic and visceral triglycerides in subjects just exercising without losing weight (247–249). Three months of resistance training improved the hepatorenal-ultrasound index (HRI) as a readout of hepatic steatosis but did not affect liver enzymes, serum triglycerides or HOMA-IR (253). Recommending exercise appears worthwhile and effective in motivated patients offering a veritable option for the management of lean NAFLD patients in whom large weight loss cannot be recommended. To date there are no data on the effect of exercise alone on histological NASH features ballooning, inflammation and most notably fibrosis.

Recommendation 36—NAFL / NASH patients shall be encouraged to abstain from alcohol in order reduce risk for comorbidity and to improve liver biochemistry and histology. (BM).

Grade of recommendation A – Strong consensus (100 % agreement)

Commentary: Addressing the questions of whether there is a continuous dose-response pattern or a threshold value or an effect of gender or end-points (morbidity vs mortality) of alcohol use Rehm and coworkers analyzed 17 studies in their systematic review and meta-analysis (291). From their findings they conclude that there is a threshold for morbidity from cirrhosis but not for mortality regardless of gender. Once there are any signs of liver disease of any etiology they propose to abstain due to the higher relative risks for any consumption associated with mortality (291). Furthermore, in NAFL / NASH risks may be aggravated by interaction with drugs taken in association with entities of metabolic syndrome. At variance to the general population, alcohol use may not reduce the risk of cardiovascular disease in patients with NAFLD (292). These findings were not included in the AASLD/AG (121) and EASL/EASD/EASO (120) guidelines recommending only to abstain from heavy amounts of alcohol. Until evidence from intervention studies is available it seems unjustified to suggest a potential health benefit from moderate alcohol consumption on NAFL / NASH (120, 121).

4.6 For celiac disease patients with NAFL / NASH, can a gluten free diet when compared to a normal diet be recommended to a. reduce the risk for comorbidity (e.g. cardiovascular,

diabetes), b. improve liver enzymes, c. improve NASH histology, d. slow progression to cirrhosis, e. reduce incidence of HCC, f. reduce mortality?

Recommendation 37—Patients with celiac disease and NAFLD / NASH should follow a gluten free diet to improve liver enzymes and histology, and to prevent progression to cirrhosis, in addition to improving intestinal pathology. (BM)

Grade of recommendation B – Strong consensus (96 % agreement)

Commentary: Celiac disease is a model condition for studying the close interaction between gut and liver (293). Liver injury in celiac disease ranges from mildly elevated transaminases, NAFLD and (rarely) cirrhosis (294–298). Elevation of transaminases has been reported in 40% of adults and in 54% of children at the time of diagnosis of celiac disease and, conversely, celiac disease is present in about 9% of patients with chronic unexplained elevation of transaminases (295, 299, 300). Celiac disease is twice as common in patients with cirrhosis than in the general population (301). Celiac disease patients are at increased risk of liver disease prior to or subsequent to the diagnosis of celiac disease (294). According to a systematic analysis (302) the hazard ratio for NAFL / NASH is 2.8 (95% CI 2.0–3.8) in celiac disease patients with and even higher in the subgroup of children (HR 4.6; 95% CI 2.3–0.1).

There are several reports on improvement or even normalization of transaminases with response rates up to 75% - 100% (303) upon institution of a gluten free diet (304–310). A case series from Finland reported on four patients with serious liver disease referred to the transplantation center in whom celiac disease was diagnosed during the evaluation. All patients responded to the gluten free diet and in two diet compliant patient's liver disease resolved completely (311). Of five US patients with LC and celiac disease ALT, AST and bilirubin improved in the four diet compliant patients; MELD score worsened in one patient with NASH cirrhosis but improved in the remaining three (301). There is an association between celiac disease and autoimmune liver disease (autoimmune hepatitis, primary biliary cholangitis) and gluten restriction seems to have a role to reduce the risk of complications (malabsorption, osteoporosis, malignancy) in this group of patients (295, 303).

4.7 For patients with NAFL / NASH, can vitamin E supplementation when compared to no such supplementation be recommended to a. reduce the risk for comorbidity (e.g. cardiovascular, diabetes), b. improve liver enzymes, c. improve NASH histology, d. slow progression to cirrhosis, e. reduce incidence of HCC, f. reduce mortality?

Recommendation 38—Vitamin E (800 IU α -tocopherol daily) should be prescribed to non-diabetic adults with histologically confirmed NASH aiming for improvement of liver enzymes and histology. (BM)

Grade of recommendation B – Strong consensus (100 % agreement)

Commentary: The efficacy of Vitamin E as an anti-oxidant to ameliorate biochemical and/or histological abnormalities of NASH has been investigated in a number of trials (245, 312–321). There is, however, a great heterogeneity among these trials regarding study power, entry criteria, dosage of vitamin E, formulations of vitamin E used, additional use of

other anti-oxidants or other drugs and histologic data to assess outcomes. Despite these limitations, the following conclusions can be drawn regarding adults with NASH (120, 121): 1. the use of vitamin E is associated with an improvement of liver enzymes (decrease in ALT, AST), 2. trials evaluating NASH features in paired liver biopsies show improvement in steatosis, inflammation, and ballooning and resolution of steatohepatitis in patients treated with vitamin E when compared to controls, and 3. vitamin E has limited or no effect on hepatic fibrosis. In the largest RCT (PIVENS trial) the predefined primary endpoint was achieved in a significantly greater number of participants receiving oral vitamin E (800 IU·d⁻¹ for two years) compared to placebo (42% vs. 19%, p<0.001, number needed to treat =4.4) (319). Re-analysis of the PIVENS trial showed that ALT responses were more frequent in the vitamin E recipients and were associated with the NAFLD Activity Score (NAS), but not fibrosis scores (322). Interestingly, vitamin E had an added effect on the improvement of ALT, NAS, and fibrosis scores obtained by weight loss > 2.0 kg (322).

The authors of a meta-analysis of 19 trials (135 967 participants) studying a variety of populations in whom the presence or absence of NASH was not specifically addressed came to the conclusion that vitamin E dosage > 400 IU·d⁻¹ was associated with an increased risk for all-cause mortality and should be avoided (323). This issue is also discussed in the light of more recent findings (121). The Cochrane Hepato-Biliary Group's meta-analysis of 20 randomized trials (1 225 participants) studying the effect of anti-oxidant supplements in patients with liver disease of various etiology included 15 trials supplementing vitamin E (324). The authors found no significant treatment effect of antioxidants on all-cause mortality or liver-related mortality. In another meta-analysis no beneficial effect of anti-oxidant treatment on liver biochemistry and histology was reported (325). In their meta-analysis Ji et al. report an effect of vitamin E on ALT and AST in NASH but not in NAFLD (326). Of the two large and well controlled trials in NASH patients with neither diabetes nor cirrhosis the abstract of the PIVENS trial was included in one meta-analysis only (325) and the TONIC trial (317) in none.

4.8 For patients with NAFL / NASH, can supplementation with anti-oxidants when compared to no such supplementation be recommended to a. reduce the risk for comorbidity (e.g. cardiovascular, diabetes), b. improve liver enzymes, c. improve NASH histology, d. slow progression to cirrhosis, e. reduce incidence of HCC, f. reduce mortality?

Recommendation 39—Until further data regarding their efficacy are available, antioxidants (e.g. vitamin C, resveratrol, anthocyanin, bayberries) cannot be recommended to treat NAFL / NASH. (BM)

Grade of recommendation 0 – Strong consensus (100 % agreement)

Commentary: In twelve overweight/obese men with NAFLD, oral resveratrol (3000 mg) for eight weeks had no effect on insulin resistance, steatosis, abdominal fat distribution and plasma lipids or antioxidant activity. ALT and AST levels, however, increased significantly in the resveratrol group (327). In a randomized controlled trial, 2 × 150 mg resveratrol p. o. for three months was found to improve AST, ALT, LDL and total cholesterol, HOMA-IR

and inflammation mediators in 30 normal weight men with NAFLD on ultrasound (328). One 500 mg capsule of resveratrol together with lifestyle intervention was more effective than lifestyle intervention alone in overweight patients regarding improvement in ALT, inflammatory cytokines and hepatic steatosis; this randomized controlled trial obviously was published in duplicate (329, 330).

Bayberry juice containing high levels of polyphenols had no effect on anthropometric measures and HOMA-IR in Chinese normal weight patients with NAFLD on ultrasound (331).

In a randomized controlled pilot trial, the flavonoid anthocyanin (320 mg p. o. for twelve weeks) decreased ALT and the 2-hour loading glucose level (332).

Oral coenzymeQ10 supplementation was reported to reduce waist circumference, serum AST levels and blood total anti-oxidant capacity (333).

In NAFLD patients, a vitamin C intake below the recommended daily allowance has been reported in epidemiological studies, suggesting an association between dietary habits, disease and vitamin C deficiency. The presently available RCTs have not found an effect of vitamin C superior to that of placebo. Thus, the role of vitamin C in NAFLD should be investigated in future adequately controlled RCTs (334).

Abnormally low choline levels have been implicated in the pathogenesis of PN associated liver disease of which some morphological features resemble NAFLD/NASH (335). A secondary analysis of food questionnaires from 664 participants of three NASH Clinical Research Network trials showed that in postmenopausal women a decreased choline intake was associated with increased fibrosis (336). Along this line, data from the Shanghai Women's and Men's Health Study suggest that higher dietary choline intake may be associated with a lower risk of NAFLD (337). On the other hand, a close relation between plasma free choline levels and the grade of liver steatosis and fibrosis has been observed in NASH (338). There is no data from choline intervention trials.

Compared to placebo, oral supplementation of L-carnitine (1 g b.i.d. for 24 weeks) was effective in reducing TNF- α and CRP and in improving liver function, glucose plasma level, lipid profile, HOMA-IR, and histological manifestations of NASH (339). In diabetic NAFLD patients, oral carnitine-ornitine (3 \times 824 mg for twelve weeks) was associated with significant improvement in ALT, hepatic steatosis and HbA1c in a double-blind placebo-controlled trial (340). These are preliminary results and, therefore L-carnitine cannot be recommended yet.

4.9 For patients with NAFL / NASH, can supplementation with omega-3 fatty acids when compared to no such supplementation be recommended to a. reduce the risk for comorbidity (e.g. cardiovascular, diabetes), b. improve liver enzymes, c. improve NASH

histology, d. slow progression to cirrhosis, e. reduce incidence of HCC, f. reduce mortality?

Recommendation 40—Until further data regarding their efficacy are available, omega-3 fatty acids cannot be recommended to treat NAFL / NASH. (BM)

Grade of recommendation 0 – Strong consensus (100 % agreement)

Commentary: Fish oil has the potential to maintain proper insulin signaling in the brain, ameliorate NAFLD and decrease the risk to metabolic syndrome suggesting that adequate levels of omega-3 fatty acids in the diet can attenuate or neutralize the metabolic challenges imposed by Western lifestyle (341). In patients with just NAFLD, there was a trend towards improvement in liver fat in those treated with 4 g of omega-3 fatty acids (342).

A multi-center trial comparing two dose regimens of ethyl-eicosapentaenoic acid (1.800 mg/d or 2.700 mg/d) with placebo found no effect on liver enzymes, insulin resistance, adiponectin, keratin 18, C-reactive protein, hyaluronic acid and liver histology in 243 patients with biopsy proven NASH (343). In a smaller controlled trial, 3 g of omega-3 fatty acids improved hepatic fat content but failed to improve NASH by 2 points (344). In a trial comparing the effect of 4 g of omega-3 fatty acids and dapagliflozin alone or in combination only the combination was more effective than placebo in lowering intrahepatic lipid (345). In 20 children paired biopsies showed improved histological NAFLD score after 18 months on docosahexaenoic acid (346).

The authors of a systematic review and meta-analysis concluded that in NAFLD patients omega-3 fatty acids reduce liver fat, but the optimal dose had not been determined and better controlled trials were needed (347). In a recent systematic review, however, the authors conclude that marine n-3 PUFAs are likely to be an important tool for NAFLD treatment but further studies are required to confirm this (348). In twelve of the seventeen published human studies the supplementation with n-3 PUFAs was accompanied by a decrease in liver fat and/or other markers of NAFLD. Five studies, including the largest study (343) were negative. The authors of another meta-analysis concluded that omega-3 LC-PUFAs are useful in the dietary management of patients with NAFLD but are ineffective on histologic findings in NASH patients (349).

4.10 For patients with NAFL / NASH, are there other nutrition supplements which can be recommended to a. reduce the risk for comorbidity (e.g. cardiovascular, diabetes), b. improve liver enzymes, c. improve NASH histology, d. slow progression to cirrhosis, e. reduce incidence of HCC, f. reduce mortality?

Recommendation 41—Nutritional supplements containing selected probiotics or synbiotics can be used to improve liver enzymes in NAFL / NASH patients. (BM)

Grade of recommendation 0 – Consensus (89 % agreement)

Commentary: A systematic review identified nine full text papers of randomized clinical trials evaluating probiotics, prebiotics or synbiotics in the treatment of adult NAFLD of which six were excluded due to methodological deficits (350). A double blind randomized

controlled trial in 30 biopsy proven NAFLD patients showed a significant but very modest decrease in ALT, AST, and gGT after three months of treatment with the probiotic but not with placebo (351). A comparison of probiotics versus standard care showed a decrease of intrahepatic triglycerides (MR spectroscopy) and of serum AST in the ten patients of the probiotic group (352).

In patients with biopsy proven NASH, *Bifidobacterium longum* with fructo-oligosaccharides and lifestyle modification for 24 weeks, when compared to lifestyle modification alone, reduced AST levels, markers of inflammation, HOMA-IR, serum endotoxin, and NASH histology in both groups but more so in the symbiotic group (353). In a randomized, double-blind, placebo-controlled clinical trial, 52 patients with NAFLD (by ultrasound) were randomized to take twice daily for 28 weeks either a synbiotic or a placebo capsule in addition to lifestyle modification. In the synbiotic group, blood levels of ALT, AST, gGT, CRP and inflammatory cytokines decreased to a greater degree than in the placebo group (354). The daily consumption of 300 g (8 weeks) of a probiotic containing yoghurt was reported to improve liver enzymes in NAFLD patients compared to conventional yoghurt (355).

4.11 In patients with NAFL / NASH, when is nutritional therapy using EN and/or PN indicated to prevent/reduce mortality and morbidity due to malnutrition (e.g. sarcopenic obesity)?

Recommendation 42—EN or PN shall be administered in NAFL / NASH patients during severe intercurrent illness, when oral nutrition alone is inadequate or impossible or contraindicated.

Grade of recommendation GPP- Strong consensus (96 % agreement)

4.12 In normal weight / overweight patients with NAFL / NASH, in which dosage should energy / protein / nutrition supplements by EN and/or PN be given to a. preserve lean body mass, b. protect from or improve sarcopenia, c. reduce inflammation, d. improve morbidity, e. improve mortality?

Recommendation 43—In NAFL / NASH patients with a BMI < 30 kg/m² EN and/or PN should be done as recommended for ASH patients (see recommendations 18, 19, 20, 25, 27, 28).

Grade of recommendation GPP – Strong consensus (100 % agreement)

Commentary to recommendations 42 and 43: There is no data from formal trials of nutrition therapy addressing these questions. An analysis using the database from the Korea National Health and Nutrition Examination Survey found 12% of NAFLD subjects to be sarcopenic and, interestingly, their BMI was significantly higher than that of non-sarcopenic individuals (356). Also, sarcopenia was consistently associated with significant liver fibrosis. Based on the many reports on the prognostic role of poor food consumption in hospitalized patients in general and patients with ASH or LC in particular experts recommend nutrition support also in NAFLD/NASH patients who cannot achieve an adequate food intake while

they are suffering from severe intercurrent illness. Also, in this patient group, malnutrition risk screening and appropriate nutritional assessment are highly encouraged.

4.13 In obese patients with NAFL / NASH, in which dosage should energy / protein / nutrition supplements by EN and/or PN be given to a. preserve lean body mass, b. protect from or improve sarcopenia, c. reduce inflammation, d. improve morbidity, e. improve mortality?

Recommendation 44—Obese NAFL / NASH patients with intercurrent illness should be given EN and/or PN with a target energy intake of $25 \text{ kcal} \cdot \text{kg}^{-1} \text{ IBW} \cdot \text{d}^{-1}$ and an increased target protein intake of $2.0\text{--}2.5 \text{ g} \cdot \text{kg}^{-1} \text{ IBW} \cdot \text{d}^{-1}$.

Grade of recommendation GPP – Majority agreement (71 % agreement)

Commentary: An increasing number (30–35 %) of adult ICU patients are obese and at least 5 % are morbidly obese (357). Nutrition support of such patients is challenging and one of the most difficult aspects in clinical nutrition. Obesity has an impact on the incidence and severity of comorbidities and patient outcome. According to ASPEN guidelines such patients should be cared for according to the basic principles of critical care nutrition aiming for a high protein intake ($2.0\text{--}2.5 \text{ g} \cdot \text{kg}^{-1} \text{ IBW} \cdot \text{d}^{-1}$) for the preservation of lean body mass but a hypocaloric regimen ($25 \text{ kcal} \cdot \text{kg}^{-1} \text{ IBW} \cdot \text{d}^{-1}$) aiming for the reduction of fat mass and insulin resistance (358). A recent NutritionDay analysis reveals that current practice of nutrition in participating ICUs by far fails to achieve the ASPEN targets (359). No recommendation specific for nutrition support of obese ICU patients is made in the current ESICM guidelines on early EN (180). Among the consensus group, agreement on this recommendation was limited due to the weak evidence available. Facing the increasing number of obese NAFL / NASH patients, however, the reference to the ASPEN critical care guideline was considered appropriate.

4.14 In overweight / obese patients with NAFL / NASH, under which conditions is bariatric surgery indicated / contraindicated to achieve weight reduction?

Recommendation 45—In otherwise eligible obese NAFL / NASH patients without cirrhosis, after weight reduction diets and intensive lifestyle interventions have failed, bariatric surgery should be proposed. (BM)

Grade of recommendation B – Strong consensus (100 % agreement)

Commentary: Lifestyle intervention, although effective in some patients, is not sufficient to achieve long-term weight loss and resolution of NASH. It is estimated that only 10% of patients who commit to a lifestyle intervention lose more than 10% of their weight, even when the intervention involves a multidisciplinary approach (360). Currently, no drug treatment has been shown effective, but many compounds are under investigation. Bariatric surgery is a potential treatment option in NAFLD, in particularly its progressive form NASH. Indeed, the majority of obese patients undergoing bariatric surgery are obese and have associated NAFLD (121). There are no systematic randomized controlled trials that evaluated any bariatric surgical procedure to specifically treat NAFLD or NASH. In a

systematic review and meta-analysis of 15 studies reporting on 766 paired liver biopsies showed that the pooled proportion of patients with improvement or resolution in steatosis was 92%, in steatohepatitis was 81%, in fibrosis was 66% and for complete resolution of NASH was 70% (239). These findings are corroborated by the Lille data from France (231). Using a state-transition model, Klebanoff et al (361) aimed to assess the effectiveness and cost-effectiveness of surgery or intensive lifestyle intervention to manage NASH. Both interventions increased QALYs compared to no intervention. Surgery was both effective and cost-effective for obese patients with NASH, regardless of fibrosis stage F0-F3. In overweight patients, surgery increased QALYs for all patients regardless of fibrosis stage, but it was cost-effective only for patients with F3 fibrosis.

In one series, cirrhosis was diagnosed intraoperatively in 4% and fibrosis in 37% of patients undergoing bariatric surgery (362). Perioperative mortality of bariatric surgery is lower in patients without cirrhosis compared to patients with compensated or decompensated cirrhosis (0.3% vs 0.9% and 16.3%) (363).

The joint European guidelines of EASL, EASD and EASO state that in patients unresponsive to lifestyle changes and pharmacotherapy, bariatric surgery is an option for reducing weight and metabolic complications, with stable results in the long-term results (120).

4.15 In obese patients with NAFL / NASH, can bariatric surgery when compared to weight losing diet with / without counselling a. reduce the risk for comorbidity (e.g. cardiovascular, diabetes), b. improve liver enzymes, c. improve NASH histology, d. slow progression to cirrhosis, e. reduce the incidence of HCC, f. reduce mortality?

Statement 13—In obese NAFL / NASH patients, the efficacy of bariatric surgery regarding weight reduction and improvement in hepatic steatosis and necroinflammation including fibrosis as well as insulin resistance should be considered. (BM)

Strong consensus (100 % agreement)

Commentary: The effect of bariatric surgery on liver histology in paired biopsies has been reported in 16 studies (226–228, 231, 232, 364–374). Clearly, the profound weight loss achieved by this approach has the potential to resolve NASH in up to 80–100% and improve fibrosis substantially, the latter being the most relevant outcome regarding patient survival (225). Also, insulin sensitivity is improved, and a considerable proportion of diabetic patients needs no more antidiabetic treatment. As to the type of bariatric surgery, a greater efficacy of gastric bypass when compared to gastric banding should be considered regarding the improvement in liver pathology as well as insulin resistance (227).

5 Cirrhosis

5.1 In cirrhotic patients, should specific nutritional counselling when compared to no nutritional counseling be used to improve patients' outcome and/or survival?

Recommendation 46—Specific nutritional counselling should be implemented in cirrhotic patients using a multidisciplinary team to improve patients' long-term outcome/survival. (BM)

Grade of recommendation GPP – Strong consensus (100% agreement)

Recommendation 47: Multidisciplinary nutrition care should include monitoring of nutritional status and provide guidance for achieving nutritional goals. (BM)

Grade of recommendation GPP – Strong consensus (95% agreement)

Commentary to recommendations 46 and 47: Nutrition therapy should be included in the management of LC patients. Specific nutrition counseling has the potential to alter patients' behavior and should include patients' education about the benefit of a healthy diet adapted to the clinical condition and addressing specific concerns. When nutrition prescriptions need to be changed in response to the severity of the disease nutrition counseling can facilitate how to deal with these changes. A small monocentric retrospective study showed a survival benefit when LC patients received specialized nutrition counseling as compared to no counseling (375). The authors also reported that counseling involving a multidisciplinary team including physicians, nurses, pharmacists and dieticians was associated with better survival than counseling by just one profession (375).

5.2 In cirrhotic patients, can nutritional intervention (either oral, EN or PN) when compared to no such intervention ameliorate outcome and survival?

Recommendation 48—In cirrhotic patients, nutritional intervention (either oral, EN or PN) shall be implemented according to current guidelines for non-cirrhotic patients. (BM)

Grade of recommendation A – Consensus (89% agreement)

Recommendation 49—In cirrhotic patients, nutritional intervention (either oral or EN or PN) should be recommended for potential clinical benefit without an increase in adverse events.

Grade of recommendation GPP– Strong consensus (100% agreement)

Commentary to recommendations 48 and 49: In principle, the differential indications for oral nutrition, EN or PN in LC patients are not different from those covered in guidelines for non-cirrhotic patients. It should be noted, however, that LC patients typically exhibit hepatic glycogen depletion and resort to protein catabolism for gluconeogenesis much earlier than non-cirrhotic patients, i.e. as early as after an over-night fast (see chapter general). Therefore, the timely institution of nutrition is of prime importance to provide metabolic fuel and substrate for protein anabolism.

As commented in detail regarding recommendations 58–64 a number of studies on nutrition therapy in LC patients showed improved clinical outcome including survival.

Recent meta-analyses, however, fail to confirm a survival benefit (187–189, 376). Methodologically, these meta-analyses suffer from various flaws like mixing LC and ASH or including trials with just three days of nutrition or excluding pertinent trials for no obvious reason.

5.3 In cirrhotic patients, is an increased energy regimen always indicated vs a normal energy regimen to meet energy need?

Recommendation 50—Cirrhotic patients in conditions of increased energy expenditure (i. e. acute complications, refractory ascites) or malnutrition, should ingest an increased amount of energy. (BM)

Grade of recommendation GPP— Strong consensus (100% agreement)

Recommendation 51—In cirrhotic patients, an increased energy intake is not recommended in overweight or obese patients. (BM)

Grade of recommendation GPP – Strong consensus (100% agreement)

Commentary to recommendations 50 and 51: In general, energy requirements in compensated LC patients are not higher than in healthy individuals (see statement 4 and recommendation 2). Moreover, LC patients have a decreased physical activity level (83, 97) and thus a decreased energy expenditure due to physical activity. Cirrhotic patients during the natural course of the disease tend to spontaneously decrease their dietary intake (89, 191). This is of special relevance in the subgroup (up to 35 % of LC patients) of hyper-metabolic LC patients (33, 80, 81) or in those with advanced cirrhosis with complications when energy expenditure may be increased. Therefore, measurement of energy expenditure is recommended whenever possible (see recommendation 1). Oral, enteral or parenteral nutrition have been utilized in short and long term studies in decompensated and/or malnourished cirrhotic patients with some advantages either in morbidity or in mortality (191).

The proportion of overweight or obese LC patients has increased even in cohorts on the wait list for transplantation (102, 170, 377). In chronic liver disease, obesity has been identified as an independent risk factor for a worse clinical outcome (378, 379). Obesity has been proposed to promote portal hypertension. Portal hypertension could be ameliorated by lifestyle intervention for 16 weeks using hypocaloric diet and increased exercise in LC patients (380). Therefore, an increased energy intake is not recommended in obese cirrhotic patients.

5.4 In all cirrhotic patients, is increased as compared to normal protein assumption/ intake always needed to face increased protein turnover and catabolism?

Recommendation 52—Non-malnourished patients with compensated cirrhosis should ingest $1.2 \text{ g} \cdot \text{kg}^{-1} \cdot \text{d}^{-1}$ protein. (BM)

Grade of recommendation B – Strong consensus (100% agreement)

Recommendation 53—To replenish malnourished and/or sarcopenic cirrhotic patients the amount of 1.5 g·kg⁻¹·d⁻¹ protein should be ingested. (BM)

Grade of recommendation B – Strong consensus (100% agreement)

Commentary to recommendations 52 and 53: LC patients can effectively accrete protein but require an increased amount of protein to achieve nitrogen balance (65). In a small study protein requirements were found to be elevated in eight cirrhotic patients and the authors recommend to always supply 60 g of protein per day in these patients (222). No trials or intervention studies are available for well-nourished compensated cirrhotic patients.

Malnourished and sarcopenic cirrhotic patients experience protein depletion both due to elevated total body protein breakdown and decreased protein synthesis in muscle (14, 381–384). Increased protein intake is generally well tolerated and safe in cirrhotic patients and ameliorates protein anabolism as shown in previous studies. (65, 222). Adequate refeeding was able to induce a significant increase of protein synthesis in a small group of carefully followed malnourished cirrhotic patients (385). Sarcopenic cirrhotic patients, including those with sarcopenic obesity, may need a higher protein intake in conjunction with exercise to accomplish muscle replenishment. In intervention studies implementing high protein intakes improvement in arm muscle circumference, handgrip strength and albumin was observed (151, 386–389). An improvement in total body protein status was observed, when ONS were consumed nocturnally (223) extending previous observations of a beneficial effect of a late evening carbohydrate or protein snack in LC patients (220–222).

5.5 In cirrhotic patients with HE, is protein restriction indicated to ameliorate HE?

Recommendation 54—Protein intake should not be restricted in cirrhotic patients with HE as it increases protein catabolism. (BM)

Grade of recommendation B – Strong consensus (100% agreement)

Commentary: A very select subgroup of LC patients, termed protein intolerant, develop encephalopathy on a normal protein intake (390, 391) but this seems to be a historical phenomenon, as such patients are rarely encountered nowadays. Based on a number of trials it was suggested that protein restriction may not be mandatory for the prevention of HE (191, 218, 385, 392). As shown in a RCT by Cordoba et al (393) protein restriction has no advantage on the clinical course of acute HE and may increase protein catabolism. After this study the dogma of prescribing protein restriction for LC patients with HE was definitively abandoned, and all efforts were focused on achieving an adequate protein intake in these patients.

5.6 In cirrhotic patients, is micronutrient supplementation always needed to correct alterations?

Recommendation 55—In cirrhotic patients, micronutrients should be administered to treat confirmed or clinically suspected deficiency. (BM)

Grade of recommendation GPP – Strong consensus (100% agreement)

Commentary: Patients with cirrhosis may present deficiencies in water-soluble vitamins, particularly thiamine, and lipid soluble vitamins such as vitamin D (394, 395). There are no reports which systematically evaluate the requirement of micronutrients in LC. Like in other conditions, the administration of micronutrients has no proven therapeutic effect apart from the prevention or correction of deficiency states.

Zinc and vitamin A supplements by improving dysgeusia may indirectly improve food intake and nutritional state (396, 397). Zinc and selenium deficiency have been observed in patients with alcoholic as well as non-alcoholic liver disease (398–400). An impressive association between HE and zinc deficiency has been described in case reports (401, 402). Randomized controlled trials, however, showed no therapeutic effect of oral zinc supplementation on HE (403–405). Oral zinc supplementation can increase urea production capacity when previously subnormal plasma levels are normalized (406).

In a pragmatic approach, liberal supplementation is recommended in the first two weeks of nutritional support, because the laboratory diagnosis of a specific trace element or vitamin deficiency may be costlier and would delay commencing supplementation. Due to the high prevalence of malnutrition LC patients are at risk for developing refeeding syndrome and thiamine deficiency.

5.7 In obese patients with cirrhosis, can a program of weight reduction ameliorate outcome and survival?

Recommendation 56—In obese patients with cirrhosis lifestyle intervention aiming for beneficial effects of weight reduction, which include reduced portal hypertension, should be implemented. (BM)

Grade of recommendation B – Strong consensus (100% agreement)

Commentary: In a recent multicenter uncontrolled study (380), the response to hypocaloric normonitrogenous diet and 60 min/wk. of supervised physical activity for 16 weeks was evaluated in 50 overweight/obese (BMI ≥ 26 kg/m²) patients with compensated cirrhosis. This lifestyle intervention significantly decreased body weight (average, -5.0 ± 4.0 kg). These patients also achieved a significant decrease in portal hypertension as assessed by hepatic venous pressure gradient. No data were reported for other outcomes. If confirmed, these results strongly support lifestyle intervention in obese cirrhotic patients.

5.8 In cirrhotic patients with malnutrition and/or sarcopenia, can quantitative and qualitative modification of the oral diet and pattern of food intake ameliorate nutritional status, muscle mass, outcome, survival?

Recommendation 57—Oral diet of cirrhotic patients with malnutrition and muscle depletion should provide 30–35 kcal·kg⁻¹·d⁻¹ and 1.5 g protein·kg⁻¹·d⁻¹. (BM)

Grade of recommendation B – Strong consensus (100% agreement)

Recommendation 58—Periods of starvation should be kept short by consuming three to five meals a day and a late evening snack should be recommended to improve total body protein status. (BM)

Grade of recommendation B – Strong consensus (100% agreement)

Recommendation 59—In cirrhotic patients who are protein “intolerant”, vegetable proteins or BCAA ($0.25 \text{ g}\cdot\text{kg}^{-1}\cdot\text{d}^{-1}$) should be used by oral route to facilitate adequate protein intake. (BM).

Grade of recommendation B – Consensus (89% agreement)

Recommendation 60—Long-term oral BCAA supplements ($0.25 \text{ g}\cdot\text{kg}^{-1}\cdot\text{d}^{-1}$) should be prescribed in patients with advanced cirrhosis in order to improve event-free survival or quality of life (BM)

Grade of recommendation B – Consensus (89% agreement)

Recommendation 61—When prescribing a low sodium (unpalatable) diet the increased risk of even lower food consumption should be balanced against its moderate advantage in the treatment of ascites. (BM). Care should be taken to avoid compromising the palatability of the diet after sodium reduction.

Grade of recommendation GPP – Consensus (78 % agreement)

Commentary to recommendations 57–61: Based on available published data, patients should have an energy intake of $30\text{--}35 \text{ kcal}\cdot\text{kg}^{-1}\cdot\text{d}^{-1}$ and a protein intake of $1.2\text{--}1.5 \text{ g}\cdot\text{kg}^{-1}\cdot\text{d}^{-1}$. Excluding trials using BCAA-enriched ONS a meta-analysis found a reduced mortality in a subgroup analysis (376). After successful treatment of portal hypertension by transjugular intrahepatic stent-shunt (TIPS), LC patients on normal food (according to ESPEN recommendations) were able to improve their body composition (82, 407).

In a well conducted prospective trial measuring total body nitrogen the nocturnal administration of ONS has been shown to be more effective in improving total body protein status than daytime ONS (223). Previously, a late evening carbohydrate snack has been shown to improve protein metabolism in LC (220, 221, 408). In their systematic review Tsien and coworkers (216) showed that a late evening snack improved nitrogen balance, irrespective of the composition or type of formulation used. They conclude that shortening periods without food by late evening snack is a promising concept to reverse anabolic resistance and sarcopenia of cirrhosis.

In the very rare case of a “protein intolerant” LC patient developing encephalopathy when ingesting normal amounts of mixed protein, a vegetable protein diet may be beneficial. A number of reviews have addressed this issue (409–411) but there is no data from randomized controlled trials comparing isocaloric and isonitrogenous regimens.

One study (412) was uncontrolled and in a more recent study nutritional therapy using a vegetable protein diet was compared to no therapy (413).

There are no data available from trials comparing a standard enteral formula and an enteral formula enriched in BCAA in LC patients. BCAA-enriched formulas, however, have been used in trials demonstrating improved survival in severely malnourished ASH and LC patients (111, 112, 392, 414) or mental state in a highly selected group of protein intolerant LC patients with encephalopathy (390). In the two largest trials (174 and 646 patients) oral BCAA supplementation (12 and 24 months) was useful to prevent progressive hepatic failure and to improve surrogate markers and health related quality of life (415, 416). In LC patients after an episode of HE, BCAA supplementation for twelve months improved minimal HE and muscle mass but the recurrence of overt HE was not decreased vs the control group (417). In a retrospective analysis, BCAA supplementation was associated with better survival in sarcopenic but not in non-sarcopenic LC patients (414). In trials reporting beneficial effects on mental state and/or protein metabolism BCAA were given at doses of 0.20–0.25 g·kgBW⁻¹·d⁻¹ (415, 416, 418, 419) or 30 g·d⁻¹ (390, 417). In a Cochrane meta-analysis, overall a beneficial effect of BCAA on mental state was found (420) but there are unresolved issues regarding trial methodology (421, 422). In most countries, however, oral BCAA supplements are not reimbursed and the combination of cost and palatability may affect compliance.

Based on the pathophysiology of ascites a moderate dietary sodium intake (60 mmol/day) is usually recommended. The potential benefit may be offset by a reduced intake of energy and protein due to poor palatability of such a diet (423, 424). Therefore, great care should be taken to ensure adequate nutrition when prescribing a sodium restricted diet. In ascitic LC patients with ascites on a low sodium diet, morbidity and mortality rates were lower in patients receiving a balanced diet with BCAA with or without PN support when compared to those recommended a low sodium diet alone (425).

5.9 In cirrhotic patients, can EN ameliorate nutritional status, muscle mass, outcome, survival?

Recommendation 62—In cirrhotic patients, who cannot be fed orally or who do not reach the nutritional target through the oral diet, EN should be performed. (BM)

Grade of recommendation B – Strong consensus (100% agreement)

Recommendation 63—Esophageal varices are no absolute contraindication for positioning a nasogastric tube (BM)

Grade of recommendation 0 – Strong consensus (100% agreement)

Recommendation 64—PEG placement is associated with a higher risk of complications, due to ascites or varices, and thus, can only be used in exceptional cases. (BM)

Grade of recommendation 0 – Strong consensus (100% agreement)

Commentary to recommendations 62–64: There is ample evidence indicating that ensuring a quantitatively adequate nutrient intake should be the primary goal (62, 146, 191, 386, 388, 389, 392, 426, 427). If nutritional requirements cannot be met by oral nutrition alone or in combination with ONS then EN is required. EN and has been shown to improve survival and liver function (191, 392, 427). A recent randomized multicenter trial showed no effect on survival or liver function one year after EN using a standard formula for on average 2.8 weeks followed by ONS recommended for two months (428). The authors, however, do not provide data on ONS treatment adherence. Total energy intake during EN was assessed only in a subgroup and exceeded recommended intake by 28% (3292 +/- 781 kcal/d) and raises questions of detrimental effects of overfeeding. In their meta-analysis Ney and co-workers (376) find a mortality reduction in the subgroup analysis of three of the four ONS studies included but not for the whole group of six trials analyzed. Their analysis, however is weakened by the inclusion of one trial aiming for only three days of EN (429) and for the exclusion of two relevant controlled trials (191, 392) for no good reasons.

In ten patients with acute HE I-II nasogastric tube feeding using a BCAA-enriched enteral formula was successful with regard to recovery from HE without any complication due to variceal bleeding (217). There is no evidence in the current literature (185, 191, 392, 429–431) that esophageal varices pose an unacceptable risk to the use of fine bore nasogastric tubes for EN.

Regarding the placement of a percutaneous endoscopic gastrostomy (PEG) feeding tube the current European guidelines (432) state that serious coagulation disorders (INR > 1.5, PTT > 50 s, platelets < 50,000/mm³) and severe ascites are contraindications. According to those guidelines no increased morbidity has been observed when a PEG was inserted in the presence of mild to moderate ascites. In a series of 26 cases, however, two deaths occurred as a direct consequence of PEG insertion (433). It should be kept in mind that in LC portal hypertension can lead to an increased number of enlarged gastric vessels that may become the source of significant hemorrhage when injured during PEG insertion.

5.10 In cirrhotic patients with malnutrition and muscle depletion, can PN ameliorate nutritional status, muscle mass, outcome, survival?

Recommendation 65—PN should be used in cirrhotic patients in whom oral and/or EN are ineffective or not feasible. (BM)

Grade of recommendation B - Strong consensus (100% agreement)

Commentary: The indication for PN in LC patients who cannot be fed orally or by EN is in keeping with recommendations in non-cirrhotic patients (4, 200). Care should be taken to avoid infections of the intravenous lines as these patients are more prone to infection and sepsis. Two aspects specific to cirrhosis should be mentioned.

In LC, infused lipids are cleared from plasma and oxidized at rates similar to that in healthy individuals (56, 57). In infants and children fish oil containing emulsions appear to be associated with a lower risk of cholestasis and liver injury (see chapter 7). At present, there are no clinical outcome data showing a benefit of such emulsions in adult LC patients.

Regarding the composition of amino acid solutions, a standard solution can be used in patients with compensated LC. Specific “hepatic formula” amino acid solutions aimed at the correction of the plasma amino acid imbalance are complete amino acid solutions high in BCAA (35–45 %) but low in tryptophan, aromatic and sulfur-containing amino acids and have been developed for LC patients with overt HE (434–436). The efficacy of BCAA or BCAA-enriched solutions has been investigated in seven controlled but very heterogeneous trials (437–443), the results of which are contradictory. Meta-analyses of these studies showed an improvement in mental state by the BCAA-enriched solutions, but no definite benefit in survival (421, 444). It is important to reiterate that in LC patients, episodes of HE are precipitated by serious and life-threatening complications such as infection or hemorrhage, which are stronger determinants of survival than HE, and therefore it is not surprising that BCAA-based PN failed to improve short term survival. Recently, it has been demonstrated that, due to the absence of isoleucine from hemoglobin, blood is a protein source of low biologic value leading to BCAA antagonism after upper gastrointestinal hemorrhage (445). This antagonism leads to hyperammonemia, but HE could potentially be overcome by the infusion of isoleucine alone (446). Isoleucine solutions for i. v. infusions, however, are not commercially available. Special hepatic formula amino acid solutions (see above) contain high amounts of isoleucine in addition to other BCAAs, leucine and valine.

6 Transplantation and Surgery

6.1 In patients with chronic liver disease / LC scheduled for surgery, when is preoperative nutrition therapy indicated / contraindicated compared to no preoperative nutrition therapy in order to a. achieve better survival, b. reduce complication rate?

Recommendation 66—LC patients scheduled for elective surgery or listed for transplantation should be screened and assessed for malnutrition timely in order to treat malnutrition prior to surgery and thereby improve body protein status. (BM)

Grade of recommendation B – Strong consensus (100% agreement)

Recommendation 67—In the immediate preoperative period LC patients should be managed according to the ERAS approach in order to prevent unnecessary starvation.

Grade of recommendation GPP – Strong consensus (100% agreement)

Commentary to recommendations 67 and 68: In malnourished LC patients, the risk of postoperative morbidity and mortality is increased after abdominal surgery (447, 448). Numerous descriptive studies have shown higher morbidity and mortality in LC patients with protein malnutrition when such patients undergo LT (25–27, 31, 117, 449–451). Recently, sarcopenia and frailty have been shown to carry an increased risk of morbidity and mortality on the waiting list and after transplantation (24, 29, 34, 157, 163–165, 170–172, 174, 377, 414). Patients on the wait are at risk due to an inadequately low food intake (452) and those consuming a low protein diet ($< 0.8 \text{ g} \cdot \text{kg}^{-1} \cdot \text{d}^{-1}$) have an increased wait-list mortality (453). Data from a pilot study suggest that preoperative nutrition support improves total body protein status and reduces postoperative infection rates (454) but there are no

controlled trials showing that preoperative nutritional intervention improves clinical outcome.

Liver glycogen is depleted in LC patients and therefore it is advisable to take great care to shorten periods without nutrient intake in order to avoid gluconeogenesis from muscle protein in an already protein depleted individual (42, 43, 221–223). In liver surgery, too, adoption of ERAS protocols improves morbidity and length of stay when among other measures patients are given carbohydrate containing clear liquid until two hours preoperatively, early feeding and mobilization (91, 455, 456).

6.2 Preoperatively in patients with chronic liver disease / cirrhosis, in which dosage should energy / protein by ONS and/or EN and/or PN be given in order to a. improve survival, b. decrease complication rate, c. maintain / improve nutritional status, d. shorten length of stay in ICU/hospital?

Recommendation 68

In LC patients scheduled for elective surgery nutrition management should proceed as recommended for cirrhosis.

Grade of recommendation GPP – Strong consensus (100% agreement)

Recommendation 69—Preoperatively, a total energy intake of 30–35 kcal·kg⁻¹·d⁻¹ (126–147 kJ·kg⁻¹·d⁻¹) and a protein intake of 1.2–1.5 g·kg⁻¹·d⁻¹ should be aimed for. These ranges cover recommended intakes depending on treatment goals, i.e. maintenance or improvement of nutritional status.

Grade of recommendation GPP – Strong consensus (100% agreement)

Recommendation 70—Obese patients can be given EN and/or PN with a target energy intake of 25 kcal ·kg⁻¹ IBW ·d⁻¹ and an increased target protein intake of 2.0–2.5 g·kg⁻¹ IBW ·d⁻¹.

Grade of recommendation GPP – Strong consensus (93% agreement)

Recommendation 71—In overweight/obese NASH patients scheduled for elective surgery nutrition management should proceed as recommended for NASH.

Grade of recommendation GPP – Strong consensus (100% agreement)

Commentary to recommendations 68–71: Cirrhotic patients scheduled for surgery should be managed like non-obese patients with cirrhosis using the same targets for energy and protein intake.

Both undernutrition (BMI < 18.5 kg·m⁻²) and severe obesity (BMI > 40 kg·m⁻²) prior to liver transplantation are associated with increased mortality and morbidity (126, 127, 457, 458). Severe obesity prior to liver transplantation is associated with a higher prevalence of comorbidities (diabetes, hypertension), cryptogenic cirrhosis and increased mortality from infectious complications, cardiovascular disease and cancer (126, 127). In this patient group,

the presence and extent of ascites seem to increase with the degree of obesity and the subtraction of the amount of ascitic fluid removed can be used to calculate “dry BMI” (126, 459). Some investigators found that severe obesity was associated with increased morbidity and mortality even when patients were classified according to “dry BMI” (126) while others found the amount of ascites and not BMI to increase mortality risk (459) or did not address this issue (127). Also, in chronic liver disease obesity is an independent risk factor for worse clinical outcome (378, 379).

6.3 Preoperatively in patients with chronic liver disease / cirrhosis, can specialized nutrition protocols when compared to no specialized nutrition protocols a. reduce postoperative mortality and morbidity, b. maintain or improve nutritional status?

6.4 Preoperatively in patients with chronic liver disease / cirrhosis, can special components (e.g. BCAA, omega-3 FA) of the nutrition solution when compared to a standard nutrition solution a. reduce postoperative mortality and morbidity, b. maintain or improve nutritional status?

Recommendation 72—In adults, for preoperative nutrition standard nutrition regimens shall be used, since specialized regimens (e. g. BCAA-enriched, immune-enhancing diets) were not superior to standard regimens regarding morbidity or mortality. (BM)

Grade of recommendation A – Strong consensus (100% agreement)

Recommendation 73—In children awaiting transplantation, BCAA-enriched formulas should be used in order to improve body cell mass. (BM)

Grade of recommendation B – Strong consensus (93% agreement)

Commentary to recommendations 72 and 73: Nutritional counselling plus ONS and nutritional counselling alone were equally effective in LC patients awaiting transplantation (388). In a controlled randomized trial in LC patients undergoing transplantation there was no advantage irrespective of whether a special immune-enhancing ONS or a standard ONS was used for preoperative nutrition support (202). The use of probiotics, however, from listing until transplantation was associated with fewer infections and a more rapid decrease of ALT, AST and lower bilirubin levels postoperatively when compared to controls in a randomized controlled trial (460). Non-randomized studies by Kaido and colleagues showed fewer postoperative infections in transplanted patients who received preoperative BCAA-enriched ONS (461, 462). A retrospective analysis indicated reduced postoperative bacteremia in LT recipients receiving oral BCAA supplementation (463).

Pediatric transplant patients with predominantly cholestatic liver disease had improved body cell mass if they received BCAA-enriched formulas (464).

6.5 Postoperatively in patients with chronic liver disease / cirrhosis, when is nutritional therapy using - oral nutrition and/or EN and/or PN indicated / contraindicated when

compared to no nutrition therapy in order to a. reduce mortality, b. reduce morbidity / co-morbidity, c. shorten length of stay in ICU/hospital?

Recommendation 74—After LT, normal food and/or EN should be initiated within 12–24 hours postoperatively to reduce infection rate. (BM)

Grade of recommendation B – Strong consensus (100% agreement)

Recommendation 75—After scheduled surgery, chronic liver disease patients should be managed according to the ERAS protocol.

Grade of recommendation GPP – Strong consensus (100% agreement)

Recommendation 76—PN should be preferred to no feeding in order to reduce complication rates and length of mechanical ventilation and length of stay in ICU, when oral nutrition or EN is impossible or not practicable. (BM)

Grade of recommendation B – Consensus (86% agreement)

Recommendation 77—PN should be used in patients with unprotected airways and HE when cough and swallow reflexes are compromised or EN is contraindicated or impracticable.

Grade of recommendation GPP – Strong consensus (100% agreement)

Recommendation 78—After the acute postoperative phase an energy intake of 30–35 kcal·kg⁻¹·d⁻¹ (126–147 kJ·kg⁻¹·d⁻¹) and a protein intake of 1.2–1.5 g·kg⁻¹·d⁻¹ should be aimed for.

Grade of recommendation GPP – Strong consensus (100% agreement)

Commentary to recommendations 74–78: After transplantation, postoperative PN is superior to the infusion of fluid and electrolytes in reducing time on the ventilator and length of stay in ICU (465). EN started as early as twelve hours after the operation is associated with a lower rate of infections than no artificial nutrition support (466). In a direct comparison between PN and early EN, both strategies proved to be equally effective with regard to the maintenance of nutritional state (467). Postoperatively there is a considerable nitrogen loss and patients remain in negative nitrogen balance for a prolonged period (92, 94, 202) necessitating an increase in the provision of protein or amino acids. Protein or amino acid intakes of 1.2–1.5 g kg⁻¹ d⁻¹ have been reported (92, 465).

After non-transplant abdominal surgery LC patients have a reduced rate of complications and improved nitrogen economy if they receive nutritional support instead of just fluid and electrolytes (468, 469). EN (via jejunostomy) was associated with improved 7-day nitrogen balance compared with sequential PN/EN (469).

6.6 Postoperatively in patients with chronic liver disease / cirrhosis, can specialized nutrition protocols when compared to no such protocols a. reduce mortality, b. reduce

morbidity, c. shorten length of stay in ICU/hospital, d. maintain or improve nutritional status, e. prevent sarcopenic obesity in long-term survivors after OLT?

Recommendation 79—For early EN nasogastric / nasojejunal tubes should be used as in non-liver disease surgery. (BM)

Grade of recommendation B – Strong consensus (100% agreement)

Commentary: Transplant patients who received early EN twelve hours after surgery developed fewer viral infections and had better nitrogen retention than those receiving no artificial nutrition support (466). In comparison with PN, EN reduced complication rates and costs in transplant patients (467). Whole protein formulas with (470–473) or without pre- and probiotics (466, 467, 474, 475) or peptide-based formulas (476, 477) have been used for early EN in adult liver transplant recipients. Formulae were administered via nasogastric or nasojejunal tubes (466, 467, 472, 474) or via catheter jejunostomy (470, 476, 477) placed during laparotomy.

Long term survivors after liver transplantation are at considerable risk of becoming overweight or even obese and develop relevant morbidity due to metabolic syndrome (97, 478, 479). More attention should be paid to approach of avoiding the problem of sarcopenic obesity (98, 99) by stringent postoperative physiotherapy and dietary counselling to overcome the deconditioning of pre-transplant chronic liver disease (100, 102, 103, 106).

6.7 Postoperatively in patients with chronic liver disease / cirrhosis, can special components (e.g. BCAA, omega-3 FA) of the nutrition solution when compared to a standard nutrition solution a. reduce mortality, b. reduce morbidity, c. shorten length of stay in ICU/hospital, d. maintain or improve nutritional status, e. prevent sarcopenic obesity in long-term survivors after OLT?

Recommendation 80—After transplantation, enteral formula together with selected probiotics should be used to reduce infection rate. (BM)

Grade of recommendation B – Consensus (86% agreement)

Recommendation 81—BCAA-enriched formulas can be used in patients with HE in need of EN.

Grade of recommendation 0 – Majority agreement (79% agreement)

Commentary to recommendations 80 and 81: Perioperative administration of pre- and probiotics (*Lactobacillus* spp. and other lactic acid metabolizing bacteria) compared to prebiotics was associated with a reduction in infectious complications (472). A recent meta-analysis (480) which included that study and two further randomized trials using a single *Lactobacillus* sp. (471) and two *Lactobacillus* spp. plus *Bifidobacterium* sp. (470) showed reduced infection rate with pre- and probiotics.

A recent meta-analysis (420) also showed that oral/enteral BCAA compared with isonitrogenous controls are beneficial for HE in LC. To date, the question of whether

BCAA-enriched formulas or other special components of the nutrition solution can prevent sarcopenic obesity in long-term survivors of LT has not been addressed in studies.

6.8 In adult organ donors, can specific nutrition regimens (e.g. glutamine, arginine) a. reduce / prevent ischemia / reperfusion injury, b. improve graft function, c. reduce postoperative mortality and morbidity?

Recommendation 82—No recommendations can be made regarding donor or organ conditioning by use of specific nutrition regimens, such as i. v. glutamine or arginine, with the object of minimizing ischemia/reperfusion damage.

Grade of recommendation GPP – Strong consensus (100% agreement)

Commentary: Animal data indicate that the balanced nutrition of a brain dead liver donor, using moderate amounts of carbohydrate, lipid (long-chain fatty acids and possibly fish oil) and amino acids, is associated with improved function of the transplanted organ (481). The value of donor or organ conditioning which aims to reduce ischemia/reperfusion damage in humans by provision of high doses of arginine or glutamine is currently unknown.

7 Nutrition Associated Liver Injury (NALI)

7.1 In adults / children, can malnutrition cause liver injury associated with a. biochemical signs of hepatocyte lesion, b. impaired liver function, c. abnormal liver histology, d. chronic liver disease?

Statement 14—Malnutrition can impair the whole spectrum of hepatic metabolic functions. Malnutrition alone can cause severe fatty liver but is not known to cause chronic liver disease.

Strong consensus (100% agreement)

Commentary: Severe malnutrition in children can cause fatty liver (482–484) which in general is fully reversible upon refeeding (483). In children with kwashiorkor, there seems to be a maladaptation associated with less efficient breakdown of fat and oxidation of fatty acids (485, 486) compared to children with marasmus. An impairment of fatty acid removal from the liver could not be observed (485). Malnutrition impairs specific hepatic functions like phase-I xenobiotic metabolism (85, 487, 488), galactose elimination capacity (85) or plasma levels of C-reactive protein in infected children (489, 490). In nutritional intervention trials in cirrhotic patients, quantitative liver function tests improved more, or more rapidly in treatment groups. Measures of liver function included antipyrine (183, 184) and aminopyrine (192) as well as galactose elimination capacity (183, 184, 196, 491). It is unknown, whether fatty liver of malnutrition can progress to chronic liver disease.

7.2 In adults / children, can overnutrition cause liver injury associated with a. biochemical signs of hepatocyte lesion, b. impaired liver function, c. abnormal liver histology, d. chronic liver disease?

Statement 15—Overnutrition can cause NAFLD or NASH which is a precursor condition for LC. Recommendations for the nutritional management of this condition are given in the section on NAFLD and NASH of these guidelines.

Strong consensus (100% agreement)

Commentary: The evidence available is reviewed in chapter 4 “NASH”.

7.3 In adults / children, can artificial nutrition (EN, PN) cause liver injury associated with a. biochemical signs of hepatocyte lesion, b. impaired liver function, c. abnormal liver histology, d. chronic liver disease?

Statement 16—In infants and children, PN can cause cholestasis, therefore named parenteral nutrition-associated cholestasis (PNAC) (BM)

Strong consensus (92% agreement)

Commentary: Due to the different features of PNAC in newborns and infants and parenteral nutrition associated liver disease (PNALD) in adults, as an exception PNAC is addressed as an exception in these guidelines on nutrition in adult liver patients.

Intestinal failure is the indication for long-term PN in many patients, particularly in infants and neonates and obviously, a clear distinction between intestinal failure vs. PN in the pathogenesis of ensuing liver injury is challenging in this population (492, 493). The beneficial effect of specialized nutrition protocols limiting the amount of lipid infused in neonates and infants as well as in adults point to the pathogenic role of PN in the development of cholestasis (see recommendations 84 and 85). A second independent factor causing liver damage is the extent of loss of intestinal mass as shown in the seminal paper by Stanko and colleagues showing an association between liver injury and extent of gut resection but not PN (494). Such intestinal failure associated liver disease (IFALD) and PNALD are difficult to separate in the individual patient and occur in up to 60 % of infants and up to 85 % of neonates who require long-term PN for intestinal failure (492, 495). Whereas adults are more likely to develop steatosis only, infants and neonates are more susceptible to hepatocellular injury or cholestasis, probably due to immature bile metabolism and transport (496). This is reflected in the term PNAC that is frequently used in the pediatric literature for this condition (497), whereas the term PNALD has been used in both adult and pediatric patients (493, 498, 499). In infants and neonates, mortality is high, up to 40 %, and PNAC has become a major indication for pediatric LT (497). In adults, the incidence of advanced IFALD/PNALD ranges from 0 % - 50 % and mortality ranges from 0 % - 22 % (492) progressive IFALD/PNALD is an accepted indication for a timely life-saving small bowel transplantation (500).

Statement 17—In adults, it is difficult to differentiate between the role of the underlying condition (extensive small bowel resection, sepsis) and that of PN in the pathogenesis of PNALD. (BM).

Strong consensus (100% agreement)

Commentary: Cholestatic liver injury occurs in 50 % of patients on long-term home PN (501). In 1985, Bowyer and colleagues (502) described steatohepatitis in nine out of 60 patients on long-term PN. Liver injury persisted for a median of 15 months (8 to 95) and progressed to cirrhosis in three patients. In their seminal paper Stanko and colleagues (494) studied adults who had been on PN for one year. They found normal liver enzymes in those who had no or only modest loss of intestine while 4/6 patients with massive loss of intestine developed progressive cholestasis and steatohepatitis four to ten months after the initiation of PN. Their observation demonstrated that liver injury can occur not only as a sequel of PN – termed PNALD – but also by intestinal failure – termed IFALD. In clinical practice a clear distinction between IFALD or PNALD more often than not is difficult (492).

Grau and colleagues analyzed the association of liver disease and PN in 756 ICU patients on PN and/or EN (503). They showed that the patients who developed liver injury had a characteristic profile in the way that they had a higher multiple organ dysfunction score on admission, they were septic, and they were treated with total PN.

In adults, IFALD/PNALD is related to female gender, age, length of time on PN, total caloric intake, and lipid or glucose overload (495, 504). The pathogenesis of IFALD/PNALD is thought to be multifactorial including factors like disturbance of enterohepatic bile acid cycling, systemic infection, bacterial overgrowth, absence of enteral nutrients and composition of PN (492, 495, 498). Both lack and excess of specific components of PN are being discussed as causal for PNALD. The fatty acid composition of lipid emulsions (501) as well as choline deficiency (505), and manganese toxicity (495, 498) have been linked to the occurrence of hepatic steatosis and cholestasis in adults and children.

7.4 In adults / children, can specialized nutrition protocols when compared to no such protocols improve/prevent a. biochemical signs of hepatocyte lesion, b. impaired liver function, c. abnormal liver histology, d. chronic liver disease?

Recommendation 83—In infants, children and adults, specialized nutrition protocols making optimal use of EN should be implemented. (BM)

Grade of recommendation B – Strong consensus (92% agreement)

Commentary: In infants and neonates, a number of reports suggest that the institution of specialized nutrition protocols is beneficial in achieving intestinal rehabilitation. Such protocols aim at limiting the infusion of soy-bean based lipid (506–510) and maximizing oral and enteral stimulation (507–510) and administering cyclic PN (507, 508, 511). A retrospective study showed that the implementation of feeding guidelines resulted in decreased times without nutrition, shorter duration of PN support, and significantly fewer infants developed PNALD after guideline implementation (512). In a multiple-variable

analysis septic episodes (odds ratio 3.23), days of lipid $>2.5 \text{ g}\cdot\text{kg}^{-1}\cdot\text{d}^{-1}$ (odds ratio 1.04), and 60 days of maximal lipid (odds ratio 10) were found to be the key elements for the development of PNAC (513). A pilot study comparing standard ($3.0 \text{ g}\cdot\text{kg}^{-1}\cdot\text{d}^{-1}$) vs reduced ($1.0 \text{ g}\cdot\text{kg}^{-1}\cdot\text{d}^{-1}$) lipid dose showed a slower rise of cholestasis markers using reduced lipid doses (514). The role of a limited lipid administration (515) is also strengthened by reports of a beneficial effect of a fish-oil emulsion given at $1.0 \text{ g}\cdot\text{kg}^{-1}\cdot\text{d}^{-1}$ when compared to traditional soy bean emulsions infused at $1\text{--}4 \text{ g}\cdot\text{kg}^{-1}\cdot\text{d}^{-1}$ (516–522). As a note of caution, the extent to which there is an overlap of cases reported in six separate publications of one group is unclear (517–520, 523).

In a recent ESPGHAN position paper (524) early EN limiting i. v. lipid to 15–30% of non-protein energy provided by PN and cyclic administration of PN once the patient is stable is recommended. The use of ursodeoxycholic acid (UDCA) and erythromycin has been reported to facilitate EN in premature infants on PN (525). The authors of the ASPEN clinical guidelines analyzed seven publications on this issue and found a very low level of evidence for a beneficial role of UDCA in the treatment of PNAC (493). They also analyzed the role of a multidisciplinary intestinal rehabilitation team in the management of IFALD and suggest to refer patients with PN-dependent intestinal failure to such a team conceding, however, a low level of evidence on this topic (493).

For the prevention of IFALD adults, the ESPEN guidelines (492) recommend infection control, maintenance of oral and/or enteral intake, cycled PN (526), avoidance of PN overfeeding and limiting the dose of soybean-oil based lipid to $1.0 \text{ g}\cdot\text{kg}^{-1}\cdot\text{d}^{-1}$ (527).

7.5 In adults / children, can special components (e.g. omega-3 FA) of the nutrition solution when compared to a standard nutrition solution improve/prevent a. biochemical signs of hepatocyte lesion, b. impaired liver function, c. abnormal liver histology, d. chronic liver disease?

Recommendation 84—In case of PNAC in infants and children, lipid emulsions enriched with omega-3-fatty acids can be used. (BM)

Grade of recommendation 0 – Strong consensus (100% agreement)

Commentary: Lipid emulsions containing fish oils as the triglyceride source were proposed to be protective in PNALD. This has been evaluated in a number of publications including cases, case series, or cohort data. In these reports a 100 % fish-oil emulsion was infused at a rate limited to $1.0 \text{ g}\cdot\text{kg}^{-1}\cdot\text{d}^{-1}$ whereas the soy-bean emulsion was given at rates up to $4.0 \text{ g}\cdot\text{kg}^{-1}\cdot\text{d}^{-1}$ and thus, it cannot be excluded that the quantity of lipid infused rather than its composition determined the observed improved outcome (516–523, 528, 529). In a retrospective analysis of 51 pediatric PNALD patients with cirrhosis the use of a fish-oil based lipid emulsion was accompanied by a resolution of cholestasis in 76 % (530). A randomized controlled trial comparing a 100 % fish-oil emulsion with a soy-bean lipid emulsion both at a dose of $1.0 \text{ g}\cdot\text{kg}^{-1}\cdot\text{d}^{-1}$ was terminated early because of an unexpectedly low incidence of PNAC (531). No patient developed fatty acid deficiency and both regimens were well tolerated and safe.

In a different approach, the reduction of soy-bean based lipid has been achieved by adding a fish-oil emulsion (510), or using lipid emulsions consisting of a mixture of either soy-bean based lipid and medium-chained triglyceride MCT-lipid (507, 532), or a mixture of a fish-oil emulsion and a soy-bean olive-oil emulsion (533), or soy-bean based lipid and olive oil and MCT-lipid and fish-oil (SMOF emulsion) (532, 534–538). In randomized controlled trials comparing a SMOF emulsion with a soy-bean based emulsion the fish-oil containing SMOF emulsion proved to be safe and more effective in reducing bilirubin levels or oxidative stress (534, 536–538).

In an analysis of 292 infants receiving more than one day of PN postoperatively, 31 infants reached a serum bilirubin > 100 $\mu\text{mol/L}$ and 13 developed liver failure, whereas 86 (83 %) reaching a serum bilirubin > 33 $\mu\text{mol/L}$ could be weaned off PN (539). The authors question the routine use of a fish-oil emulsion in such a population outside of formal research protocols.

These results again bring into focus the uncertainty in the diagnosis of IFALD, PNALD and PNAC (492, 493) because cholestasis alone is not necessarily equivalent to liver injury and in this view PNAC may be seen as a component of PNALD.

Both, the ASPEN guidelines paper on PNALD (493) and the ESPGHAN position paper on intestinal failure (524) conclude that currently there is no sound evidence favoring a specific lipid emulsion and that soy-bean based lipid infusion should be limited in hyperbilirubinemia. Despite promising observations, the role of fish-oil emulsions needs to be established in randomized controlled trials. The authors of the ASPEN guideline delineate four questions to be answered (493):

1. Will a long-term reduction in soy-based fat emulsion dose to $1.0 \text{ g}\cdot\text{kg}^{-1}\cdot\text{d}^{-1}$ result in adequate growth and neurological development, and will essential fatty acid deficiency be prevented?
2. Is a fish-oil emulsion more effective than an equivalently dosed soy-based emulsion at preventing PNALD, promoting neurological development?
3. What is the incidence of essential fatty acid deficiency if the low dose is given over a long duration, and how should essential fatty acid deficiency be tracked in these individuals?
4. Is SMOF given at conventional lipid doses effective at preventing the development of PNALD while optimizing growth and development over the long term?

Recommendation 85—In adults with suspected PNALD, lipid emulsions with a reduced n6/n3 ratio can be used. (BM)

Grade of recommendation 0 – Strong consensus (92% agreement)

Commentary: In adults, less data is available regarding the effect of modifying quantity and/or composition of parenteral lipid on the course of PNALD. Limiting soy-bean based lipid to $1.0 \text{ g}\cdot\text{kg}^{-1}\cdot\text{d}^{-1}$ has been suggested also in adults (527). The exchange of soy-bean

based lipid by a 100 % fish-oil emulsion has been reported effective in two cases of PNALD (540, 541). In a series of 15 patients, the addition of a fish-oil emulsion to a soy-bean based lipid emulsion was associated with reversal of biopsy proven PNALD (542). In one case, the use of a fish-oil emulsion together with an olive-oil based PN regimen was associated with a reduction in liver steatosis and inflammation (543). Taken together, more data are needed before the routine use of fish-oil containing fat emulsions can be recommended for the treatment of PNALD (492).

Acknowledgement

The authors express their gratitude to Anna Schweinlin for expert assistance in this guideline project.

We also thank Cees Smit for his participation as patient representative at the final consensus conference in April 2017 and his advices on the manuscript.

Abbreviations

ALF	acute liver failure
ASH	alcoholic steatohepatitis
BCAA	branched chain amino acids
CT	computed tomography
DXA	dual energy X-ray absorptiometry
EN	enteral nutrition
GL	guideline
HCC	hepatocellular carcinoma
HE	hepatic encephalopathy
ICU	intensive care unit
IFALD	intestinal failure associated liver disease
LC	liver cirrhosis
LT	liver transplantation
MCT	medium-chain triglyceride
MEDD	Mediterranean diet
MRT	magnetic resonance tomography
NAFL	non-alcoholic fatty liver
NAFLD	non-alcoholic fatty liver disease
NASH	non-alcoholic steatohepatitis

OLT	orthotopic liver transplant
ONS	oral nutritional supplements
PEG	percutaneous endoscopic gastrostomy
PN	parenteral nutrition
PNAC	parenteral nutrition-associated cholestasis
PNALD	parenteral nutrition associated liver disease
REE	resting energy expenditure
RFH-NPT	Royal Free Hospital Nutrition Prioritizing Tool
RFH-SGA	Royal Free Hospital SGA
SGA	subjective global assessment
SMOF	soy-bean based lipid and olive oil and MCT-lipid and fish oil
UDCA	ursodeoxycholic acid
VA study	Veteran Affairs study

References

1. Patek AJ, Post J. Treatment of cirrhosis of the liver by a nutritious diet and supplements rich in vitamin B complex. *The Journal of clinical investigation* 1941;20(5):481–505. [PubMed: 16694854]
2. Child CGTJ. Surgery and portal hypertension. In: CG C, editor. *The Liver and Portal Hypertension* Philadelphia: Saunders; 1964 p. 50–1.
3. Plauth M, Merli M, Kondrup J, Weimann A, Ferenci P, Müller M, et al. ESPEN guidelines for nutrition in liver disease and transplantation. *Clin Nutr* 1997;16(2):43–55. [PubMed: 16844569]
4. Plauth M, Cabre E, Riggio O, Assis-Camilo M, Pirlich M, Kondrup J, et al. ESPEN Guidelines on Enteral Nutrition: Liver disease. *Clin Nutr* 2006;25(2):285–94. [PubMed: 16707194]
5. Plauth M, Cabre E, Campillo B, Kondrup J, Marchesini G, Schütz T, et al. ESPEN guidelines on parenteral nutrition: hepatology. *Clin Nutr* 2009;28(4):436–44. [PubMed: 19520466]
6. Bischoff SC, Singer P, Koller M, Barazzoni R, Cederholm T, van Gossum A. *Standard operating procedures for ESPEN guidelines and consensus papers* Elsevier; 2015.
7. Plauth M, Schütz T, Pirlich M, Canbay A, Committee dDS. S3-Leitlinie der Deutschen Gesellschaft für Ernährungsmedizin (DGEM) in Zusammenarbeit mit der GESKES, der AKE und der DGVS. *Aktuelle Ernährungsmedizin* 2014;39(01):e1–e42.
8. Scottish Intercollegiate Guidelines Network (SIGN). *SIGN 50: a guideline developer's handbook*. Revised version Edinburgh: SIGN 2014.
9. Koller M, Schütz T, Valentini L, Kopp I, Pichard C, Lochs H, et al. Outcome models in clinical studies: Implications for designing and evaluating trials in clinical nutrition. *Clin Nutr* 2013;32(4): 650–7. [PubMed: 23021606]
10. German Association of the Scientific Medical Societies (AWMF). *Standing Guidelines Commission. AWMF Guidance Manual and Rules for Guideline Development, 1st Edition 2012* English version.
11. Lautz H, Selberg O, Körber J, Bürger M, Müller M. Protein-calorie malnutrition in liver cirrhosis. *The clinical investigator* 1992;70(6):478–86. [PubMed: 1392415]

12. Mendenhall CL, Anderson S, Weesner RE, Goldberg SJ, Cronic KA. Protein-calorie malnutrition associated with alcoholic hepatitis: Veterans Administration Cooperative Study Group on alcoholic hepatitis. *The American journal of medicine* 1984;76(2):211–22. [PubMed: 6421159]
13. Cirrhosis NSI. Italian multicentre cooperative project on nutrition in liver cirrhosis. *J Hepatol* 1994;21(3):317–25. [PubMed: 7836699]
14. Peng S, Plank LD, McCall JL, Gillanders LK, McIlroy K, Gane EJ. Body composition, muscle function, and energy expenditure in patients with liver cirrhosis: a comprehensive study. *Am J Clin Nutr* 2007;85(5):1257–66. [PubMed: 17490961]
15. Prijatmoko D, Strauss BJ, Lambert JR, Sievert W, Stroud DB, Wahlqvist ML, et al. Early detection of protein depletion in alcoholic cirrhosis: role of body composition analysis. *Gastroenterology* 1993;105(6):1839–45. [PubMed: 8253360]
16. Selberg O, Böttcher J, Pirlich M, Henkel E, Manns MP, Müller MJ. Clinical significance and correlates of whole body potassium status in patients with liver cirrhosis. *Hepatol Res* 1999;16(1):36–48.
17. Mills PR, Shenkin A, Anthony RS, McLelland AS, Main A, MacSween R, et al. Assessment of nutritional status and in vivo immune responses in alcoholic liver disease. *The American journal of clinical nutrition* 1983;38(6):849–59. [PubMed: 6650446]
18. Schenker S, Halff GA, editors. *Nutritional therapy in alcoholic liver disease*. Semin Liver Dis; 1993.
19. Lieber CS. Alcohol, liver, and nutrition. *J Am Coll Nutr* 1991;10(6):602–32. [PubMed: 1770192]
20. Lindor KD, editor *Management of osteopenia of liver disease with special emphasis on primary biliary cirrhosis*. Semin Liver Dis; 1993.
21. Sam J, Nguyen GC. Protein-calorie malnutrition as a prognostic indicator of mortality among patients hospitalized with cirrhosis and portal hypertension. *Liver International* 2009;29(9):1396–402. [PubMed: 19602136]
22. Alberino F, Gatta A, Amodio P, Merkel C, Di Pascoli L, Boffo G, et al. Nutrition and survival in patients with liver cirrhosis. *Nutrition* 2001;17(6):445–50. [PubMed: 11399401]
23. Selberg O, Selberg D. Norms and correlates of bioimpedance phase angle in healthy human subjects, hospitalized patients, and patients with liver cirrhosis. *Eur J Appl Physiol* 2002;86(6):509–16. [PubMed: 11944099]
24. DiMartini A, Cruz RJ Jr., Dew MA, Myaskovsky L, Goodpaster B, Fox K, et al. Muscle mass predicts outcomes following liver transplantation. *Liver Transpl* 2013;19(11):1172–80. [PubMed: 23960026]
25. Harrison J, McKiernan J, Neuberger JM. A prospective study on the effect of recipient nutritional status on outcome in liver transplantation. *Transpl Int* 1997;10(5):369–74. [PubMed: 9287402]
26. Moukarzel AA, Najm I, Vargas J, McDiarmid SV, Busuttill RW, Ament ME. Effect of nutritional status on outcome of orthotopic liver transplantation in pediatric patients. *Transplant Proc* 1990;22(4):1560–3. [PubMed: 2389401]
27. Pikul J, Sharpe MD, Lowndes R, Ghent CN. Degree of preoperative malnutrition is predictive of postoperative morbidity and mortality in liver transplant recipients. *Transplantation* 1994;57(3):469–72. [PubMed: 8108888]
28. Figueiredo F, Dickson ER, Pasha T, Kasparova P, Therneau T, Malinchoc M, et al. Impact of nutritional status on outcomes after liver transplantation. *Transplantation* 2000;70(9):1347–52. [PubMed: 11087151]
29. Kalafateli M, Mantzoukis K, Choi Yau Y, Mohammad AO, Arora S, Rodrigues S, et al. Malnutrition and sarcopenia predict post-liver transplantation outcomes independently of the Model for End-stage Liver Disease score. *Journal of cachexia, sarcopenia and muscle* 2017;8(1):113–21.
30. Dharancy S, Lemyze M, Boleslawski E, Neviere R, Declerck N, Canva V, et al. Impact of impaired aerobic capacity on liver transplant candidates. *Transplantation* 2008;86(8):1077–83. [PubMed: 18946345]
31. Selberg O, Bottcher J, Tusch G, Pichlmayr R, Henkel E, Muller MJ. Identification of high- and low-risk patients before liver transplantation: a prospective cohort study of nutritional and metabolic parameters in 150 patients. *Hepatology* 1997;25(3):652–7. [PubMed: 9049214]

32. Epstein SK, Freeman RB, Khayat A, Unterborn JN, Pratt DS, Kaplan MM. Aerobic capacity is associated with 100-day outcome after hepatic transplantation. *Liver Transpl* 2004;10(3):418–24. [PubMed: 15004771]
33. Muller MJ, Lautz HU, Plogmann B, Burger M, Korber J, Schmidt FW. Energy expenditure and substrate oxidation in patients with cirrhosis: the impact of cause, clinical staging and nutritional state. *Hepatology* 1992;15(5):782–94. [PubMed: 1568718]
34. Englesbe MJ, Patel SP, He K, Lynch RJ, Schaubel DE, Harbaugh C, et al. Sarcopenia and mortality after liver transplantation. *J Am Coll Surg* 2010;211(2):271–8. [PubMed: 20670867]
35. Clemmesen JO, Kondrup J, Ott P. Splanchnic and leg exchange of amino acids and ammonia in acute liver failure. *Gastroenterology* 2000;118(6):1131–9. [PubMed: 10833488]
36. Record C, Buxton B, Chase R, Curzon G, Murray-Lyon I, Williams R. Plasma and brain amino acids in fulminant hepatic failure and their relationship to hepatic encephalopathy. *Eur J Clin Invest* 1976;6(1):387–94. [PubMed: 10164]
37. Rosen HM, Yoshimura N, Hodgman JM, Fischer JE. Plasma amino acid patterns in hepatic encephalopathy of differing etiology. *Gastroenterology* 1977;72(3):483–7. [PubMed: 832796]
38. Bernau J, Rueff B, Benhamou J-P, editors. Fulminant and subfulminant liver failure: definitions and causes. *Semin Liver Dis*; 1986.
39. Samson R, Trey C, Timme A, Saunders S. Fulminating hepatitis with recurrent hypoglycemia and hemorrhage. *Gastroenterology* 1967;53(2):291–&.
40. Vilstrup H, Iversen J, Tygstrup N. Glucoregulation in acute liver failure. *Eur J Clin Invest* 1986;16(3):193–7. [PubMed: 3089815]
41. Clemmesen JO, Høy C-E, Kondrup J, Ott P. Splanchnic metabolism of fuel substrates in acute liver failure. *J Hepatol* 2000;33(6):941–8. [PubMed: 11131456]
42. Owen OE, Reichle FA, Mozzoli MA, Kreulen T, Patel MS, Elfenbein IB, et al. Hepatic, gut, and renal substrate flux rates in patients with hepatic cirrhosis. *J Clin Invest* 1981;68(1):240–52. [PubMed: 7251861]
43. Owen O, Trapp V, Reichard G, Mozzoli M, Moctezuma J, Paul P, et al. Nature and quantity of fuels consumed in patients with alcoholic cirrhosis. *The Journal of clinical investigation* 1983;72(5):1821–32. [PubMed: 6630528]
44. Müller MJ, Willmann O, Rieger A, Fenk A, Selberg O, Lautz HU, et al. Mechanism of insulin resistance associated with liver cirrhosis. *Gastroenterology* 1992;102(6):2033–41. [PubMed: 1587421]
45. Selberg O, Burchert W, Vd Hoff J, Meyer GJ, Hundeshagen H, Radoch E, et al. Insulin resistance in liver cirrhosis. Positron-emission tomography scan analysis of skeletal muscle glucose metabolism. *The Journal of clinical investigation* 1993;91(5):1897–902. [PubMed: 8486761]
46. Kruszynska Y, Williams N, Perry M, Home P. The relationship between insulin sensitivity and skeletal muscle enzyme activities in hepatic cirrhosis. *Hepatology* 1988;8(6):1615–9. [PubMed: 3142811]
47. Selberg O, Radoch E, Walter GF, Müller MJ. Skeletal muscle glycogen content in patients with cirrhosis. *Hepatology* 1994;20(1):135–41. [PubMed: 8020882]
48. Bianchi G, Marchesini G, Zoli M, Bugianesi E, Fabbri A, Pisi E. Prognostic significance of diabetes in patients with cirrhosis. *Hepatology* 1994;20(1):119–25. [PubMed: 8020880]
49. Müller M, Pirlich M, Balks H, Selberg O. Glucose intolerance in liver cirrhosis: role of hepatic and non-hepatic influences. *Clin Chem Lab Med* 1994;32(10):749–58.
50. Kalaitzakis E, Olsson R, Henfridsson P, Hugosson I, Bengtsson M, Jalan R, et al. Malnutrition and diabetes mellitus are related to hepatic encephalopathy in patients with liver cirrhosis. *Liver International* 2007;27(9):1194–201. [PubMed: 17919230]
51. Merli M, Eriksson LS, Hagenfeldt L, Wahren J. Splanchnic and leg exchange of free fatty acids in patients with liver cirrhosis. *J Hepatol* 1986;3(3):348–55. [PubMed: 3559145]
52. Merli M, Riggio O, Romiti A, Ariosto F, Mango L, Pinto G, et al. Basal energy production rate and substrate use in stable cirrhotic patients. *Hepatology* 1990;12(1):106–12. [PubMed: 2373471]
53. Müller MJ, Lautz HU, Plogmann B, Bürger M, Körber J, Schmidt FW. Energy expenditure and substrate oxidation in patients with cirrhosis: the impact of cause, clinical staging and nutritional state. *Hepatology* 1992;15(5):782–94. [PubMed: 1568718]

54. Muller MJ, Fenk A, Lautz HU, Selberg O, Canzler H, Balks HJ, et al. Energy expenditure and substrate metabolism in ethanol-induced liver cirrhosis. *American Journal of Physiology-Endocrinology And Metabolism* 1991;260(3):E338–E44.
55. Riggio O, Merli M, Romiti A, Pinto G, Fanella R, Attili AF, et al. Early postprandial energy expenditure and macronutrient use after a mixed meal in cirrhotic patients. *Journal of Parenteral and Enteral Nutrition* 1992;16(5):445–50. [PubMed: 1433778]
56. Druml W, Fischer M, Pidlich J, Lenz K. Fat elimination in chronic hepatic failure: long-chain vs medium-chain triglycerides. *The American journal of clinical nutrition* 1995;61(4):812–7. [PubMed: 7702024]
57. Müller M, Rieger A, Willmann O, Lautz H, Balks H, Von Zur Mühlen A, et al. Metabolic responses to lipid infusions in patients with liver cirrhosis. *Clin Nutr* 1992;11(4):193–206. [PubMed: 16839998]
58. Cabre E, Abad-Lacruz A, Nunez M, González-Huix F, Fernandez-Banares F, Gil A, et al. The relationship of plasma polyunsaturated fatty acid deficiency with survival in advanced liver cirrhosis: multivariate analysis. *Am J Gastroenterol* 1993;88(5).
59. Cabre E, Nunez M, Gonzalez-Huin F, Fernandez-Banares F, Abad A, Gil A, et al. Clinical and nutritional factors predictive of plasma lipid unsaturation deficiency in advanced liver cirrhosis: a logistic regression analysis. *Am J Gastroenterol* 1993;88(10).
60. Croci I, Byrne NM, Choquette S, Hills AP, Chachay VS, Clouston AD, et al. Whole-body substrate metabolism is associated with disease severity in patients with non-alcoholic fatty liver disease. *Gut* 2012;gutjnl-2012-302789.
61. McCullough AJ, Tavill AS, editors. *Disordered energy and protein metabolism in liver disease. Semin Liver Dis*; 1991.
62. Hirsch S, de la Maza MP, Gattás V, Barrera G, Petermann M, Gotteland M, et al. Nutritional support in alcoholic cirrhotic patients improves host defenses. *J Am Coll Nutr* 1999;18(5):434–41. [PubMed: 10511325]
63. Ballmer PE, Reichen J, McNurlan MA, Sterchi A, Anderson SE, Garlick PJ. Albumin but not fibrinogen synthesis correlates with galactose elimination capacity in patients with cirrhosis of the liver. *Hepatology* 1996;24(1):53–9. [PubMed: 8707282]
64. Ballmer PE, Walshe D, McNurlan MA, Watson H, Brunt PW, Garlic PJ. Albumin synthesis rates in cirrhosis: Correlation with child-turcotte classification. *Hepatology* 1993;18(2):292–7. [PubMed: 8340057]
65. Nielsen K, Kondrup J, Martinsen L, Døssing H, Larsson B, Stilling B, et al. Long-term oral refeeding of patients with cirrhosis of the liver. *Br J Nutr* 1995;74(4):557–67. [PubMed: 7577893]
66. Schütz T, Bechstein W-O, Neuhaus P, Lochs H, Plauth M. Clinical practice of nutrition in acute liver failure—a European survey. *Clin Nutr* 2004;23(5):975–82. [PubMed: 15380885]
67. Schneeweiss B, Pammer J, Ratheiser K, Schneider B, Madl C, Kramer L, et al. Energy metabolism in acute hepatic failure. *Gastroenterology* 1993;105(5):1515–21. [PubMed: 8224656]
68. Walsh TS, Wigmore SJ, Hopton P, Richardson R, Lee A. Energy expenditure in acetaminophen-induced fulminant hepatic failure. *Crit Care Med* 2000;28(3):649–54. [PubMed: 10752809]
69. Campillo B, Bories P, Pornin B, Devanlay M, Linsker S, Guillemin A, et al. Energy expenditure and the use of nutrients in cirrhotic patients fasting and at rest. Influence of alcoholic hepatitis and the severity score of the disease. *Gastroenterol Clin Biol* 1989;13(6–7):544–50. [PubMed: 2753301]
70. John WJ, Phillips R, Ott L, Adams LJ, McClain CJ. Resting energy expenditure in patients with alcoholic hepatitis. *Journal of Parenteral and Enteral Nutrition* 1989;13(2):124–7. [PubMed: 2709599]
71. Pierrugues R, Blanc P, Daures J, Michel H. Relationship of resting energy expenditure with liver function and nutritional status in patients with alcoholic cirrhosis. *Nutrition (Burbank, Los Angeles County, Calif)* 1992;8(1):22–5.
72. Jhangiani SS, Agarwal N, Holmes R, Cayten C, Pitchumoni C. Energy expenditure in chronic alcoholics with and without liver disease. *The American journal of clinical nutrition* 1986;44(3):323–9. [PubMed: 3092630]

73. Levine J, Harris M, Morgan M. Energy expenditure in chronic alcohol abuse. *Eur J Clin Invest* 2000;30(9):779–86. [PubMed: 10998077]
74. Addolorato G, Capristo E, Caputo F, Greco AV, Ceccanti M, Stefanini GF, et al. Nutritional status and body fluid distribution in chronic alcoholics compared with controls. *Alcoholism: Clinical and Experimental Research* 1999;23(7):1232–7.
75. Tarantino G, Marra M, Contaldo F, Pasanisi F. Basal metabolic rate in morbidly obese patients with non-alcoholic fatty liver disease. *Clinical & Investigative Medicine* 2008;31(1):24–9.
76. Kotronen A, Seppälä-Lindroos A, Vehkavaara S, Bergholm R, Frayn KN, Fielding BA, et al. Liver fat and lipid oxidation in humans. *Liver International* 2009;29(9):1439–46. [PubMed: 19602132]
77. Perseghin G, Mazzaferro V, Benedini S, Pulvirenti A, Coppa J, Regalia E, et al. Resting energy expenditure in diabetic and nondiabetic patients with liver cirrhosis: relation with insulin sensitivity and effect of liver transplantation and immunosuppressive therapy. *The American journal of clinical nutrition* 2002;76(3):541–8. [PubMed: 12197997]
78. Shanbhogue RL, Bistrrian BR, Jenkins RL, Jones C, Benotti P, Blackburn GL. Resting energy expenditure in patients with end-stage liver disease and in normal population. *Journal of Parenteral and Enteral Nutrition* 1987;11(3):305–8. [PubMed: 3599357]
79. Madden AM, Morgan MY. Resting energy expenditure should be measured in patients with cirrhosis, not predicted. *Hepatology* 1999;30(3):655–64. [PubMed: 10462371]
80. Mathur S, Peng S, Gane EJ, McCall JL, Plank LD. Hypermetabolism predicts reduced transplant-free survival independent of MELD and Child-Pugh scores in liver cirrhosis. *Nutrition* 2007;23(5):398–403. [PubMed: 17395427]
81. Müller MJ, Böttcher J, Selberg O, Weselmann S, Böker KH, Schwarze M, et al. Hypermetabolism in clinically stable patients with liver cirrhosis. *The American journal of clinical nutrition* 1999;69(6):1194–201. [PubMed: 10357739]
82. Plauth M, Schütz T, Buckendahl DP, Kreymann G, Pirlich M, Grüngreiff S, et al. Weight gain after transjugular intrahepatic portosystemic shunt is associated with improvement in body composition in malnourished patients with cirrhosis and hypermetabolism. *J Hepatol* 2004;40(2):228–33. [PubMed: 14739092]
83. Hipskind P, Glass C, Charlton D, Nowak D, Dasarathy S. Do handheld calorimeters have a role in assessment of nutrition needs in hospitalized patients? A systematic review of literature. *Nutr Clin Pract* 2011;26(4):426–33. [PubMed: 21775638]
84. Glass C, Hipskind P, Cole D, Lopez R, Dasarathy S. Handheld calorimeter is a valid instrument to quantify resting energy expenditure in hospitalized cirrhotic patients: a prospective study. *Nutr Clin Pract* 2012;27(5):677–88. [PubMed: 22668853]
85. Nielsen K, Kondrup J, Martinsen L, Stilling B, Wikman B. Nutritional assessment and adequacy of dietary intake in hospitalized patients with alcoholic liver cirrhosis. *Br J Nutr* 1993;69(3):665–79. [PubMed: 8329343]
86. Campillo B, Bories PN, Devanlay M, Sommer F, Wirquin E, Fouet P. The thermogenic and metabolic effects of food in liver cirrhosis: consequences on the storage of nutrients and the hormonal counterregulatory response. *Metabolism* 1992;41(5):476–82. [PubMed: 1588825]
87. DeLissio M, Goodyear LJ, Fuller S, Krawitt EL, Devlin JT. Effects of treadmill exercise on fuel metabolism in hepatic cirrhosis. *Journal of applied physiology (Bethesda, Md: 1985)* 1991;70(1):210–5.
88. Muller MJ, Dettmer A, Tettenborn M, Radoch E, Fichter J, Wagner TO, et al. Metabolic, endocrine, haemodynamic and pulmonary responses to different types of exercise in individuals with normal or reduced liver function. *Eur J Appl Physiol Occup Physiol* 1996;74(3):246–57. [PubMed: 8897031]
89. Kondrup J, Muller MJ. Energy and protein requirements of patients with chronic liver disease. *J Hepatol* 1997;27(1):239–47. [PubMed: 9252101]
90. Dolz C, Raurich JM, Ibanez J, Obrador A, Marse P, Gaya J. Ascites increases the resting energy expenditure in liver cirrhosis. *Gastroenterology* 1991;100(3):738–44. [PubMed: 1993495]
91. Weimann A, Braga M, Carli F, Higashiguchi T, Hubner M, Klek S, et al. ESPEN guideline: Clinical nutrition in surgery. *Clin Nutr* 2017;36(3):623–50. [PubMed: 28385477]

92. Plevak DJ, DiCecco SR, Wiesner RH, Porayko MK, Wahlstrom HE, Janzow DJ, et al. Nutritional support for liver transplantation: identifying caloric and protein requirements. *Mayo Clin Proc* 1994;69(3):225–30. [PubMed: 8133659]
93. Weimann A, Kuse ER, Bechstein WO, Neuberger JM, Plauth M, Pichlmayr R. Perioperative parenteral and enteral nutrition for patients undergoing orthotopic liver transplantation. Results of a questionnaire from 16 European transplant units. *Transpl Int* 1998;11 Suppl 1:S289–91. [PubMed: 9664999]
94. Plank LD, Metzger DJ, McCall JL, Barclay KL, Gane EJ, Streat SJ, et al. Sequential changes in the metabolic response to orthotopic liver transplantation during the first year after surgery. *Ann Surg* 2001;234(2):245–55. [PubMed: 11505071]
95. Hussaini SH, Oldroyd B, Stewart SP, Soo S, Roman F, Smith MA, et al. Effects of orthotopic liver transplantation on body composition. *Liver* 1998;18(3):173–9. [PubMed: 9716227]
96. Tietge UJ, Selberg O, Kreter A, Bahr MJ, Pirlich M, Burchert W, et al. Alterations in glucose metabolism associated with liver cirrhosis persist in the clinically stable long-term course after liver transplantation. *Liver Transpl* 2004;10(8):1030–40. [PubMed: 15390330]
97. Laryea M, Watt KD, Molinari M, Walsh MJ, McAlister VC, Marotta PJ, et al. Metabolic syndrome in liver transplant recipients: prevalence and association with major vascular events. *Liver Transpl* 2007;13(8):1109–14. [PubMed: 17663411]
98. Merli M, Giusto M, Riggio O, Gentili F, Molinaro A, Attili AF, et al. Improvement of nutritional status in malnourished cirrhotic patients one year after liver transplantation. *E Spen Eur E J Clin Nutr Metab* 2011;6(3):e142–e7.
99. Schutz T, Hudjetz H, Roske AE, Katzorke C, Kreymann G, Budde K, et al. Weight gain in long-term survivors of kidney or liver transplantation--another paradigm of sarcopenic obesity? *Nutrition* 2012;28(4):378–83. [PubMed: 22304858]
100. Krasnoff JB, Vintro AQ, Ascher NL, Bass NM, Dodd MJ, Painter PL. Objective measures of health-related quality of life over 24 months post-liver transplantation. *Clin Transplant* 2005;19(1):1–9. [PubMed: 15659126]
101. Wiesinger GF, Quittan M, Zimmermann K, Nuhr M, Wichlas M, Bodingbauer M, et al. Physical performance and health-related quality of life in men on a liver transplantation waiting list. *J Rehabil Med* 2001;33(6):260–5. [PubMed: 11766955]
102. Dunn MA, Josbeno DA, Schmotzer AR, Tevar AD, DiMartini AF, Landsittel DP, et al. The gap between clinically assessed physical performance and objective physical activity in liver transplant candidates. *Liver Transpl* 2016;22(10):1324–32. [PubMed: 27348200]
103. Roman E, Torrades MT, Nadal MJ, Cardenas G, Nieto JC, Vidal S, et al. Randomized pilot study: effects of an exercise programme and leucine supplementation in patients with cirrhosis. *Dig Dis Sci* 2014;59(8):1966–75. [PubMed: 24599772]
104. Pieber K, Crevenna R, Nuhr MJ, Quittan M, Peck-Radosavljevic M, Fialka-Moser V, et al. Aerobic capacity, muscle strength and health-related quality of life before and after orthotopic liver transplantation: preliminary data of an Austrian transplantation centre. *J Rehabil Med* 2006;38(5):322–8. [PubMed: 16931463]
105. Williams TJ, McKenna MJ. Exercise limitation following transplantation. *Comprehensive Physiology* 2012;2(3):1937–79. [PubMed: 23723030]
106. Krasnoff JB, Vintro AQ, Ascher NL, Bass NM, Paul SM, Dodd MJ, et al. A randomized trial of exercise and dietary counseling after liver transplantation. *Am J Transplant* 2006;6(8):1896–905. [PubMed: 16889545]
107. Rutherford A, Davern T, Hay JE, Murray NG, Hassanein T, Lee WM, et al. Influence of high body mass index on outcome in acute liver failure. *Clin Gastroenterol Hepatol* 2006;4(12):1544–9. [PubMed: 16996806]
108. Canbay A, Chen SY, Gieseler RK, Malago M, Karliova M, Gerken G, et al. Overweight patients are more susceptible for acute liver failure. *Hepatogastroenterology* 2005;52(65):1516–20. [PubMed: 16201109]
109. De Caprio C, Alfano A, Senatore I, Zarrella L, Pasanisi F, Contaldo F. Severe acute liver damage in anorexia nervosa: two case reports. *Nutrition* 2006;22(5):572–5. [PubMed: 16600819]

110. Rautou PE, Cazals-Hatem D, Moreau R, Francoz C, Feldmann G, Lebrech D, et al. Acute liver cell damage in patients with anorexia nervosa: a possible role of starvation-induced hepatocyte autophagy. *Gastroenterology* 2008;135(3):840–8, 8.e1–3. [PubMed: 18644371]
111. Mendenhall CL, Moritz TE, Roselle GA, Morgan TR, Nemchausky BA, Tamburro CH, et al. A study of oral nutritional support with oxandrolone in malnourished patients with alcoholic hepatitis: results of a Department of Veterans Affairs cooperative study. *Hepatology* 1993;17(4):564–76. [PubMed: 8477961]
112. Mendenhall CL, Moritz TE, Roselle GA, Morgan TR, Nemchausky BA, Tamburro CH, et al. Protein energy malnutrition in severe alcoholic hepatitis: diagnosis and response to treatment. The VA Cooperative Study Group #275. *JPEN J Parenter Enteral Nutr* 1995;19(4):258–65. [PubMed: 8523623]
113. Mendenhall CL, Tosch T, Weesner RE, Garcia-Pont P, Goldberg SJ, Kiernan T, et al. VA cooperative study on alcoholic hepatitis. II: Prognostic significance of protein-calorie malnutrition. *Am J Clin Nutr* 1986;43(2):213–8. [PubMed: 3080866]
114. Moreno C, Deltenre P, Senterre C, Louvet A, Gustot T, Bastens B, et al. Intensive Enteral Nutrition Is Ineffective for Patients With Severe Alcoholic Hepatitis Treated With Corticosteroids. *Gastroenterology* 2016;150(4):903–10.e8. [PubMed: 26764182]
115. Caregaro L, Alberino F, Amodio P, Merkel C, Bolognesi M, Angeli P, et al. Malnutrition in alcoholic and virus-related cirrhosis. *Am J Clin Nutr* 1996;63(4):602–9. [PubMed: 8599326]
116. Merli M, Riggio O, Dally L. Does malnutrition affect survival in cirrhosis? PINC (Policentrica Italiana Nutrizione Cirrosi). *Hepatology* 1996;23(5):1041–6. [PubMed: 8621131]
117. Merli M, Giusto M, Gentili F, Novelli G, Ferretti G, Riggio O, et al. Nutritional status: its influence on the outcome of patients undergoing liver transplantation. *Liver international: official journal of the International Association for the Study of the Liver* 2010;30(2):208–14. [PubMed: 19840246]
118. Merli M, Giusto M, Lucidi C, Giannelli V, Pentassuglio I, Di Gregorio V, et al. Muscle depletion increases the risk of overt and minimal hepatic encephalopathy: results of a prospective study. *Metab Brain Dis* 2013;28(2):281–4. [PubMed: 23224378]
119. Soros P, Bottcher J, Weissenborn K, Selberg O, Muller MJ. Malnutrition and hypermetabolism are not risk factors for the presence of hepatic encephalopathy: a cross-sectional study. *J Gastroenterol Hepatol* 2008;23(4):606–10. [PubMed: 18005013]
120. EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. *J Hepatol* 2016;64(6):1388–402. [PubMed: 27062661]
121. Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. *Gastroenterology* 2012;142(7):1592–609. [PubMed: 22656328]
122. Caldwell S, Argo C. The natural history of non-alcoholic fatty liver disease. *Dig Dis* 2010;28(1):162–8. [PubMed: 20460906]
123. Musso G, Gambino R, Cassader M, Pagano G. Meta-analysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity. *Ann Med* 2011;43(8):617–49. [PubMed: 21039302]
124. Targher G, Day CP. Liver enzymes, nonalcoholic fatty liver disease, and incident cardiovascular disease. *Hepatology* 2011;53(1):375.
125. Hafliadottir S, Jonasson JG, Norland H, Einarsdottir SO, Kleiner DE, Lund SH, et al. Long-term follow-up and liver-related death rate in patients with non-alcoholic and alcoholic related fatty liver disease. *BMC Gastroenterol* 2014;14:166. [PubMed: 25260964]
126. Dick AA, Spitzer AL, Seifert CF, Deckert A, Carithers RL Jr., Reyes JD, et al. Liver transplantation at the extremes of the body mass index. *Liver Transpl* 2009;15(8):968–77. [PubMed: 19642131]
127. Nair S, Verma S, Thuluvath PJ. Obesity and its effect on survival in patients undergoing orthotopic liver transplantation in the United States. *Hepatology* 2002;35(1):105–9. [PubMed: 11786965]

128. Loomba R, Abraham M, Unalp A, Wilson L, Lavine J, Doo E, et al. Association between diabetes, family history of diabetes, and risk of nonalcoholic steatohepatitis and fibrosis. *Hepatology* 2012;56(3):943–51. [PubMed: 22505194]
129. Vernon G, Baranova A, Younossi ZM. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. *Aliment Pharmacol Ther* 2011;34(3):274–85. [PubMed: 21623852]
130. Fracanzani AL, Valenti L, Bugianesi E, Andreoletti M, Colli A, Vanni E, et al. Risk of severe liver disease in nonalcoholic fatty liver disease with normal aminotransferase levels: a role for insulin resistance and diabetes. *Hepatology* 2008;48(3):792–8. [PubMed: 18752331]
131. Armstrong MJ, Adams LA, Canbay A, Syn WK. Extrahepatic complications of nonalcoholic fatty liver disease. *Hepatology* 2014;59(3):1174–97. [PubMed: 24002776]
132. Kondrup J, Rasmussen HH, Hamberg O, Stanga Z. Nutritional risk screening (NRS 2002): a new method based on an analysis of controlled clinical trials. *Clin Nutr* 2003;22(3):321–36. [PubMed: 12765673]
133. Sorensen J, Kondrup J, Prokopowicz J, Schiesser M, Krahenbuhl L, Meier R, et al. EuroOOPS: an international, multicentre study to implement nutritional risk screening and evaluate clinical outcome. *Clin Nutr* 2008;27(3):340–9. [PubMed: 18504063]
134. Kondrup J, Allison SP, Elia M, Vellas B, Plauth M. ESPEN guidelines for nutrition screening 2002. *Clin Nutr* 2003;22(4):415–21. [PubMed: 12880610]
135. Amodio P, Bemeur C, Butterworth R, Cordoba J, Kato A, Montagnese S, et al. The nutritional management of hepatic encephalopathy in patients with cirrhosis: International Society for Hepatic Encephalopathy and Nitrogen Metabolism Consensus. *Hepatology* 2013;58(1):325–36. [PubMed: 23471642]
136. Arora S, Mattina C, McAnenny C, O’Sullivan N, McGeeney L, Calder N, et al. The development and validation of a nutritional prioritising tool for use in patients with chronic liver disease. *J Hepatol* 2012;56:S241.
137. Borhofen SM, Gerner C, Lehmann J, Fimmers R, Gortzen J, Hey B, et al. The Royal Free Hospital-Nutritional Prioritizing Tool Is an Independent Predictor of Deterioration of Liver Function and Survival in Cirrhosis. *Dig Dis Sci* 2016;61(6):1735–43. [PubMed: 26725059]
138. Schutte K, Tippelt B, Schulz C, Rohl FW, Feneberg A, Seidensticker R, et al. Malnutrition is a prognostic factor in patients with hepatocellular carcinoma (HCC). *Clin Nutr* 2015;34(6):1122–7. [PubMed: 25434576]
139. Tandon P, Raman M, Mourtzakis M, Merli M. A practical approach to nutritional screening and assessment in cirrhosis. *Hepatology* 2017;65(3):1044–57. [PubMed: 28027577]
140. Figueiredo FA, Perez RM, Freitas MM, Kondo M. Comparison of three methods of nutritional assessment in liver cirrhosis: subjective global assessment, traditional nutritional parameters, and body composition analysis. *J Gastroenterol* 2006;41(5):476–82. [PubMed: 16799890]
141. Morgan MY, Madden AM, Jennings G, Elia M, Fuller NJ. Two-component models are of limited value for the assessment of body composition in patients with cirrhosis. *Am J Clin Nutr* 2006;84(5):1151–62. [PubMed: 17093169]
142. Pirlich M, Schutz T, Spachos T, Ertl S, Weiss ML, Lochs H, et al. Bioelectrical impedance analysis is a useful bedside technique to assess malnutrition in cirrhotic patients with and without ascites. *Hepatology* 2000;32(6):1208–15. [PubMed: 11093726]
143. Mendenhall C, Roselle GA, Gartside P, Moritz T. Relationship of protein calorie malnutrition to alcoholic liver disease: a reexamination of data from two Veterans Administration Cooperative Studies. *Alcohol Clin Exp Res* 1995;19(3):635–41. [PubMed: 7573786]
144. Peres WA, Lento DF, Baluz K, Ramalho A. Phase angle as a nutritional evaluation tool in all stages of chronic liver disease. *Nutr Hosp* 2012;27(6):2072–8. [PubMed: 23588459]
145. Morgan MY, Madden AM, Soulsby CT, Morris RW. Derivation and validation of a new global method for assessing nutritional status in patients with cirrhosis. *Hepatology* 2006;44(4):823–35. [PubMed: 17006918]
146. Gunsar F, Raimondo ML, Jones S, Terreni N, Wong C, Patch D, et al. Nutritional status and prognosis in cirrhotic patients. *Aliment Pharmacol Ther* 2006;24(4):563–72. [PubMed: 16827812]

147. Figueiredo FA, Dickson ER, Pasha TM, Porayko MK, Therneau TM, Malinchoc M, et al. Utility of standard nutritional parameters in detecting body cell mass depletion in patients with end-stage liver disease. *Liver Transpl* 2000;6(5):575–81. [PubMed: 10980056]
148. Huisman EJ, Trip EJ, Siersema PD, van Hoek B, van Erpecum KJ. Protein energy malnutrition predicts complications in liver cirrhosis. *Eur J Gastroenterol Hepatol* 2011;23(11):982–9. [PubMed: 21971339]
149. Alvares-da-Silva MR, Reverbel da Silveira T. Comparison between handgrip strength, subjective global assessment, and prognostic nutritional index in assessing malnutrition and predicting clinical outcome in cirrhotic outpatients. *Nutrition* 2005;21(2):113–7. [PubMed: 15723736]
150. Stanca CM, Bach N, Krause C, Tandon N, Freni MA, Gutierrez JA, et al. Evaluation of fatigue in U.S. patients with primary biliary cirrhosis. *Am J Gastroenterol* 2005;100(5):1104–9. [PubMed: 15842585]
151. Norman K, Kirchner H, Freudenreich M, Ockenga J, Lochs H, Pirlich M. Three month intervention with protein and energy rich supplements improve muscle function and quality of life in malnourished patients with non-neoplastic gastrointestinal disease--a randomized controlled trial. *Clin Nutr* 2008;27(1):48–56. [PubMed: 17964008]
152. Fernandes SA, Bassani L, Nunes FF, Aydos ME, Alves AV, Marroni CA. Nutritional assessment in patients with cirrhosis. *Arq Gastroenterol* 2012;49(1):19–27. [PubMed: 22481682]
153. Norman K, Stobaus N, Pirlich M, Bosy-Westphal A. Bioelectrical phase angle and impedance vector analysis--clinical relevance and applicability of impedance parameters. *Clin Nutr* 2012;31(6):854–61. [PubMed: 22698802]
154. Belarmino G, Gonzalez MC, Torrinhas RS, Sala P, Andraus W, D'Albuquerque LA, et al. Phase angle obtained by bioelectrical impedance analysis independently predicts mortality in patients with cirrhosis. *World J Hepatol* 2017;9(7):401–8. [PubMed: 28321276]
155. Ruiz-Margain A, Macias-Rodriguez RU, Duarte-Rojo A, Rios-Torres SL, Espinosa-Cuevas A, Torre A. Malnutrition assessed through phase angle and its relation to prognosis in patients with compensated liver cirrhosis: a prospective cohort study. *Dig Liver Dis* 2015;47(4):309–14. [PubMed: 25618555]
156. Muscaritoli M, Anker SD, Argiles J, Aversa Z, Bauer JM, Biolo G, et al. Consensus definition of sarcopenia, cachexia and pre-cachexia: joint document elaborated by Special Interest Groups (SIG) “cachexia-anorexia in chronic wasting diseases” and “nutrition in geriatrics”. *Clin Nutr* 2010;29(2):154–9. [PubMed: 20060626]
157. Montano-Loza AJ, Meza-Junco J, Prado CM, Lieffers JR, Baracos VE, Bain VG, et al. Muscle wasting is associated with mortality in patients with cirrhosis. *Clin Gastroenterol Hepatol* 2012;10(2):166–73. e1. [PubMed: 21893129]
158. Tsien C, Shah SN, McCullough AJ, Dasarathy S. Reversal of sarcopenia predicts survival after a transjugular intrahepatic portosystemic stent. *Eur J Gastroenterol Hepatol* 2013;25(1):85–93. [PubMed: 23011041]
159. Prado CM, Birdsell LA, Baracos VE. The emerging role of computerized tomography in assessing cancer cachexia. *Current opinion in supportive and palliative care* 2009;3(4):269–75. [PubMed: 19667996]
160. Carey EJ, Lai JC, Wang CW, Dasarathy S, Lobach I, Montano-Loza AJ, et al. A multicenter study to define sarcopenia in patients with end-stage liver disease. *Liver Transpl* 2017;23(5):625–33. [PubMed: 28240805]
161. Hanai T, Shiraki M, Nishimura K, Imai K, Suetsugu A, Takai K, et al. Free fatty acid as a marker of energy malnutrition in liver cirrhosis. *Hepatol Res* 2014;44(2):218–28. [PubMed: 23601060]
162. Montano-Loza AJ, Angulo P, Meza-Junco J, Prado CM, Sawyer MB, Beaumont C, et al. Sarcopenic obesity and myosteatoses are associated with higher mortality in patients with cirrhosis. *Journal of cachexia, sarcopenia and muscle* 2016;7(2):126–35.
163. Durand F, Buyse S, Francoz C, Laouenan C, Bruno O, Belghiti J, et al. Prognostic value of muscle atrophy in cirrhosis using psoas muscle thickness on computed tomography. *J Hepatol* 2014;60(6):1151–7. [PubMed: 24607622]
164. Dasarathy S Posttransplant sarcopenia: an underrecognized early consequence of liver transplantation. *Dig Dis Sci* 2013;58(11):3103–11. [PubMed: 23912247]

165. Tsien C, Garber A, Narayanan A, Shah SN, Barnes D, Eghtesad B, et al. Post-liver transplantation sarcopenia in cirrhosis: a prospective evaluation. *J Gastroenterol Hepatol* 2014;29(6):1250–7. [PubMed: 24443785]
166. Issa D, Alkhouri N, Tsien C, Shah S, Lopez R, McCullough A, et al. Presence of sarcopenia (muscle wasting) in patients with nonalcoholic steatohepatitis. *Hepatology* 2014;60(1):428–9. [PubMed: 24990106]
167. Rutten IJG, Ubachs J, Kruitwagen R, Beets-Tan RGH, Olde Damink SWM, Van Gorp T. Psoas muscle area is not representative of total skeletal muscle area in the assessment of sarcopenia in ovarian cancer. *Journal of cachexia, sarcopenia and muscle* 2017;8(4):630–8.
168. Baracos VE. Psoas as a sentinel muscle for sarcopenia: a flawed premise. *Journal of cachexia, sarcopenia and muscle* 2017;8(4):527–8.
169. Tandon P, Low G, Mourtzakis M, Zenith L, Myers RP, Abraldes JG, et al. A Model to Identify Sarcopenia in Patients With Cirrhosis. *Clin Gastroenterol Hepatol* 2016;14(10):1473–80.e3. [PubMed: 27189915]
170. Wang CW, Feng S, Covinsky KE, Hayssen H, Zhou LQ, Yeh BM, et al. A Comparison of Muscle Function, Mass, and Quality in Liver Transplant Candidates: Results From the Functional Assessment in Liver Transplantation Study. *Transplantation* 2016;100(8):1692–8. [PubMed: 27314169]
171. Yadav A, Chang YH, Carpenter S, Silva AC, Rakela J, Aqel BA, et al. Relationship between sarcopenia, six-minute walk distance and health-related quality of life in liver transplant candidates. *Clin Transplant* 2015;29(2):134–41. [PubMed: 25430554]
172. Dunn MA, Josbeno DA, Tevar AD, Rachakonda V, Ganesh SR, Schmotzer AR, et al. Frailty as Tested by Gait Speed is an Independent Risk Factor for Cirrhosis Complications that Require Hospitalization. *Am J Gastroenterol* 2016;111(12):1768–75. [PubMed: 27575708]
173. Lai JC. Defining the threshold for too sick for transplant. *Current opinion in organ transplantation* 2016;21(2):127–32. [PubMed: 26825359]
174. Sinclair M, Poltavskiy E, Dodge JL, Lai JC. Frailty is independently associated with increased hospitalisation days in patients on the liver transplant waitlist. *World J Gastroenterol* 2017;23(5): 899–905. [PubMed: 28223735]
175. Painter PL, Luetkemeier MJ, Moore GE, Dibble SL, Green GA, Myll JO, et al. Health-related fitness and quality of life in organ transplant recipients. *Transplantation* 1997;64(12):1795–800. [PubMed: 9422422]
176. Bernal W, Hyyrylainen A, Gera A, Audimoolam VK, McPhail MJ, Auzinger G, et al. Lessons from look-back in acute liver failure? A single centre experience of 3300 patients. *J Hepatol* 2013;59(1):74–80. [PubMed: 23439263]
177. Rabinowich L, Wendon J, Bernal W, Shibolet O. Clinical management of acute liver failure: Results of an international multi-center survey. *World J Gastroenterol* 2016;22(33):7595–603. [PubMed: 27672280]
178. Clemmesen JO, Larsen FS, Kondrup J, Hansen BA, Ott P. Cerebral herniation in patients with acute liver failure is correlated with arterial ammonia concentration. *Hepatology* 1999;29(3):648–53. [PubMed: 10051463]
179. Tofteng F, Hauerberg J, Hansen BA, Pedersen CB, Jørgensen L, Larsen FS. Persistent arterial hyperammonemia increases the concentration of glutamine and alanine in the brain and correlates with intracranial pressure in patients with fulminant hepatic failure. *J Cereb Blood Flow Metab* 2006;26(1):21–7. [PubMed: 15959460]
180. Reintam Blaser A, Starkopf J, Alhazzani W, Berger MM, Casaer MP, Deane AM, et al. Early enteral nutrition in critically ill patients: ESICM clinical practice guidelines. *Intensive Care Med* 2017;43(3):380–98. [PubMed: 28168570]
181. McClave SA, Taylor BE, Martindale RG, Warren MM, Johnson DR, Braunschweig C, et al. Guidelines for the Provision and Assessment of Nutrition Support Therapy in the Adult Critically Ill Patient: Society of Critical Care Medicine (SCCM) and American Society for Parenteral and Enteral Nutrition (A.S.P.E.N.). *JPEN J Parenter Enteral Nutr* 2016;40(2):159–211. [PubMed: 26773077]

182. Mendenhall C, Bongiovanni G, Goldberg S, Miller B, Moore J, Rouster S, et al. VA Cooperative Study on Alcoholic Hepatitis. III: Changes in protein-calorie malnutrition associated with 30 days of hospitalization with and without enteral nutritional therapy. *JPEN J Parenter Enteral Nutr* 1985;9(5):590–6. [PubMed: 3930765]
183. Bonkovsky HL, Fiellin DA, Smith GS, Slaker DP, Simon D, Galambos JT. A randomized, controlled trial of treatment of alcoholic hepatitis with parenteral nutrition and oxandrolone. I. Short-term effects on liver function. *Am J Gastroenterol* 1991;86(9):1200–8. [PubMed: 1909085]
184. Bonkovsky HL, Singh RH, Jafri IH, Fiellin DA, Smith GS, Simon D, et al. A randomized, controlled trial of treatment of alcoholic hepatitis with parenteral nutrition and oxandrolone. II. Short-term effects on nitrogen metabolism, metabolic balance, and nutrition. *Am J Gastroenterol* 1991;86(9):1209–18. [PubMed: 1909086]
185. Cabre E, Rodriguez-Iglesias P, Caballeria J, Quer JC, Sanchez-Lombrana JL, Pares A, et al. Short- and long-term outcome of severe alcohol-induced hepatitis treated with steroids or enteral nutrition: a multicenter randomized trial. *Hepatology* 2000;32(1):36–42. [PubMed: 10869286]
186. Nasrallah SM, Galambos JT. Aminoacid therapy of alcoholic hepatitis. *Lancet* 1980;2(8207):1276–7. [PubMed: 6108449]
187. Koretz RL, Avenell A, Lipman TO. Nutritional support for liver disease. *Cochrane Database Syst Rev* 2012(5):Cd008344.
188. Antar R, Wong P, Ghali P. A meta-analysis of nutritional supplementation for management of hospitalized alcoholic hepatitis. *Can J Gastroenterol* 2012;26(7):463–7. [PubMed: 22803023]
189. Fialla AD, Israelsen M, Hamberg O, Krag A, Gluud LL. Nutritional therapy in cirrhosis or alcoholic hepatitis: a systematic review and meta-analysis. *Liver international: official journal of the International Association for the Study of the Liver* 2015;35(9):2072–8. [PubMed: 25645300]
190. Koretz RL. The evidence for the use of nutritional support in liver disease. *Curr Opin Gastroenterol* 2014;30(2):208–14. [PubMed: 24468804]
191. Kearns PJ, Young H, Garcia G, Blaschke T, O'Hanlon G, Rinki M, et al. Accelerated improvement of alcoholic liver disease with enteral nutrition. *Gastroenterology* 1992;102(1):200–5. [PubMed: 1727754]
192. Mezey E, Caballeria J, Mitchell MC, Pares A, Herlong HF, Rodes J. Effect of parenteral amino acid supplementation on short-term and long-term outcomes in severe alcoholic hepatitis: a randomized controlled trial. *Hepatology* 1991;14(6):1090–6. [PubMed: 1959859]
193. Galambos JT, Hersh T, Fulenwider JT, Ansley JD, Rudman D. Hyperalimentation in alcoholic hepatitis. *Am J Gastroenterol* 1979;72(5):535–41. [PubMed: 119434]
194. Diehl AM, Boitnott JK, Herlong HF, Potter JJ, Van Duyn MA, Chandler E, et al. Effect of parenteral amino acid supplementation in alcoholic hepatitis. *Hepatology* 1985;5(1):57–63. [PubMed: 3917968]
195. Calvey H, Davis M, Williams R. Controlled trial of nutritional supplementation, with and without branched chain amino acid enrichment, in treatment of acute alcoholic hepatitis. *J Hepatol* 1985;1(2):141–51. [PubMed: 3932509]
196. Achord JL. A prospective randomized clinical trial of peripheral amino acid-glucose supplementation in acute alcoholic hepatitis. *Am J Gastroenterol* 1987;82(9):871–5. [PubMed: 3307390]
197. Simon D, Galambos JT. A randomized controlled study of peripheral parenteral nutrition in moderate and severe alcoholic hepatitis. *J Hepatol* 1988;7(2):200–7. [PubMed: 3142949]
198. John WJ, Phillips R, Ott L, Adams LJ, McClain CJ. Resting energy expenditure in patients with alcoholic hepatitis. *JPEN J Parenter Enteral Nutr* 1989;13(2):124–7. [PubMed: 2709599]
199. McClave SA, DiBaise JK, Mullin GE, Martindale RG. ACG Clinical Guideline: Nutrition Therapy in the Adult Hospitalized Patient. *Am J Gastroenterol* 2016;111(3):315–34; quiz 35. [PubMed: 26952578]
200. Plauth M, Cabre E, Campillo B, Kondrup J, Marchesini G, Schutz T, et al. ESPEN Guidelines on Parenteral Nutrition: hepatology. *Clin Nutr* 2009;28(4):436–44. [PubMed: 19520466]
201. Annetta MG, Pittiruti M, Vecchiarelli P, Silvestri D, Caricato A, Antonelli M. Immunonutrients in critically ill patients: an analysis of the most recent literature. *Minerva Anestesiol* 2016;82(3):320–31. [PubMed: 25969140]

202. Plank LD, Mathur S, Gane EJ, Peng SL, Gillanders LK, McIlroy K, et al. Perioperative immunonutrition in patients undergoing liver transplantation: a randomized double-blind trial. *Hepatology* 2015;61(2):639–47. [PubMed: 25212278]
203. Soberon S, Pauley MP, Duplantier R, Fan A, Halsted CH. Metabolic effects of enteral formula feeding in alcoholic hepatitis. *Hepatology* 1987;7(6):1204–9. [PubMed: 3119452]
204. Smith J, Horowitz J, Henderson JM, Heymsfield S. Enteral hyperalimentation in undernourished patients with cirrhosis and ascites. *Am J Clin Nutr* 1982;35(1):56–72. [PubMed: 6801958]
205. Majumdar SK, Shaw GK, O’Gorman P, Aps EJ, Offerman EL, Thomson AD. Blood vitamin status (B1, B2, B6, folic acid and B12) in patients with alcoholic liver disease. *Int J Vitam Nutr Res* 1982;52(3):266–71. [PubMed: 7174224]
206. Ouziel R, Trepo E, Cremer A, Moreno C, Degre D, Chaoui M, et al. Correction of all-trans retinoic acid deficiency in alcoholic cirrhosis lessens the excessive inflammatory monocyte response: a translational study. *Liver Int* 2014;34(3):343–52. [PubMed: 23834309]
207. Anty R, Canivet CM, Patoureaux S, Ferrari-Panaia P, Saint-Paul MC, Huet PM, et al. Severe Vitamin D Deficiency May be an Additional Cofactor for the Occurrence of Alcoholic Steatohepatitis. *Alcohol Clin Exp Res* 2015;39(6):1027–33. [PubMed: 25941109]
208. Flannery AH, Adkins DA, Cook AM. Unpeeling the Evidence for the Banana Bag: Evidence-Based Recommendations for the Management of Alcohol-Associated Vitamin and Electrolyte Deficiencies in the ICU. *Crit Care Med* 2016;44(8):1545–52. [PubMed: 27002274]
209. Mitchell MC, Friedman LS, McClain CJ. Medical Management of Severe Alcoholic Hepatitis: Expert Review from the Clinical Practice Updates Committee of the AGA Institute. *Clin Gastroenterol Hepatol* 2017;15(1):5–12. [PubMed: 27979049]
210. McClain CJ, Antonow DR, Cohen DA, Shedlofsky SI. Zinc metabolism in alcoholic liver disease. *Alcohol Clin Exp Res* 1986;10(6):582–9. [PubMed: 3544908]
211. Hu J, Juan W, Sahyoun NR. Intake and Biomarkers of Folate and Risk of Cancer Morbidity in Older Adults, NHANES 1999–2002 with Medicare Linkage. *PLoS One* 2016;11(2):e0148697. [PubMed: 26862893]
212. Demir R, Acar G, Tanriover G, Seval Y, Kayisli UA, Agar A. Effects of excess vitamin B6 intake on cerebral cortex neurons in rat: an ultrastructural study. *Folia Histochem Cytobiol* 2005;43(3):143–50. [PubMed: 16201314]
213. Kaur P, Mishra SK, Mithal A. Vitamin D toxicity resulting from overzealous correction of vitamin D deficiency. *Clin Endocrinol (Oxf)* 2015;83(3):327–31. [PubMed: 26053339]
214. Rachakonda V, Gabbert C, Raina A, Bell LN, Cooper S, Malik S, et al. Serum metabolomic profiling in acute alcoholic hepatitis identifies multiple dysregulated pathways. *PLoS One* 2014;9(12):e113860. [PubMed: 25461442]
215. Levine JA, Harris MM, Morgan MY. Energy expenditure in chronic alcohol abuse. *Eur J Clin Invest* 2000;30(9):779–86. [PubMed: 10998077]
216. Tsien CD, McCullough AJ, Dasarathy S. Late evening snack: exploiting a period of anabolic opportunity in cirrhosis. *J Gastroenterol Hepatol* 2012;27(3):430–41. [PubMed: 22004479]
217. Keohane PP, Attrill H, Grimble G, Spiller R, Frost P, Silk DB. Enteral nutrition in malnourished patients with hepatic cirrhosis and acute encephalopathy. *JPEN J Parenter Enteral Nutr* 1983;7(4):346–50. [PubMed: 6413710]
218. Morgan TR, Moritz TE, Mendenhall CL, Haas R. Protein consumption and hepatic encephalopathy in alcoholic hepatitis. VA Cooperative Study Group #275. *J Am Coll Nutr* 1995;14(2):152–8. [PubMed: 7790689]
219. Thursz MR, Richardson P, Allison M, Austin A, Bowers M, Day CP, et al. Prednisolone or pentoxifylline for alcoholic hepatitis. *N Engl J Med* 2015;372(17):1619–28. [PubMed: 25901427]
220. Verboeket-van de Venne WP, Westerterp KR, van Hoek B, Swart GR. Energy expenditure and substrate metabolism in patients with cirrhosis of the liver: effects of the pattern of food intake. *Gut* 1995;36(1):110–6. [PubMed: 7890212]
221. Zillikens MC, van den Berg JW, Wattimena JL, Rietveld T, Swart GR. Nocturnal oral glucose supplementation. The effects on protein metabolism in cirrhotic patients and in healthy controls. *J Hepatol* 1993;17(3):377–83. [PubMed: 8315266]

222. Swart GR, Zillikens MC, van Vuure JK, van den Berg JW. Effect of a late evening meal on nitrogen balance in patients with cirrhosis of the liver. *BMJ* 1989;299(6709):1202–3. [PubMed: 2513050]
223. Plank LD, Gane EJ, Peng S, Muthu C, Mathur S, Gillanders L, et al. Nocturnal nutritional supplementation improves total body protein status of patients with liver cirrhosis: a randomized 12-month trial. *Hepatology* 2008;48(2):557–66. [PubMed: 18627001]
224. Wang RT, Koretz RL, Yee HF, Jr. Is weight reduction an effective therapy for nonalcoholic fatty liver? A systematic review. *Am J Med* 2003;115(7):554–9. [PubMed: 14599635]
225. Angulo P, Kleiner DE, Dam-Larsen S, Adams LA, Bjornsson ES, Charatcharoenwithaya P, et al. Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease. *Gastroenterology* 2015;149(2):389–97.e10. [PubMed: 25935633]
226. Barker KB, Palekar NA, Bowers SP, Goldberg JE, Pulcini JP, Harrison SA. Non-alcoholic steatohepatitis: effect of Roux-en-Y gastric bypass surgery. *Am J Gastroenterol* 2006;101(2):368–73. [PubMed: 16454845]
227. Caiazzo R, Lassailly G, Leteurtre E, Baud G, Verkindt H, Raverdy V, et al. Roux-en-Y gastric bypass versus adjustable gastric banding to reduce nonalcoholic fatty liver disease: a 5-year controlled longitudinal study. *Ann Surg* 2014;260(5):893–8; discussion 8–9. [PubMed: 25379859]
228. Dixon JB, Bhathal PS, O'Brien PE. Weight loss and non-alcoholic fatty liver disease: falls in gamma-glutamyl transferase concentrations are associated with histologic improvement. *Obes Surg* 2006;16(10):1278–86. [PubMed: 17059735]
229. Harrison SA, Fecht W, Brunt EM, Neuschwander-Tetri BA. Orlistat for overweight subjects with nonalcoholic steatohepatitis: A randomized, prospective trial. *Hepatology* 2009;49(1):80–6. [PubMed: 19053049]
230. Harrison SA, Fincke C, Helinski D, Torgerson S, Hayashi P. A pilot study of orlistat treatment in obese, non-alcoholic steatohepatitis patients. *Aliment Pharmacol Ther* 2004;20(6):623–8. [PubMed: 15352910]
231. Lassailly G, Caiazzo R, Buob D, Pigeyre M, Verkindt H, Labreuche J, et al. Bariatric Surgery Reduces Features of Nonalcoholic Steatohepatitis in Morbidly Obese Patients. *Gastroenterology* 2015;149(2):379–88; quiz e15–6. [PubMed: 25917783]
232. Stratopoulos C, Papakonstantinou A, Terzis I, Spiliadi C, Dimitriades G, Komesidou V, et al. Changes in liver histology accompanying massive weight loss after gastroplasty for morbid obesity. *Obes Surg* 2005;15(8):1154–60. [PubMed: 16197789]
233. Tendler D, Lin S, Yancy WS Jr., Mavropoulos J, Sylvestre P, Rockey DC, et al. The effect of a low-carbohydrate, ketogenic diet on nonalcoholic fatty liver disease: a pilot study. *Dig Dis Sci* 2007;52(2):589–93. [PubMed: 17219068]
234. Vilar-Gomez E, Martinez-Perez Y, Calzadilla-Bertot L, Torres-Gonzalez A, Gra-Oramas B, Gonzalez-Fabian L, et al. Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis. *Gastroenterology* 2015;149(2):367–78.e5; quiz e14–5. [PubMed: 25865049]
235. Haufe S, Engeli S, Kast P, Bohnke J, Utz W, Haas V, et al. Randomized comparison of reduced fat and reduced carbohydrate hypocaloric diets on intrahepatic fat in overweight and obese human subjects. *Hepatology* 2011;53(5):1504–14. [PubMed: 21400557]
236. Huang MA, Greenon JK, Chao C, Anderson L, Peterman D, Jacobson J, et al. One-year intense nutritional counseling results in histological improvement in patients with non-alcoholic steatohepatitis: a pilot study. *Am J Gastroenterol* 2005;100(5):1072–81. [PubMed: 15842581]
237. Promrat K, Kleiner DE, Niemeier HM, Jackvony E, Kearns M, Wands JR, et al. Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. *Hepatology* 2010;51(1):121–9. [PubMed: 19827166]
238. Zelber-Sagi S, Kessler A, Brazowsky E, Webb M, Lurie Y, Santo M, et al. A double-blind randomized placebo-controlled trial of orlistat for the treatment of nonalcoholic fatty liver disease. *Clin Gastroenterol Hepatol* 2006;4(5):639–44. [PubMed: 16630771]

239. Mummadi RR, Kasturi KS, Chennareddygar S, Sood GK. Effect of bariatric surgery on nonalcoholic fatty liver disease: systematic review and meta-analysis. *Clin Gastroenterol Hepatol* 2008;6(12):1396–402. [PubMed: 18986848]
240. Sasaki A, Nitta H, Otsuka K, Umemura A, Baba S, Obuchi T, et al. Bariatric surgery and non-alcoholic Fatty liver disease: current and potential future treatments. *Front Endocrinol (Lausanne)* 2014;5:164. [PubMed: 25386164]
241. de Jonge C, Rensen SS, Koek GH, Joosten MF, Buurman WA, Bouvy ND, et al. Endoscopic duodenal-jejunal bypass liner rapidly improves plasma parameters of nonalcoholic fatty liver disease. *Clin Gastroenterol Hepatol* 2013;11(11):1517–20. [PubMed: 23920034]
242. Schafer S, Kantartzis K, Machann J, Venter C, Niess A, Schick F, et al. Lifestyle intervention in individuals with normal versus impaired glucose tolerance. *Eur J Clin Invest* 2007;37(7):535–43. [PubMed: 17576204]
243. Thomas EL, Brynes AE, Hamilton G, Patel N, Spong A, Goldin RD, et al. Effect of nutritional counselling on hepatic, muscle and adipose tissue fat content and distribution in non-alcoholic fatty liver disease. *World J Gastroenterol* 2006;12(36):5813–9. [PubMed: 17007047]
244. Hickman IJ, Jonsson JR, Prins JB, Ash S, Purdie DM, Clouston AD, et al. Modest weight loss and physical activity in overweight patients with chronic liver disease results in sustained improvements in alanine aminotransferase, fasting insulin, and quality of life. *Gut* 2004;53(3):413–9. [PubMed: 14960526]
245. Nobili V, Manco M, Devito R, Di Ciommo V, Comparcola D, Sartorelli MR, et al. Lifestyle intervention and antioxidant therapy in children with nonalcoholic fatty liver disease: a randomized, controlled trial. *Hepatology* 2008;48(1):119–28. [PubMed: 18537181]
246. Larson-Meyer DE, Newcomer BR, Heilbronn LK, Volaufova J, Smith SR, Alfonso AJ, et al. Effect of 6-month calorie restriction and exercise on serum and liver lipids and markers of liver function. *Obesity (Silver Spring)* 2008;16(6):1355–62. [PubMed: 18421281]
247. Houghton D, Thoma C, Hallsworth K, Cassidy S, Hardy T, Burt AD, et al. Exercise Reduces Liver Lipids and Visceral Adiposity in Patients With Nonalcoholic Steatohepatitis in a Randomized Controlled Trial. *Clin Gastroenterol Hepatol* 2017;15(1):96–102.e3. [PubMed: 27521509]
248. Johnson NA, Sachinwalla T, Walton DW, Smith K, Armstrong A, Thompson MW, et al. Aerobic exercise training reduces hepatic and visceral lipids in obese individuals without weight loss. *Hepatology* 2009;50(4):1105–12. [PubMed: 19637289]
249. Sullivan S, Kirk EP, Mittendorfer B, Patterson BW, Klein S. Randomized trial of exercise effect on intrahepatic triglyceride content and lipid kinetics in nonalcoholic fatty liver disease. *Hepatology* 2012;55(6):1738–45. [PubMed: 22213436]
250. Lazo M, Solga SF, Horska A, Bonekamp S, Diehl AM, Brancati FL, et al. Effect of a 12-month intensive lifestyle intervention on hepatic steatosis in adults with type 2 diabetes. *Diabetes Care* 2010;33(10):2156–63. [PubMed: 20664019]
251. Gerber L, Otgonsuren M, Mishra A, Escheik C, Biredinc A, Stepanova M, et al. Non-alcoholic fatty liver disease (NAFLD) is associated with low level of physical activity: a population-based study. *Aliment Pharmacol Ther* 2012;36(8):772–81. [PubMed: 22958053]
252. Stewart KE, Haller DL, Sargeant C, Levenson JL, Puri P, Sanyal AJ. Readiness for behaviour change in non-alcoholic fatty liver disease: implications for multidisciplinary care models. *Liver international: official journal of the International Association for the Study of the Liver* 2015;35(3):936–43. [PubMed: 24521540]
253. Zelber-Sagi S, Buch A, Yeshua H, Vaisman N, Webb M, Harari G, et al. Effect of resistance training on non-alcoholic fatty-liver disease a randomized-clinical trial. *World J Gastroenterol* 2014;20(15):4382–92. [PubMed: 24764677]
254. Centre for Public Health Excellence at NICE (UK); National Collaborating Centre for Primary Care (UK). Obesity: The Prevention, Identification, Assessment and Management of Overweight and Obesity in Adults and Children National Institute for Health and Clinical Excellence: Guidance London, 2006.

255. Lau DC. Synopsis of the 2006 Canadian clinical practice guidelines on the management and prevention of obesity in adults and children. *Can Med Assoc J* 2007;176(8):1103–6. [PubMed: 17420493]
256. Lau DC, Douketis JD, Morrison KM, Hramiak IM, Sharma AM, Ur E. 2006 Canadian clinical practice guidelines on the management and prevention of obesity in adults and children [summary]. *CMAJ* 2007;176(8):S1–13.
257. Poole R, Kennedy OJ, Roderick P, Fallowfield JA, Hayes PC, Parkes J. Coffee consumption and health: umbrella review of meta-analyses of multiple health outcomes. *BMJ* 2017;359:j5024. [PubMed: 29167102]
258. Lin WY, Wu CH, Chu NF, Chang CJ. Efficacy and safety of very-low-calorie diet in Taiwanese: a multicenter randomized, controlled trial. *Nutrition* 2009;25(11–12):1129–36. [PubMed: 19592223]
259. Elias MC, Parise ER, de Carvalho L, Szejnfeld D, Netto JP. Effect of 6-month nutritional intervention on non-alcoholic fatty liver disease. *Nutrition* 2010;26(11–12):1094–9. [PubMed: 20022466]
260. Browning JD, Baker JA, Rogers T, Davis J, Satapati S, Burgess SC. Short-term weight loss and hepatic triglyceride reduction: evidence of a metabolic advantage with dietary carbohydrate restriction. *Am J Clin Nutr* 2011;93(5):1048–52. [PubMed: 21367948]
261. Ryan MC, Abbasi F, Lamendola C, Carter S, McLaughlin TL. Serum alanine aminotransferase levels decrease further with carbohydrate than fat restriction in insulin-resistant adults. *Diabetes Care* 2007;30(5):1075–80. [PubMed: 17351275]
262. Kirk E, Reeds DN, Finck BN, Mayurranjan MS, Patterson BW, Klein S. Dietary fat and carbohydrates differentially alter insulin sensitivity during caloric restriction. *Gastroenterology* 2009;136(5):1552–60. [PubMed: 19208352]
263. Aller R, de Luis DA, Izaola O, de la Fuente B, Bachiller R. Effect of a high monounsaturated vs high polyunsaturated fat hypocaloric diets in nonalcoholic fatty liver disease. *Eur Rev Med Pharmacol Sci* 2014;18(7):1041–7. [PubMed: 24763885]
264. Utzschneider KM, Bayer-Carter JL, Arbuckle MD, Tidwell JM, Richards TL, Craft S. Beneficial effect of a weight-stable, low-fat/low-saturated fat/low-glycaemic index diet to reduce liver fat in older subjects. *Br J Nutr* 2013;109(6):1096–104. [PubMed: 22849970]
265. Markova M, Pivovarova O, Hornemann S, Sucher S, Frahnow T, Wegner K, et al. Isocaloric Diets High in Animal or Plant Protein Reduce Liver Fat and Inflammation in Individuals With Type 2 Diabetes. *Gastroenterology* 2017;152(3):571–85.e8. [PubMed: 27765690]
266. Bray GA. Medical consequences of obesity. *The Journal of Clinical Endocrinology & Metabolism* 2004;89(6):2583–9. [PubMed: 15181027]
267. Stanhope KL, Schwarz JM, Keim NL, Griffen SC, Bremer AA, Graham JL, et al. Consuming fructose-sweetened, not glucose-sweetened, beverages increases visceral adiposity and lipids and decreases insulin sensitivity in overweight/obese humans. *The Journal of clinical investigation* 2009;119(5):1322–34. [PubMed: 19381015]
268. Ouyang X, Cirillo P, Sautin Y, McCall S, Bruchette JL, Diehl AM, et al. Fructose consumption as a risk factor for non-alcoholic fatty liver disease. *J Hepatol* 2008;48(6):993–9. [PubMed: 18395287]
269. Volynets V, Machann J, Kuper MA, Maier IB, Spruss A, Konigsrainer A, et al. A moderate weight reduction through dietary intervention decreases hepatic fat content in patients with non-alcoholic fatty liver disease (NAFLD): a pilot study. *Eur J Nutr* 2013;52(2):527–35. [PubMed: 22543623]
270. Chiu S, Sievenpiper J, De Souza R, Cozma A, Mirrahimi A, Carleton A, et al. Effect of fructose on markers of non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of controlled feeding trials. *Eur J Clin Nutr* 2014;68(4):416. [PubMed: 24569542]
271. Chung M, Ma J, Patel K, Berger S, Lau J, Lichtenstein AH. Fructose, high-fructose corn syrup, sucrose, and nonalcoholic fatty liver disease or indexes of liver health: a systematic review and meta-analysis. *The American journal of clinical nutrition* 2014;100(3):833–49. [PubMed: 25099546]

272. Johnston RD, Stephenson MC, Crossland H, Cordon SM, Palcidi E, Cox EF, et al. No difference between high-fructose and high-glucose diets on liver triacylglycerol or biochemistry in healthy overweight men. *Gastroenterology* 2013;145(5):1016–25.e2. [PubMed: 23872500]
273. Gelli C, Tarocchi M, Abenavoli L, Di Renzo L, Galli A, De Lorenzo A. Effect of a counseling-supported treatment with the Mediterranean diet and physical activity on the severity of the non-alcoholic fatty liver disease. *World J Gastroenterol* 2017;23(17):3150–62. [PubMed: 28533672]
274. Katsagoni CN, Georgoulis M, Papatheodoridis GV, Fragopoulou E, Ioannidou P, Papageorgiou M, et al. Associations Between Lifestyle Characteristics and the Presence of Nonalcoholic Fatty Liver Disease: A Case-Control Study. *Metab Syndr Relat Disord* 2017;15(2):72–9. [PubMed: 27869531]
275. Misciagna G, Del Pilar Diaz M, Caramia DV, Bonfiglio C, Franco I, Noviello MR, et al. Effect of a Low Glycemic Index Mediterranean Diet on Non-Alcoholic Fatty Liver Disease. A Randomized Controlled Clinical Trial. *J Nutr Health Aging* 2017;21(4):404–12. [PubMed: 28346567]
276. Perez-Guisado J, Munoz-Serrano A. The effect of the Spanish Ketogenic Mediterranean Diet on nonalcoholic fatty liver disease: a pilot study. *J Med Food* 2011;14(7–8):677–80. [PubMed: 21688989]
277. Ryan MC, Itsiopoulos C, Thodis T, Ward G, Trost N, Hofferberth S, et al. The Mediterranean diet improves hepatic steatosis and insulin sensitivity in individuals with non-alcoholic fatty liver disease. *J Hepatol* 2013;59(1):138–43. [PubMed: 23485520]
278. Shai I, Schwarzfuchs D, Henkin Y, Shahar DR, Witkow S, Greenberg I, et al. Weight loss with a low-carbohydrate, Mediterranean, or low-fat diet. *N Engl J Med* 2008;359(3):229–41. [PubMed: 18635428]
279. Trovato FM, Catalano D, Martines GF, Pace P, Trovato GM. Mediterranean diet and non-alcoholic fatty liver disease: the need of extended and comprehensive interventions. *Clin Nutr* 2015;34(1):86–8. [PubMed: 24529325]
280. Aller R, Izaola O, de la Fuente B, De Luis Roman DA. Mediterranean diet is associated with liver histology in patients with non alcoholic fatty liver disease. *Nutr Hosp* 2015;32(6):2518–24. [PubMed: 26667698]
281. Della Corte C, Mosca A, Vania A, Alterio A, Iasevoli S, Nobili V. Good adherence to the Mediterranean diet reduces the risk for NASH and diabetes in pediatric patients with obesity: The results of an Italian Study. *Nutrition* 2017;39–40:8–14.
282. Kontogianni MD, Tileli N, Margariti A, Georgoulis M, Deutsch M, Tiniakos D, et al. Adherence to the Mediterranean diet is associated with the severity of non-alcoholic fatty liver disease. *Clin Nutr* 2014;33(4):678–83. [PubMed: 24064253]
283. Trovato FM, Martines GF, Brischetto D, Trovato G, Catalano D. Neglected features of lifestyle: Their relevance in non-alcoholic fatty liver disease. *World J Hepatol* 2016;8(33):1459–65. [PubMed: 27957244]
284. Tzima N, Pitsavos C, Panagiotakos DB, Chrysohoou C, Polychronopoulos E, Skoumas J, et al. Adherence to the Mediterranean diet moderates the association of aminotransferases with the prevalence of the metabolic syndrome; the ATTICA study. *Nutr Metab (Lond)* 2009;6:30. [PubMed: 19642977]
285. Abenavoli L, Milic N, Peta V, Alfieri F, De Lorenzo A, Bellentani S. Alimentary regimen in non-alcoholic fatty liver disease: Mediterranean diet. *World J Gastroenterol* 2014;20(45):16831–40. [PubMed: 25492997]
286. Suarez M, Boque N, Del Bas JM, Mayneris-Perxachs J, Arola L, Caimari A. Mediterranean Diet and Multi-Ingredient-Based Interventions for the Management of Non-Alcoholic Fatty Liver Disease. *Nutrients* 2017;9(10).
287. Velasco N, Contreras A, Grassi B. The Mediterranean diet, hepatic steatosis and nonalcoholic fatty liver disease. *Curr Opin Clin Nutr Metab Care* 2014;17(5):453–7. [PubMed: 25023188]
288. Gepner Y, Shelef I, Schwarzfuchs D, Zelicha H, Tene L, Yaskolka Meir A, et al. Effect of Distinct Lifestyle Interventions on Mobilization of Fat Storage Pools: CENTRAL Magnetic Resonance Imaging Randomized Controlled Trial. *Circulation* 2018;137(11):1143–57. [PubMed: 29142011]

289. Ma J, Hennein R, Liu C, Long MT, Hoffmann U, Jacques PF, et al. Improved Diet Quality Associates With Reduction in Liver Fat, Particularly in Individuals With High Genetic Risk Scores for Nonalcoholic Fatty Liver Disease. *Gastroenterology* 2018;155(1):107–17. [PubMed: 29604292]
290. Papamiltiadous ES, Roberts SK, Nicoll AJ, Ryan MC, Itsiopoulos C, Salim A, et al. A randomised controlled trial of a Mediterranean Dietary Intervention for Adults with Non Alcoholic Fatty Liver Disease (MEDINA): study protocol. *BMC Gastroenterol* 2016;16:14. [PubMed: 26831892]
291. Rehm J, Taylor B, Mohapatra S, Irving H, Baliunas D, Patra J, et al. Alcohol as a risk factor for liver cirrhosis: a systematic review and meta-analysis. *Drug Alcohol Rev* 2010;29(4):437–45. [PubMed: 20636661]
292. VanWagner LB, Ning H, Allen NB, Ajmera V, Lewis CE, Carr JJ, et al. Alcohol use and cardiovascular disease risk in patients with nonalcoholic fatty liver disease. *Gastroenterology* 2017;153(5):1260–72. e3. [PubMed: 28802566]
293. Marciano F, Savoia M, Vajro P. Celiac disease-related hepatic injury: Insights into associated conditions and underlying pathomechanisms. *Dig Liver Dis* 2016;48(2):112–9. [PubMed: 26711682]
294. Ludvigsson JF, Elfstrom P, Broome U, Ekblom A, Montgomery SM. Celiac disease and risk of liver disease: a general population-based study. *Clin Gastroenterol Hepatol* 2007;5(1):63–9.e1. [PubMed: 17161656]
295. Rubio-Tapia A, Murray JA. The liver in celiac disease. *Hepatology* 2007;46(5):1650–8. [PubMed: 17969053]
296. Volta U. Pathogenesis and clinical significance of liver injury in celiac disease. *Clin Rev Allergy Immunol* 2009;36(1):62–70. [PubMed: 18496773]
297. Volta U, De Franceschi L, Lari F, Molinaro N, Zoli M, Bianchi FB. Coeliac disease hidden by cryptogenic hypertransaminasaemia. *Lancet* 1998;352(9121):26–9. [PubMed: 9800742]
298. Zippelius A, Diebold J. Images in hepatology. Steatosis hepatitis in celiac disease. *J Hepatol* 1999;30(3):531. [PubMed: 10190740]
299. Abdo A, Meddings J, Swain M. Liver abnormalities in celiac disease. *Clin Gastroenterol Hepatol* 2004;2(2):107–12. [PubMed: 15017614]
300. Bardella MT, Vecchi M, Conte D, Del Ninno E, Fraquelli M, Pacchetti S, et al. Chronic unexplained hypertransaminasemia may be caused by occult celiac disease. *Hepatology* 1999;29(3):654–7. [PubMed: 10051464]
301. Wakim-Fleming J, Pagadala MR, McCullough AJ, Lopez R, Bennett AE, Barnes DS, et al. Prevalence of celiac disease in cirrhosis and outcome of cirrhosis on a gluten free diet: a prospective study. *J Hepatol* 2014;61(3):558–63. [PubMed: 24842303]
302. Reilly NR, Lebwohl B, Hultcrantz R, Green PH, Ludvigsson JF. Increased risk of non-alcoholic fatty liver disease after diagnosis of celiac disease. *J Hepatol* 2015;62(6):1405–11. [PubMed: 25617505]
303. Duggan JM, Duggan AE. Systematic review: the liver in coeliac disease. *Aliment Pharmacol Ther* 2005;21(5):515–8. [PubMed: 15740533]
304. Arslan N, Buyukgebiz B, Ozturk Y, Ozer E. The prevalence of liver function abnormalities in pediatric celiac disease patients and its relation with intestinal biopsy findings. *Acta Gastroenterol Belg* 2005;68(4):424–7. [PubMed: 16432994]
305. Bardella MT, Fraquelli M, Quatrini M, Molteni N, Bianchi P, Conte D. Prevalence of hypertransaminasemia in adult celiac patients and effect of gluten-free diet. *Hepatology* 1995;22(3):833–6. [PubMed: 7657290]
306. Bonamico M, Pitzalis G, Culasso F, Vania A, Monti S, Benedetti C, et al. [Hepatic damage in celiac disease in children]. *Minerva Pediatr* 1986;38(21):959–62. [PubMed: 3807839]
307. Christl S, Müller J. Fettleber bei adulter Sprue. *DMW-Deutsche Medizinische Wochenschrift* 1999;124(22):691–4.
308. Hagander B, Berg NO, Brandt L, Norden A, Sjolund K, Stenstam M. Hepatic injury in adult coeliac disease. *Lancet* 1977;2(8032):270–2. [PubMed: 69880]

309. Jacobsen MB, Fausa O, Elgjo K, Schrumpf E. Hepatic lesions in adult coeliac disease. *Scand J Gastroenterol* 1990;25(7):656–62. [PubMed: 2396080]
310. Novacek G, Miehsler W, Wrba F, Ferenci P, Penner E, Vogelsang H. Prevalence and clinical importance of hypertransaminasaemia in coeliac disease. *Eur J Gastroenterol Hepatol* 1999;11(3):283–8. [PubMed: 10333201]
311. Kaukinen K, Halme L, Collin P, Farkkila M, Maki M, Vehmanen P, et al. Celiac disease in patients with severe liver disease: gluten-free diet may reverse hepatic failure. *Gastroenterology* 2002;122(4):881–8. [PubMed: 11910339]
312. Bugianesi E, Gentilecore E, Manini R, Natale S, Vanni E, Villanova N, et al. A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease. *Am J Gastroenterol* 2005;100(5):1082–90. [PubMed: 15842582]
313. Dufour JF, Oneta CM, Gonvers JJ, Bihl F, Cerny A, Cereda JM, et al. Randomized placebo-controlled trial of ursodeoxycholic acid with vitamin e in nonalcoholic steatohepatitis. *Clin Gastroenterol Hepatol* 2006;4(12):1537–43. [PubMed: 17162245]
314. Harrison SA, Torgerson S, Hayashi P, Ward J, Schenker S. Vitamin E and vitamin C treatment improves fibrosis in patients with nonalcoholic steatohepatitis. *Am J Gastroenterol* 2003;98(11):2485–90. [PubMed: 14638353]
315. Hasegawa T, Yoneda M, Nakamura K, Makino I, Terano A. Plasma transforming growth factor-beta1 level and efficacy of alpha-tocopherol in patients with non-alcoholic steatohepatitis: a pilot study. *Aliment Pharmacol Ther* 2001;15(10):1667–72. [PubMed: 11564008]
316. Kugelmas M, Hill DB, Vivian B, Marsano L, McClain CJ. Cytokines and NASH: a pilot study of the effects of lifestyle modification and vitamin E. *Hepatology* 2003;38(2):413–9. [PubMed: 12883485]
317. Lavine JE, Schwimmer JB, Van Natta ML, Molleston JP, Murray KF, Rosenthal P, et al. Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial. *JAMA* 2011;305(16):1659–68. [PubMed: 21521847]
318. Magosso E, Ansari MA, Gopalan Y, Shuaib IL, Wong JW, Khan NA, et al. Tocotrienols for normalisation of hepatic echogenic response in nonalcoholic fatty liver: a randomised placebo-controlled clinical trial. *Nutr J* 2013;12(1):166. [PubMed: 24373555]
319. Sanyal AJ, Chalasani N, Kowdley KV, McCullough A, Diehl AM, Bass NM, et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. *N Engl J Med* 2010;362(18):1675–85. [PubMed: 20427778]
320. Sanyal AJ, Mofrad PS, Contos MJ, Sargeant C, Luketic VA, Sterling RK, et al. A pilot study of vitamin E versus vitamin E and pioglitazone for the treatment of nonalcoholic steatohepatitis. *Clin Gastroenterol Hepatol* 2004;2(12):1107–15. [PubMed: 15625656]
321. Yakaryilmaz F, Guliter S, Savas B, Erdem O, Ersoy R, Erden E, et al. Effects of vitamin E treatment on peroxisome proliferator-activated receptor-alpha expression and insulin resistance in patients with non-alcoholic steatohepatitis: results of a pilot study. *Intern Med J* 2007;37(4):229–35. [PubMed: 17388862]
322. Hoofnagle JH, Van Natta ML, Kleiner DE, Clark JM, Kowdley KV, Loomba R, et al. Vitamin E and changes in serum alanine aminotransferase levels in patients with non-alcoholic steatohepatitis. *Aliment Pharmacol Ther* 2013;38(2):134–43. [PubMed: 23718573]
323. Miller ER 3rd, Pastor-Barriuso R, Dalal D, Riemersma RA, Appel LJ, Guallar E. Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality. *Ann Intern Med* 2005;142(1):37–46. [PubMed: 15537682]
324. Bjelakovic G, Gluud LL, Nikolova D, Bjelakovic M, Nagorni A, Gluud C. Meta-analysis: antioxidant supplements for liver diseases - the Cochrane Hepato-Biliary Group. *Aliment Pharmacol Ther* 2010;32(3):356–67. [PubMed: 20497142]
325. Musso G, Gambino R, Cassader M, Pagano G. A meta-analysis of randomized trials for the treatment of nonalcoholic fatty liver disease. *Hepatology* 2010;52(1):79–104. [PubMed: 20578268]

326. Ji HF, Sun Y, Shen L. Effect of vitamin E supplementation on aminotransferase levels in patients with NAFLD, NASH, and CHC: results from a meta-analysis. *Nutrition* 2014;30(9):986–91. [PubMed: 24976430]
327. Chachay VS, Macdonald GA, Martin JH, Whitehead JP, O’Moore-Sullivan TM, Lee P, et al. Resveratrol does not benefit patients with nonalcoholic fatty liver disease. *Clin Gastroenterol Hepatol* 2014;12(12):2092–103.e1–6. [PubMed: 24582567]
328. Chen S, Zhao X, Ran L, Wan J, Wang X, Qin Y, et al. Resveratrol improves insulin resistance, glucose and lipid metabolism in patients with non-alcoholic fatty liver disease: a randomized controlled trial. *Dig Liver Dis* 2015;47(3):226–32. [PubMed: 25577300]
329. Faghihzadeh F, Adibi P, Hekmatdoost A. The effects of resveratrol supplementation on cardiovascular risk factors in patients with non-alcoholic fatty liver disease: a randomised, double-blind, placebo-controlled study. *Br J Nutr* 2015;114(5):796–803. [PubMed: 26234526]
330. Faghihzadeh F, Adibi P, Rafiei R, Hekmatdoost A. Resveratrol supplementation improves inflammatory biomarkers in patients with nonalcoholic fatty liver disease. *Nutr Res* 2014;34(10):837–43. [PubMed: 25311610]
331. Guo H, Zhong R, Liu Y, Jiang X, Tang X, Li Z, et al. Effects of bayberry juice on inflammatory and apoptotic markers in young adults with features of non-alcoholic fatty liver disease. *Nutrition* 2014;30(2):198–203. [PubMed: 24377455]
332. Zhang PW, Chen FX, Li D, Ling WH, Guo HH. A CONSORT-compliant, randomized, double-blind, placebo-controlled pilot trial of purified anthocyanin in patients with nonalcoholic fatty liver disease. *Medicine (Baltimore)* 2015;94(20):e758. [PubMed: 25997043]
333. Farhangi MA, Alipour B, Jafarvand E, Khoshbaten M. Oral coenzyme Q10 supplementation in patients with nonalcoholic fatty liver disease: effects on serum vaspin, chemerin, pentraxin 3, insulin resistance and oxidative stress. *Arch Med Res* 2014;45(7):589–95. [PubMed: 25450583]
334. Ipsen DH, Tveden-Nyborg P, Lykkesfeldt J. Does vitamin C deficiency promote fatty liver disease development? *Nutrients* 2014;6(12):5473–99. [PubMed: 25533004]
335. Buchman AL. The addition of choline to parenteral nutrition. *Gastroenterology* 2009;137(5 Suppl):S119–28. [PubMed: 19874943]
336. Guerrerio AL, Colvin RM, Schwartz AK, Molleston JP, Murray KF, Diehl A, et al. Choline intake in a large cohort of patients with nonalcoholic fatty liver disease. *Am J Clin Nutr* 2012;95(4):892–900. [PubMed: 22338037]
337. Yu D, Shu XO, Xiang YB, Li H, Yang G, Gao YT, et al. Higher dietary choline intake is associated with lower risk of nonalcoholic fatty liver in normal-weight Chinese women. *J Nutr* 2014;144(12):2034–40. [PubMed: 25320186]
338. Imajo K, Fujita K, Yoneda M, Shinohara Y, Suzuki K, Mawatari H, et al. Plasma free choline is a novel non-invasive biomarker for early-stage non-alcoholic steatohepatitis: A multi-center validation study. *Hepatol Res* 2012;42(8):757–66. [PubMed: 22780848]
339. Malaguarnera M, Gargante MP, Russo C, Antic T, Vacante M, Malaguarnera M, et al. L-carnitine supplementation to diet: a new tool in treatment of nonalcoholic steatohepatitis--a randomized and controlled clinical trial. *Am J Gastroenterol* 2010;105(6):1338–45. [PubMed: 20068559]
340. Bae JC, Lee WY, Yoon KH, Park JY, Son HS, Han KA, et al. Improvement of Nonalcoholic Fatty Liver Disease With Carnitine-Orotate Complex in Type 2 Diabetes (CORONA): A Randomized Controlled Trial. *Diabetes Care* 2015;38(7):1245–52. [PubMed: 25877813]
341. Simopoulos AP. Dietary omega-3 fatty acid deficiency and high fructose intake in the development of metabolic syndrome, brain metabolic abnormalities, and non-alcoholic fatty liver disease. *Nutrients* 2013;5(8):2901–23. [PubMed: 23896654]
342. Scorletti E, Bhatia L, McCormick KG, Clough GF, Nash K, Hodson L, et al. Effects of purified eicosapentaenoic and docosahexaenoic acids in nonalcoholic fatty liver disease: results from the Welcome* study. *Hepatology* 2014;60(4):1211–21. [PubMed: 25043514]
343. Sanyal AJ, Abdelmalek MF, Suzuki A, Cummings OW, Chojkier M. No significant effects of ethyl-eicosapentanoic acid on histologic features of nonalcoholic steatohepatitis in a phase 2 trial. *Gastroenterology* 2014;147(2):377–84.e1. [PubMed: 24818764]

344. Argo CK, Patrie JT, Lackner C, Henry TD, de Lange EE, Weltman AL, et al. Effects of n-3 fish oil on metabolic and histological parameters in NASH: a double-blind, randomized, placebo-controlled trial. *J Hepatol* 2015;62(1):190–7. [PubMed: 25195547]
345. Eriksson JW, Lundkvist P, Jansson PA, Johansson L, Kvarnstrom M, Moris L, et al. Effects of dapagliflozin and n-3 carboxylic acids on non-alcoholic fatty liver disease in people with type 2 diabetes: a double-blind randomised placebo-controlled study. *Diabetologia* 2018;61(9):1923–34. [PubMed: 29971527]
346. Nobili V, Carpino G, Alisi A, De Vito R, Franchitto A, Alpini G, et al. Role of docosahexaenoic acid treatment in improving liver histology in pediatric nonalcoholic fatty liver disease. *PLoS One* 2014;9(2):e88005. [PubMed: 24505350]
347. Parker HM, Johnson NA, Burdon CA, Cohn JS, O'Connor HT, George J. Omega-3 supplementation and non-alcoholic fatty liver disease: a systematic review and meta-analysis. *J Hepatol* 2012;56(4):944–51. [PubMed: 22023985]
348. de Castro GS, Calder PC. Non-alcoholic fatty liver disease and its treatment with n-3 polyunsaturated fatty acids. *Clin Nutr* 2018;37(1):37–55. [PubMed: 28139281]
349. Musa-Veloso K, Venditti C, Lee HY, Darch M, Floyd S, West S, et al. Systematic review and meta-analysis of controlled intervention studies on the effectiveness of long-chain omega-3 fatty acids in patients with nonalcoholic fatty liver disease. *Nutr Rev* 2018;76(8):581–602. [PubMed: 29917092]
350. Buss C, Valle-Tovo C, Miozzo S, Alves de Mattos A. Probiotics and synbiotics may improve liver aminotransferases levels in non-alcoholic fatty liver disease patients. *Ann Hepatol* 2014;13(5):482–8. [PubMed: 25152979]
351. Aller R, De Luis DA, Izaola O, Conde R, Gonzalez Sagrado M, Primo D, et al. Effect of a probiotic on liver aminotransferases in nonalcoholic fatty liver disease patients: a double blind randomized clinical trial. *Eur Rev Med Pharmacol Sci* 2011;15(9):1090–5. [PubMed: 22013734]
352. Wong VW, Won GL, Chim AM, Chu WC, Yeung DK, Li KC, et al. Treatment of nonalcoholic steatohepatitis with probiotics. A proof-of-concept study. *Ann Hepatol* 2013;12(2):256–62. [PubMed: 23396737]
353. Malaguarnera M, Vacante M, Antic T, Giordano M, Chisari G, Acquaviva R, et al. Bifidobacterium longum with fructo-oligosaccharides in patients with non alcoholic steatohepatitis. *Dig Dis Sci* 2012;57(2):545–53. [PubMed: 21901256]
354. Eslamparast T, Poustchi H, Zamani F, Sharafkhan M, Malekzadeh R, Hekmatdoost A. Synbiotic supplementation in nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled pilot study. *Am J Clin Nutr* 2014;99(3):535–42. [PubMed: 24401715]
355. Nabavi S, Rafraf M, Somi MH, Homayouni-Rad A, Asghari-Jafarabadi M. Effects of probiotic yogurt consumption on metabolic factors in individuals with nonalcoholic fatty liver disease. *J Dairy Sci* 2014;97(12):7386–93. [PubMed: 25306266]
356. Lee YH, Kim SU, Song K, Park JY, Kim DY, Ahn SH, et al. Sarcopenia is associated with significant liver fibrosis independently of obesity and insulin resistance in nonalcoholic fatty liver disease: Nationwide surveys (KNHANES 2008–2011). *Hepatology* 2016;63(3):776–86. [PubMed: 26638128]
357. Nelson BV, Van Way CW 3rd. Nutrition in the critically-ill obese patient. *Mo Med* 2012;109(5):393–6. [PubMed: 23097946]
358. McClave SA, Kushner R, Van Way CW 3rd, Cave M, DeLegge M, Dibaise J, et al. Nutrition therapy of the severely obese, critically ill patient: summation of conclusions and recommendations. *JPEN J Parenter Enteral Nutr* 2011;35(5 Suppl):88s–96s. [PubMed: 21881019]
359. Bendavid I, Singer P, Theilla M, Themessl-Huber M, Sulz I, Mouhieddine M, et al. NutritionDay ICU: A 7 year worldwide prevalence study of nutrition practice in intensive care. *Clin Nutr* 2017;36(4):1122–9. [PubMed: 27637833]
360. Lassailly G, Caiazzo R, Pattou F, Mathurin P. Perspectives on Treatment for Nonalcoholic Steatohepatitis. *Gastroenterology* 2016;150(8):1835–48. [PubMed: 26971824]

361. Klebanoff MJ, Corey KE, Chhatwal J, Kaplan LM, Chung RT, Hur C. Bariatric surgery for nonalcoholic steatohepatitis: A clinical and cost-effectiveness analysis. *Hepatology* 2017;65(4):1156–64. [PubMed: 27880977]
362. Wolter S, Dupree A, Coelius C, El Gammal A, Kluwe J, Sauer N, et al. Influence of Liver Disease on Perioperative Outcome After Bariatric Surgery in a Northern German Cohort. *Obes Surg* 2017;27(1):90–5. [PubMed: 27272667]
363. Mosko JD, Nguyen GC. Increased perioperative mortality following bariatric surgery among patients with cirrhosis. *Clin Gastroenterol Hepatol* 2011;9(10):897–901. [PubMed: 21782772]
364. Clark JM, Alkhuraishi AR, Solga SF, Alli P, Diehl AM, Magnuson TH. Roux-en-Y gastric bypass improves liver histology in patients with non-alcoholic fatty liver disease. *Obes Res* 2005;13(7):1180–6. [PubMed: 16076987]
365. Csendes A, Smok G, Burgos AM. Histological findings in the liver before and after gastric bypass. *Obes Surg* 2006;16(5):607–11. [PubMed: 16687030]
366. de Almeida SR, Rocha PR, Sanches MD, Leite VH, da Silva RA, Diniz MT, et al. Roux-en-Y gastric bypass improves the nonalcoholic steatohepatitis (NASH) of morbid obesity. *Obes Surg* 2006;16(3):270–8. [PubMed: 16545157]
367. Dixon JB, Bhathal PS, Hughes NR, O'Brien PE. Nonalcoholic fatty liver disease: Improvement in liver histological analysis with weight loss. *Hepatology* 2004;39(6):1647–54. [PubMed: 15185306]
368. Furuya CK Jr., de Oliveira CP, de Mello ES, Faintuch J, Raskovski A, Matsuda M, et al. Effects of bariatric surgery on nonalcoholic fatty liver disease: preliminary findings after 2 years. *J Gastroenterol Hepatol* 2007;22(4):510–4. [PubMed: 17376042]
369. Kral JG, Thung SN, Biron S, Hould FS, Lebel S, Marceau S, et al. Effects of surgical treatment of the metabolic syndrome on liver fibrosis and cirrhosis. *Surgery* 2004;135(1):48–58. [PubMed: 14694300]
370. Mathurin P, Gonzalez F, Kerdraon O, Leteurtre E, Arnalsteen L, Hollebecque A, et al. The evolution of severe steatosis after bariatric surgery is related to insulin resistance. *Gastroenterology* 2006;130(6):1617–24. [PubMed: 16697725]
371. Mathurin P, Hollebecque A, Arnalsteen L, Buob D, Leteurtre E, Caiazzo R, et al. Prospective study of the long-term effects of bariatric surgery on liver injury in patients without advanced disease. *Gastroenterology* 2009;137(2):532–40. [PubMed: 19409898]
372. Mattar SG, Velcu LM, Rabinovitz M, Demetris AJ, Krasinskas AM, Barinas-Mitchell E, et al. Surgically-induced weight loss significantly improves nonalcoholic fatty liver disease and the metabolic syndrome. *Ann Surg* 2005;242(4):610–7; discussion 8–20. [PubMed: 16192822]
373. Taitano AA, Markow M, Finan JE, Wheeler DE, Gonzalvo JP, Murr MM. Bariatric surgery improves histological features of nonalcoholic fatty liver disease and liver fibrosis. *J Gastrointest Surg* 2015;19(3):429–36; discussion 36–7. [PubMed: 25537957]
374. Weiner RA. Surgical treatment of non-alcoholic steatohepatitis and non-alcoholic fatty liver disease. *Dig Dis* 2010;28(1):274–9. [PubMed: 20460923]
375. Iwasa M, Iwata K, Hara N, Hattori A, Ishidome M, Sekoguchi-Fujikawa N, et al. Nutrition therapy using a multidisciplinary team improves survival rates in patients with liver cirrhosis. *Nutrition* 2013;29(11–12):1418–21. [PubMed: 24103520]
376. Ney M, Vandermeer B, van Zanten SJ, Ma MM, Gramlich L, Tandon P. Meta-analysis: oral or enteral nutritional supplementation in cirrhosis. *Aliment Pharmacol Ther* 2013;37(7):672–9. [PubMed: 23421379]
377. Lai JC, Dodge JL, Sen S, Covinsky K, Feng S. Functional decline in patients with cirrhosis awaiting liver transplantation: Results from the functional assessment in liver transplantation (FrAILT) study. *Hepatology* 2016;63(2):574–80. [PubMed: 26517301]
378. Berzigotti A, Garcia-Tsao G, Bosch J, Grace ND, Burroughs AK, Morillas R, et al. Obesity is an independent risk factor for clinical decompensation in patients with cirrhosis. *Hepatology* 2011;54(2):555–61. [PubMed: 21567436]
379. Everhart JE, Lok AS, Kim HY, Morgan TR, Lindsay KL, Chung RT, et al. Weight-related effects on disease progression in the hepatitis C antiviral long-term treatment against cirrhosis trial. *Gastroenterology* 2009;137(2):549–57. [PubMed: 19445938]

380. Berzigotti A, Albillos A, Villanueva C, Genesca J, Ardevol A, Augustin S, et al. Effects of an intensive lifestyle intervention program on portal hypertension in patients with cirrhosis and obesity: The SportDiet study. *Hepatology* 2017;65(4):1293–305. [PubMed: 27997989]
381. McCullough AJ, Mullen KD, Kalhan SC. Defective nonoxidative leucine degradation and endogenous leucine flux in cirrhosis during an amino acid infusion. *Hepatology* 1998;28(5):1357–64. [PubMed: 9794922]
382. Tessari P, Barazzoni R, Kiwanuka E, Davanzo G, De Pergola G, Orlando R, et al. Impairment of albumin and whole body postprandial protein synthesis in compensated liver cirrhosis. *Am J Physiol Endocrinol Metab* 2002;282(2):E304–11. [PubMed: 11788361]
383. Tessari P, Inchiostro S, Barazzoni R, Zanetti M, Orlando R, Biolo G, et al. Fasting and postprandial phenylalanine and leucine kinetics in liver cirrhosis. *American Journal of Physiology-Endocrinology And Metabolism* 1994;267(1):E140–E9.
384. Tsien C, Davuluri G, Singh D, Allawy A, Ten Have GA, Thapaliya S, et al. Metabolic and molecular responses to leucine-enriched branched chain amino acid supplementation in the skeletal muscle of alcoholic cirrhosis. *Hepatology* 2015;61(6):2018–29. [PubMed: 25613922]
385. Kondrup J, Nielsen K, Juul A. Effect of long-term refeeding on protein metabolism in patients with cirrhosis of the liver. *Br J Nutr* 1997;77(2):197–212. [PubMed: 9135367]
386. Bories PN, Campillo B. One-month regular oral nutrition in alcoholic cirrhotic patients. Changes of nutritional status, hepatic function and serum lipid pattern. *Br J Nutr* 1994;72(6):937–46. [PubMed: 7827013]
387. ampillo B, Bories PN, Pornin B, Devanlay M. Influence of liver failure, ascites, and energy expenditure on the response to oral nutrition in alcoholic liver cirrhosis. *Nutrition* 1997;13(7–8):613–21. [PubMed: 9263252]
388. Le Cornu KA, McKiernan FJ, Kapadia SA, Neuberger JM. A prospective randomized study of preoperative nutritional supplementation in patients awaiting elective orthotopic liver transplantation. *Transplantation* 2000;69(7):1364–9. [PubMed: 10798755]
389. Manguso F, D’Ambra G, Menchise A, Sollazzo R, D’Agostino L. Effects of an appropriate oral diet on the nutritional status of patients with HCV-related liver cirrhosis: a prospective study. *Clin Nutr* 2005;24(5):751–9. [PubMed: 16182039]
390. Horst D, Grace ND, Conn HO, Schiff E, Schenker S, Viteri A, et al. Comparison of dietary protein with an oral, branched chain-enriched amino acid supplement in chronic portal-systemic encephalopathy: a randomized controlled trial. *Hepatology* 1984;4(2):279–87. [PubMed: 6706302]
391. Sherlock S, Summerskill W, White L, Phear E. Portal-systemic encephalopathy neurological complications of liver disease. *The Lancet* 1954;264(6836):453–7.
392. Cabre E, Gonzalez-Huix F, Abad-Lacruz A, Esteve M, Acero D, Fernandez-Banares F, et al. Effect of total enteral nutrition on the short-term outcome of severely malnourished cirrhotics. A randomized controlled trial. *Gastroenterology* 1990;98(3):715–20. [PubMed: 2105256]
393. Cordoba J, Lopez-Hellin J, Planas M, Sabin P, Sanpedro F, Castro F, et al. Normal protein diet for episodic hepatic encephalopathy: results of a randomized study. *J Hepatol* 2004;41(1):38–43. [PubMed: 15246205]
394. Rossi RE, Conte D, Massironi S. Diagnosis and treatment of nutritional deficiencies in alcoholic liver disease: Overview of available evidence and open issues. *Dig Liver Dis* 2015;47(10):819–25. [PubMed: 26164399]
395. Paternostro R, Wagner D, Reiberger T, Mandorfer M, Schwarzer R, Ferlitsch M, et al. Low 25-OH-vitamin D levels reflect hepatic dysfunction and are associated with mortality in patients with liver cirrhosis. *Wien Klin Wochenschr* 2017;129(1–2):8–15. [PubMed: 27888359]
396. Garrett-Laster M, Russell RM, Jacques PF. Impairment of taste and olfaction in patients with cirrhosis: the role of vitamin A. *Hum Nutr Clin Nutr* 1984;38(3):203–14. [PubMed: 6746322]
397. Weismann K, Christensen E, Dreyer V. Zinc supplementation in alcoholic cirrhosis. A double-blind clinical trial. *Acta Med Scand* 1979;205(5):361–6. [PubMed: 375690]
398. Barry M, Keeling PW, Feely J. Tissue zinc status and drug elimination in patients with chronic liver disease. *Clin Sci (Lond)* 1990;78(6):547–9. [PubMed: 2165886]

399. Halsted JA, Hackley B, Rudzki C, Smith JC Jr. Plasma zinc concentration in liver diseases. Comparison with normal controls and certain other chronic diseases. *Gastroenterology* 1968;54(6):1098–105. [PubMed: 5656329]
400. Thuluvath PJ, Triger DR. Selenium in chronic liver disease. *J Hepatol* 1992;14(2–3):176–82. [PubMed: 1500682]
401. Grungreiff K, Abicht K, Kluge M, Presser HJ, Franke D, Kleine FD, et al. Clinical studies on zinc in chronic liver diseases. *Z Gastroenterol* 1988;26(8):409–15. [PubMed: 3218283]
402. Van der Rijt CC, Schalm SW, Schat H, Foeken K, De Jong G. Overt hepatic encephalopathy precipitated by zinc deficiency. *Gastroenterology* 1991;100(4):1114–8. [PubMed: 2001810]
403. Bresci G, Parisi G, Banti S. Management of hepatic encephalopathy with oral zinc supplementation: a long-term treatment. *Eur J Med* 1993;2(7):414–6. [PubMed: 8258031]
404. Reding P, Duchateau J, Bataille C. Oral zinc supplementation improves hepatic encephalopathy. Results of a randomised controlled trial. *Lancet* 1984;2(8401):493–5. [PubMed: 6147551]
405. Riggio O, Ariosto F, Merli M, Caschera M, Zullo A, Balducci G, et al. Short-term oral zinc supplementation does not improve chronic hepatic encephalopathy. Results of a double-blind crossover trial. *Dig Dis Sci* 1991;36(9):1204–8. [PubMed: 1893805]
406. Marchesini G, Fabbri A, Bianchi G, Brizi M, Zoli M. Zinc supplementation and amino acid-nitrogen metabolism in patients with advanced cirrhosis. *Hepatology* 1996;23(5):1084–92. [PubMed: 8621138]
407. Allard JP, Chau J, Sandokji K, Blendis LM, Wong F. Effects of ascites resolution after successful TIPS on nutrition in cirrhotic patients with refractory ascites. *Am J Gastroenterol* 2001;96(8):2442–7. [PubMed: 11513188]
408. Swart G, Van den Berg J, Van Vuure J, Rietveld T, Wattimena D, Frenkel M. Minimum protein requirements in liver cirrhosis determined by nitrogen balance measurements at three levels of protein intake. *Clin Nutr* 1989;8(6):329–36. [PubMed: 16837309]
409. Amodio P, Caregaro L, Patteno E, Marcon M, Del Piccolo F, Gatta A. Vegetarian diets in hepatic encephalopathy: facts or fantasies? *Dig Liver Dis* 2001;33(6):492–500. [PubMed: 11572577]
410. Merli M, Iebba V, Giusto M. What is new about diet in hepatic encephalopathy. *Metab Brain Dis* 2016;31(6):1289–94. [PubMed: 26419384]
411. Merli M, Riggio O. Dietary and nutritional indications in hepatic encephalopathy. *Metab Brain Dis* 2009;24(1):211–21. [PubMed: 19052853]
412. Gheorghe L, Iacob R, Vadan R, Iacob S, Gheorghe C. Improvement of hepatic encephalopathy using a modified high-calorie high-protein diet. *Rom J Gastroenterol* 2005;14(3):231–8. [PubMed: 16200232]
413. Maharshi S, Sharma BC, Sachdeva S, Srivastava S, Sharma P. Efficacy of Nutritional Therapy for Patients With Cirrhosis and Minimal Hepatic Encephalopathy in a Randomized Trial. *Clin Gastroenterol Hepatol* 2016;14(3):454–60.e3; quiz e33. [PubMed: 26453952]
414. Hanai T, Shiraki M, Nishimura K, Ohnishi S, Imai K, Suetsugu A, et al. Sarcopenia impairs prognosis of patients with liver cirrhosis. *Nutrition* 2015;31(1):193–9. [PubMed: 25441595]
415. Marchesini G, Bianchi G, Merli M, Amodio P, Panella C, Loguercio C, et al. Nutritional supplementation with branched-chain amino acids in advanced cirrhosis: a double-blind, randomized trial. *Gastroenterology* 2003;124(7):1792–801. [PubMed: 12806613]
416. Muto Y, Sato S, Watanabe A, Moriwaki H, Suzuki K, Kato A, et al. Effects of oral branched-chain amino acid granules on event-free survival in patients with liver cirrhosis. *Clin Gastroenterol Hepatol* 2005;3(7):705–13. [PubMed: 16206505]
417. Les I, Doval E, Garcia-Martinez R, Planas M, Cardenas G, Gomez P, et al. Effects of branched-chain amino acids supplementation in patients with cirrhosis and a previous episode of hepatic encephalopathy: a randomized study. *Am J Gastroenterol* 2011;106(6):1081–8. [PubMed: 21326220]
418. Marchesini G, Dioguardi FS, Bianchi GP, Zoli M, Bellati G, Roffi L, et al. Long-term oral branched-chain amino acid treatment in chronic hepatic encephalopathy. A randomized double-blind casein-controlled trial. The Italian Multicenter Study Group. *J Hepatol* 1990;11(1):92–101. [PubMed: 2204661]

419. Plauth M, Egberts EH, Hamster W, Torok M, Muller PH, Brand O, et al. Long-term treatment of latent portosystemic encephalopathy with branched-chain amino acids. A double-blind placebo-controlled crossover study. *J Hepatol* 1993;17(3):308–14. [PubMed: 8315258]
420. Gluud LL, Dam G, Les I, Marchesini G, Borre M, Aagaard NK, et al. Branched-chain amino acids for people with hepatic encephalopathy. *Cochrane Database Syst Rev* 2017;5:Cd001939. [PubMed: 28518283]
421. Als-Nielsen B, Koretz RL, Kjaergard LL, Gluud C. Branched-chain amino acids for hepatic encephalopathy. *Cochrane Database Syst Rev* 2003(2):Cd001939. [PubMed: 12804416]
422. Plauth M, Schutz T. Branched-chain amino acids in liver disease: new aspects of long known phenomena. *Curr Opin Clin Nutr Metab Care* 2011;14(1):61–6. [PubMed: 21088568]
423. Gu XB, Yang XJ, Zhu HY, Xu BY. Effect of a diet with unrestricted sodium on ascites in patients with hepatic cirrhosis. *Gut and liver* 2012;6(3):355–61. [PubMed: 22844565]
424. Morando F, Rosi S, Gola E, Nardi M, Piano S, Fasolato S, et al. Adherence to a moderate sodium restriction diet in outpatients with cirrhosis and ascites: a real-life cross-sectional study. *Liver international: official journal of the International Association for the Study of the Liver* 2015;35(5):1508–15. [PubMed: 24811138]
425. Sorrentino P, Castaldo G, Tarantino L, Bracigliano A, Perrella A, Perrella O, et al. Preservation of nutritional-status in patients with refractory ascites due to hepatic cirrhosis who are undergoing repeated paracentesis. *J Gastroenterol Hepatol* 2012;27(4):813–22. [PubMed: 22142548]
426. Bunout D, Aicardi V, Hirsch S, Petermann M, Kelly M, Silva G, et al. Nutritional support in hospitalized patients with alcoholic liver disease. *Eur J Clin Nutr* 1989;43(9):615–21. [PubMed: 2691239]
427. Smith J, Horowitz J, Henderson J, Heymsfield S. Enteral hyperalimentation in undernourished patients with cirrhosis and ascites. *The American journal of clinical nutrition* 1982;35(1):56–72. [PubMed: 6801958]
428. Dupont B, Dao T, Joubert C, Dupont-Lucas C, Gloro R, Nguyen-Khac E, et al. Randomised clinical trial: enteral nutrition does not improve the long-term outcome of alcoholic cirrhotic patients with jaundice. *Aliment Pharmacol Ther* 2012;35(10):1166–74. [PubMed: 22452620]
429. de Ledinghen V, Beau P, Mannant PR, Borderie C, Ripault MP, Silvain C, et al. Early feeding or enteral nutrition in patients with cirrhosis after bleeding from esophageal varices? A randomized controlled study. *Dig Dis Sci* 1997;42(3):536–41. [PubMed: 9073135]
430. Calvey H, Davis M, Williams R. Prospective study of nasogastric feeding via East Grinstead or Viomedex tubes compared with oral dietary supplementation in patients with cirrhosis. *Clin Nutr* 1984;3(2):63–6. [PubMed: 16829436]
431. Crippin JS. Is tube feeding an option in patients with liver disease? *Nutr Clin Pract* 2006;21(3):296–8. [PubMed: 16772547]
432. Loser C, Aschl G, Hebuterne X, Mathus-Vliegen EM, Muscaritoli M, Niv Y, et al. ESPEN guidelines on artificial enteral nutrition—percutaneous endoscopic gastrostomy (PEG). *Clin Nutr* 2005;24(5):848–61. [PubMed: 16261664]
433. Baltz JG, Argo CK, Al-Osaimi AM, Northup PG. Mortality after percutaneous endoscopic gastrostomy in patients with cirrhosis: a case series. *Gastrointest Endosc* 2010;72(5):1072–5. [PubMed: 20855067]
434. Fischer JE, Rosen HM, Ebeid AM, James JH, Keane JM, Soeters PB. The effect of normalization of plasma amino acids on hepatic encephalopathy in man. *Surgery* 1976;80(1):77–91. [PubMed: 818729]
435. Freund H, Dienstag J, Lehrich J, Yoshimura N, Bradford RR, Rosen H, et al. Infusion of branched-chain enriched amino acid solution in patients with hepatic encephalopathy. *Ann Surg* 1982;196(2):209–20. [PubMed: 6284073]
436. Holm E, Striebel JP, Meisinger E, Haux P, Langhans W, Becker HD. [Amino-acid mixtures for parenteral feeding in liver insufficiency]. *Infusionsther Klin Ernahr* 1978;5(5):274–92. [PubMed: 101451]
437. Cerra FB, Cheung NK, Fischer JE, Kaplowitz N, Schiff ER, Dienstag JL, et al. Disease-specific amino acid infusion (F080) in hepatic encephalopathy: a prospective, randomized, double-blind, controlled trial. *JPEN J Parenter Enteral Nutr* 1985;9(3):288–95. [PubMed: 3892073]

438. Fiaccadori F Branched-chain enriched amino acid solutions in the treatment of hepatic encephalopathy: a controlled trial. *Ital J Gastroenterol* 1985;17:5–10.
439. Michel H, Borjes P, Aubin JP, Pomier-Layrargues G, Bauret P, Bellet-Herman H. Treatment of acute hepatic encephalopathy in cirrhotics with a branched-chain amino acids enriched versus a conventional amino acids mixture. A controlled study of 70 patients. *Liver* 1985;5(5):282–9. [PubMed: 4079669]
440. Rossi-Fanelli F, Riggio O, Cangiano C, Cascino A, De Conciliis D, Merli M, et al. Branched-chain amino acids vs lactulose in the treatment of hepatic coma: a controlled study. *Dig Dis Sci* 1982;27(10):929–35. [PubMed: 6749458]
441. Strauss E Treatment of hepatic encephalopathy: a randomized clinical trial comparing branched chain enriched amino acid solution to oral neomycin. *Nutr Supp Serv* 1986;6:18–21.
442. Vilstrup H, Gluud C, Hardt F, Kristensen M, Kohler O, Melgaard B, et al. Branched chain enriched amino acid versus glucose treatment of hepatic encephalopathy. A double-blind study of 65 patients with cirrhosis. *J Hepatol* 1990;10(3):291–6. [PubMed: 2195106]
443. Wahren J, Denis J, Desurmont P, Eriksson LS, Escoffier JM, Gauthier AP, et al. Is intravenous administration of branched chain amino acids effective in the treatment of hepatic encephalopathy? A multicenter study. *Hepatology* 1983;3(4):475–80. [PubMed: 6345330]
444. aylor CD, O'Rourke K, Detsky AS, Baker JP. Parenteral nutrition with branched-chain amino acids in hepatic encephalopathy. A meta-analysis. *Gastroenterology* 1989;97(4):1033–42. [PubMed: 2506095]
445. Olde Damink SW, Jalan R, Deutz NE, Hayes PC, Soeters PB. Protein synthesis is severely diminished following a simulated upper GI bleed in patients with cirrhosis. *J Hepatol* 2008;49(5):726–31. [PubMed: 18602715]
446. Olde Damink SW, Jalan R, Deutz NE, Dejong CH, Redhead DN, Hynd P, et al. Isoleucine infusion during “simulated” upper gastrointestinal bleeding improves liver and muscle protein synthesis in cirrhotic patients. *Hepatology* 2007;45(3):560–8. [PubMed: 17326149]
447. Garrison RN, Cryer HM, Howard DA, Polk HC Jr. Clarification of risk factors for abdominal operations in patients with hepatic cirrhosis. *Ann Surg* 1984;199(6):648–55. [PubMed: 6732310]
448. Merli M, Nicolini G, Angeloni S, Riggio O. Malnutrition is a risk factor in cirrhotic patients undergoing surgery. *Nutrition* 2002;18(11–12):978–86. [PubMed: 12431721]
449. Bilbao I, Armadans L, Lazaro JL, Hidalgo E, Castells L, Margarit C. Predictive factors for early mortality following liver transplantation. *Clin Transplant* 2003;17(5):401–11. [PubMed: 14703921]
450. Shaw BW Jr., Wood RP, Gordon RD, Iwatsuki S, Gillquist WP, Starzl TE. Influence of selected patient variables and operative blood loss on six-month survival following liver transplantation. *Semin Liver Dis* 1985;5(4):385–93. [PubMed: 3909433]
451. Shepherd RW, Chin SE, Cleghorn GJ, Patrick M, Ong TH, Lynch SV, et al. Malnutrition in children with chronic liver disease accepted for liver transplantation: clinical profile and effect on outcome. *J Paediatr Child Health* 1991;27(5):295–9. [PubMed: 1931221]
452. Ferreira LG, Martins AIF, Cunha CE, Anastácio LR, Lima AS, Correia MITD. Negative energy balance secondary to inadequate dietary intake of patients on the waiting list for liver transplantation. *Nutrition* 2013;29(10):1252–8. [PubMed: 24012087]
453. Ney M, Abraldes JG, Ma M, Belland D, Harvey A, Robbins S, et al. Insufficient protein intake is associated with increased mortality in 630 patients with cirrhosis awaiting liver transplantation. *Nutr Clin Pract* 2015;30(4):530–6. [PubMed: 25667232]
454. Plank LD, McCall JL, Gane EJ, Rafique M, Gillanders LK, McIlroy K, et al. Pre-and postoperative immunonutrition in patients undergoing liver transplantation: a pilot study of safety and efficacy. *Clin Nutr* 2005;24(2):288–96. [PubMed: 15784491]
455. Coolsen MM, Wong-Lun-Hing EM, van Dam RM, van der Wilt AA, Slim K, Lassen K, et al. A systematic review of outcomes in patients undergoing liver surgery in an enhanced recovery after surgery pathways. *HPB (Oxford)* 2013;15(4):245–51. [PubMed: 23458424]
456. Hughes MJ, McNally S, Wigmore SJ. Enhanced recovery following liver surgery: a systematic review and meta-analysis. *HPB (Oxford)* 2014;16(8):699–706. [PubMed: 24661306]

457. Keeffe EBGC, Esquivel CO. Liver transplantation in patients with severe obesity. *Transplantation* 1994;57:309–11. [PubMed: 8310529]
458. Sawyer RG, Pelletier SJ, Pruett TL. Increased early morbidity and mortality with acceptable long-term function in severely obese patients undergoing liver transplantation. *Clin Transplant* 1999;13(1pt2):126–30. [PubMed: 10081649]
459. Leonard J, Heimbach J, Malinchoc M, Watt K, Charlton M. The impact of obesity on long-term outcomes in liver transplant recipients—results of the NIDDK liver transplant database. *Am J Transplant* 2008;8(3):667–72. [PubMed: 18294163]
460. Gr t M, Wronka KM, Lewandowski Z, Gr t K, Krasnod bski M, Stypułkowski J, et al. Effects of continuous use of probiotics before liver transplantation: A randomized, double-blind, placebo-controlled trial. *Clin Nutr* 2017;36(6):1530–9. [PubMed: 28506447]
461. Kaido T, Mori A, Ogura Y, Ogawa K, Hata K, Yoshizawa A, et al. Pre- and perioperative factors affecting infection after living donor liver transplantation. *Nutrition* 2012;28(11–12):1104–8. [PubMed: 23044161]
462. Kaido T, Mori A, Oike F, Mizumoto M, Ogura Y, Hata K, et al. Impact of pretransplant nutritional status in patients undergoing liver transplantation. *Hepatogastroenterology* 2010;57(104):1489–92. [PubMed: 21443108]
463. Shirabe K, Yoshimatsu M, Motomura T, Takeishi K, Toshima T, Muto J, et al. Beneficial effects of supplementation with branched-chain amino acids on postoperative bacteremia in living donor liver transplant recipients. *Liver Transpl* 2011;17(9):1073–80. [PubMed: 21542128]
464. Chin SE, Shepherd RW, Thomas BJ, Cleghorn GJ, Patrick MK, Wilcox JA, et al. Nutritional support in children with end-stage liver disease: a randomized crossover trial of a branched-chain amino acid supplement. *Am J Clin Nutr* 1992;56(1):158–63. [PubMed: 1609753]
465. Reilly J, Mehta R, Teperman L, Cemaj S, Tzakis A, Yanaga K, et al. Nutritional support after liver transplantation: a randomized prospective study. *JPEN J Parenter Enteral Nutr* 1990;14(4):386–91. [PubMed: 2119446]
466. Hasse JM, Blue LS, Liepa GU, Goldstein RM, Jennings LW, Mor E, et al. Early enteral nutrition support in patients undergoing liver transplantation. *JPEN J Parenter Enteral Nutr* 1995;19(6):437–43. [PubMed: 8748357]
467. Wicks C, Somasundaram S, Bjarnason I, Menzies IS, Routley D, Potter D, et al. Comparison of enteral feeding and total parenteral nutrition after liver transplantation. *Lancet* 1994;344(8926):837–40. [PubMed: 7916398]
468. Fan ST, Lo CM, Lai EC, Chu KM, Liu CL, Wong J. Perioperative nutritional support in patients undergoing hepatectomy for hepatocellular carcinoma. *N Engl J Med* 1994;331(23):1547–52. [PubMed: 7969324]
469. Hu QG, Zheng QC. The influence of Enteral Nutrition in postoperative patients with poor liver function. *World J Gastroenterol* 2003;9(4):843–6. [PubMed: 12679945]
470. Eguchi S, Takatsuki M, Hidaka M, Soyama A, Ichikawa T, Kanematsu T. Perioperative synbiotic treatment to prevent infectious complications in patients after elective living donor liver transplantation: a prospective randomized study. *Am J Surg* 2011;201(4):498–502. [PubMed: 20619394]
471. Rayes N, Seehofer D, Hansen S, Boucsein K, Muller AR, Serke S, et al. Early enteral supply of lactobacillus and fiber versus selective bowel decontamination: a controlled trial in liver transplant recipients. *Transplantation* 2002;74(1):123–7. [PubMed: 12134110]
472. Rayes N, Seehofer D, Theruvath T, Schiller RA, Langrehr JM, Jonas S, et al. Supply of pre- and probiotics reduces bacterial infection rates after liver transplantation--a randomized, double-blind trial. *Am J Transplant* 2005;5(1):125–30. [PubMed: 15636620]
473. Zhang Y, Chen J, Wu J, Chalson H, Merigan L, Mitchell A. Probiotic use in preventing postoperative infection in liver transplant patients. *Hepatobiliary surgery and nutrition* 2013;2(3):142. [PubMed: 24570932]
474. Ikegami T, Shirabe K, Yoshiya S, Yoshizumi T, Ninomiya M, Uchiyama H, et al. Bacterial sepsis after living donor liver transplantation: the impact of early enteral nutrition. *J Am Coll Surg* 2012;214(3):288–95. [PubMed: 22244203]

475. Kim JM, Joh JW, Kim HJ, Kim SH, Rha M, Sinn DH, et al. Early Enteral Feeding After Living Donor Liver Transplantation Prevents Infectious Complications: A Prospective Pilot Study. *Medicine (Baltimore)* 2015;94(44):e1771. [PubMed: 26554774]
476. Mehta PL, Alaka KJ, Filo RS, Leapman SB, Milgrom ML, Pescovitz MD. Nutrition support following liver transplantation: comparison of jejunal versus parenteral routes. *Clin Transplant* 1995;9(5):364–9. [PubMed: 8541628]
477. Pescovitz MD, Mehta PL, Leapman SB, Milgrom ML, Jindal RM, Filo RS. Tube jejunostomy in liver transplant recipients. *Surgery* 1995;117(6):642–7. [PubMed: 7778028]
478. Bianchi G, Marchesini G, Marzocchi R, Pinna AD, Zoli M. Metabolic syndrome in liver transplantation: relation to etiology and immunosuppression. *Liver Transpl* 2008;14(11):1648–54. [PubMed: 18975273]
479. Richards J, Gunson B, Johnson J, Neuberger J. Weight gain and obesity after liver transplantation. *Transpl Int* 2005;18(4):461–6. [PubMed: 15773968]
480. Sawas T, Al Halabi S, Hernaez R, Carey WD, Cho WK. Patients Receiving Prebiotics and Probiotics Before Liver Transplantation Develop Fewer Infections Than Controls: A Systematic Review and Meta-Analysis. *Clin Gastroenterol Hepatol* 2015;13(9):1567–74.e3; quiz e143–4. [PubMed: 26044318]
481. Singer P, Cohen J, Cynober L. Effect of nutritional state of brain-dead organ donor on transplantation. *Nutrition* 2001;17(11–12):948–52. [PubMed: 11744347]
482. McLean AE. Hepatic failure in malnutrition. *Lancet* 1962;2(7269):1292–4. [PubMed: 13932155]
483. Waterlow JC. Amount and rate of disappearance of liver fat in malnourished infants in Jamaica. *Am J Clin Nutr* 1975;28(11):1330–6. [PubMed: 1190111]
484. Webber BL, Freiman I. The liver in kwashiorkor. A clinical and electron microscopical study. *Arch Pathol* 1974;98(6):400–8. [PubMed: 4138580]
485. Badaloo A, Reid M, Soares D, Forrester T, Jahoor F. Relation between liver fat content and the rate of VLDL apolipoprotein B-100 synthesis in children with protein-energy malnutrition. *Am J Clin Nutr* 2005;81(5):1126–32. [PubMed: 15883438]
486. Manary MJ, Broadhead RL, Yarasheski KE. Whole-body protein kinetics in marasmus and kwashiorkor during acute infection. *Am J Clin Nutr* 1998;67(6):1205–9. [PubMed: 9625094]
487. Pantuck EJ, Pantuck CB, Weissman C, Gil KM, Askanazi J. Stimulation of oxidative drug metabolism by parenteral refeeding of nutritionally depleted patients. *Gastroenterology* 1985;89(2):241–5. [PubMed: 3924720]
488. Tranvouez JL, Lerebours E, Chretien P, Fouin-Fortunet H, Colin R. Hepatic antipyrine metabolism in malnourished patients: influence of the type of malnutrition and course after nutritional rehabilitation. *Am J Clin Nutr* 1985;41(6):1257–64. [PubMed: 3923817]
489. Manary MJ, Yarasheski KE, Berger R, Abrams ET, Hart CA, Broadhead RL. Whole-body leucine kinetics and the acute phase response during acute infection in marasmic Malawian children. *Pediatr Res* 2004;55(6):940–6. [PubMed: 15155863]
490. Reid M, Badaloo A, Forrester T, Morlese JF, Heird WC, Jahoor F. The acute-phase protein response to infection in edematous and nonedematous protein-energy malnutrition. *Am J Clin Nutr* 2002;76(6):1409–15. [PubMed: 12450910]
491. Bonkovsky HL, Healey JF, Lourie AN, Gerron GG. Intravenous heme-albumin in acute intermittent porphyria: evidence for repletion of hepatic hemoproteins and regulatory heme pools. *Am J Gastroenterol* 1991;86(8):1050–6. [PubMed: 1713408]
492. Pironi L, Arends J, Bozzetti F, Cuerda C, Gillanders L, Jeppesen PB, et al. ESPEN guidelines on chronic intestinal failure in adults. *Clin Nutr* 2016;35(2):247–307. [PubMed: 26944585]
493. Wales PW, Allen N, Worthington P, George D, Compher C, Teitelbaum D. A.S.P.E.N. clinical guidelines: support of pediatric patients with intestinal failure at risk of parenteral nutrition-associated liver disease. *JPEN J Parenter Enteral Nutr* 2014;38(5):538–57. [PubMed: 24696095]
494. Stanko RT, Nathan G, Mendelow H, Adibi SA. Development of hepatic cholestasis and fibrosis in patients with massive loss of intestine supported by prolonged parenteral nutrition. *Gastroenterology* 1987;92(1):197–202. [PubMed: 3096806]
495. Kelly DA. Intestinal failure-associated liver disease: what do we know today? *Gastroenterology* 2006;130(2 Suppl 1):S70–7. [PubMed: 16473076]

496. Naini BV, Lassman CR. Total parenteral nutrition therapy and liver injury: a histopathologic study with clinical correlation. *Hum Pathol* 2012;43(6):826–33. [PubMed: 22075110]
497. Koletzko B, Goulet O. Fish oil containing intravenous lipid emulsions in parenteral nutrition-associated cholestatic liver disease. *Curr Opin Clin Nutr Metab Care* 2010;13(3):321–6. [PubMed: 20393276]
498. Buchman AL, Iyer K, Fryer J. Parenteral nutrition-associated liver disease and the role for isolated intestine and intestine/liver transplantation. *Hepatology* 2006;43(1):9–19. [PubMed: 16374841]
499. Staun M, Pironi L, Bozzetti F, Baxter J, Forbes A, Joly F, et al. ESPEN Guidelines on Parenteral Nutrition: home parenteral nutrition (HPN) in adult patients. *Clin Nutr* 2009;28(4):467–79. [PubMed: 19464089]
500. Pironi L, Joly F, Forbes A, Colomb V, Lyszkowska M, Baxter J, et al. Long-term follow-up of patients on home parenteral nutrition in Europe: implications for intestinal transplantation. *Gut* 2011;60(1):17–25. [PubMed: 21068130]
501. Goulet O, Joly F, Corriol O, Colomb-Jung V. Some new insights in intestinal failure-associated liver disease. *Current opinion in organ transplantation* 2009;14(3):256–61. [PubMed: 19444108]
502. Bowyer BA, Fleming CR, Ludwig J, Petz J, McGill DB. Does long-term home parenteral nutrition in adult patients cause chronic liver disease? *JPEN J Parenter Enteral Nutr* 1985;9(1):11–7. [PubMed: 3918194]
503. Grau T, Bonet A, Rubio M, Mateo D, Farre M, Acosta JA, et al. Liver dysfunction associated with artificial nutrition in critically ill patients. *Crit Care* 2007;11(1):R10. [PubMed: 17254321]
504. Salvino R, Ghanta R, Seidner DL, Mascha E, Xu Y, Steiger E. Liver failure is uncommon in adults receiving long-term parenteral nutrition. *JPEN J Parenter Enteral Nutr* 2006;30(3):202–8. [PubMed: 16639066]
505. Buchman AL, Ament ME, Sohel M, Dubin M, Jenden DJ, Roch M, et al. Choline deficiency causes reversible hepatic abnormalities in patients receiving parenteral nutrition: proof of a human choline requirement: a placebo-controlled trial. *JPEN J Parenter Enteral Nutr* 2001;25(5):260–8. [PubMed: 11531217]
506. Cober MP, Teitelbaum DH. Prevention of parenteral nutrition-associated liver disease: lipid minimization. *Current opinion in organ transplantation* 2010;15(3):330–3. [PubMed: 20386446]
507. Colomb V, Jobert-Giraud A, Lacaille F, Goulet O, Fournet JC, Ricour C. Role of lipid emulsions in cholestasis associated with long-term parenteral nutrition in children. *JPEN J Parenter Enteral Nutr* 2000;24(6):345–50. [PubMed: 11071594]
508. Cowles RA, Ventura KA, Martinez M, Lobritto SJ, Harren PA, Brodnie S, et al. Reversal of intestinal failure-associated liver disease in infants and children on parenteral nutrition: experience with 93 patients at a referral center for intestinal rehabilitation. *J Pediatr Surg* 2010;45(1):84–7; discussion 7–8. [PubMed: 20105585]
509. Jakobsen MS, Jorgensen MH, Husby S, Andersen L, Jeppesen PB. Low-fat, high-carbohydrate parenteral nutrition (PN) may potentially reverse liver disease in long-term PN-dependent infants. *Dig Dis Sci* 2015;60(1):252–9. [PubMed: 25107446]
510. Sant'Anna AM, Altamimi E, Clause RF, Saab J, Mileski H, Cameron B, et al. Implementation of a multidisciplinary team approach and fish oil emulsion administration in the management of infants with short bowel syndrome and parenteral nutrition-associated liver disease. *Can J Gastroenterol* 2012;26(5):277–80. [PubMed: 22590701]
511. Jensen AR, Goldin AB, Koopmeiners JS, Stevens J, Waldhausen JH, Kim SS. The association of cyclic parenteral nutrition and decreased incidence of cholestatic liver disease in patients with gastroschisis. *J Pediatr Surg* 2009;44(1):183–9. [PubMed: 19159741]
512. Tillman EM, Norman JL, Huang EY, Lazar LF, Crill CM. Evaluation of parenteral nutrition-associated liver disease in infants with necrotizing enterocolitis before and after the implementation of feeding guidelines. *Nutr Clin Pract* 2014;29(2):234–7. [PubMed: 24569791]
513. Diamond IR, de Silva NT, Tomlinson GA, Pencharz PB, Feldman BM, Moore AM, et al. The role of parenteral lipids in the development of advanced intestinal failure-associated liver disease in infants: a multiple-variable analysis. *JPEN J Parenter Enteral Nutr* 2011;35(5):596–602. [PubMed: 21825088]

514. Rollins MD, Ward RM, Jackson WD, Mulroy CW, Spencer CP, Ying J, et al. Effect of decreased parenteral soybean lipid emulsion on hepatic function in infants at risk for parenteral nutrition-associated liver disease: a pilot study. *J Pediatr Surg* 2013;48(6):1348–56. [PubMed: 23845629]
515. Sanchez SE, Arnold MA. Lipid management in pediatric intestinal failure. *Current opinion in organ transplantation* 2016;21(2):153–8. [PubMed: 26741112]
516. Cheung HM, Lam HS, Tam YH, Lee KH, Ng PC. Rescue treatment of infants with intestinal failure and parenteral nutrition-associated cholestasis (PNAC) using a parenteral fish-oil-based lipid. *Clin Nutr* 2009;28(2):209–12. [PubMed: 19261360]
517. Gura KM, Lee S, Valim C, Zhou J, Kim S, Modi BP, et al. Safety and efficacy of a fish-oil-based fat emulsion in the treatment of parenteral nutrition-associated liver disease. *Pediatrics* 2008;121(3):e678–86. [PubMed: 18310188]
518. Le HD, de Meijer VE, Zurakowski D, Meisel JA, Gura KM, Puder M. Parenteral fish oil as monotherapy improves lipid profiles in children with parenteral nutrition-associated liver disease. *JPEN J Parenter Enteral Nutr* 2010;34(5):477–84. [PubMed: 20852175]
519. Le HD, Meisel JA, de Meijer VE, Fallon EM, Gura KM, Nose V, et al. Docosahexaenoic acid and arachidonic acid prevent essential fatty acid deficiency and hepatic steatosis. *JPEN J Parenter Enteral Nutr* 2012;36(4):431–41. [PubMed: 22038210]
520. Lee SI, Valim C, Johnston P, Le HD, Meisel J, Arsenault DA, et al. Impact of fish oil-based lipid emulsion on serum triglyceride, bilirubin, and albumin levels in children with parenteral nutrition-associated liver disease. *Pediatr Res* 2009;66(6):698–703. [PubMed: 19687773]
521. Premkumar MH, Carter BA, Hawthorne KM, King K, Abrams SA. High rates of resolution of cholestasis in parenteral nutrition-associated liver disease with fish oil-based lipid emulsion monotherapy. *J Pediatr* 2013;162(4):793–8.e1. [PubMed: 23164314]
522. Premkumar MH, Carter BA, Hawthorne KM, King K, Abrams SA. Fish oil-based lipid emulsions in the treatment of parenteral nutrition-associated liver disease: an ongoing positive experience. *Adv Nutr* 2014;5(1):65–70. [PubMed: 24425724]
523. Puder M, Valim C, Meisel JA, Le HD, de Meijer VE, Robinson EM, et al. Parenteral fish oil improves outcomes in patients with parenteral nutrition-associated liver injury. *Ann Surg* 2009;250(3):395–402. [PubMed: 19661785]
524. Lacaille F, Gupte G, Colomb V, D'Antiga L, Hartman C, Hojsak I, et al. Intestinal failure-associated liver disease: a position paper of the ESPGHAN Working Group of Intestinal Failure and Intestinal Transplantation. *J Pediatr Gastroenterol Nutr* 2015;60(2):272–83. [PubMed: 25272324]
525. Gokmen T, Oguz SS, Bozdog S, Erdeve O, Uras N, Dilmen U. A controlled trial of erythromycin and UDCA in premature infants during parenteral nutrition in minimizing feeding intolerance and liver function abnormalities. *J Perinatol* 2012;32(2):123–8. [PubMed: 21566568]
526. Hwang TL, Lue MC, Chen LL. Early use of cyclic TPN prevents further deterioration of liver functions for the TPN patients with impaired liver function. *Hepatogastroenterology* 2000;47(35):1347–50. [PubMed: 11100349]
527. Cavicchi M, Beau P, Crenn P, Degott C, Messing B. Prevalence of liver disease and contributing factors in patients receiving home parenteral nutrition for permanent intestinal failure. *Ann Intern Med* 2000;132(7):525–32. [PubMed: 10744588]
528. Calkins K, Lowe A, Shew SB, Dunn JC, Reyen L, Farmer DG, et al. Short-term intravenous fish oil and pediatric intestinal failure associated liver disease: 3-year follow-up on liver function and nutrition. *J Pediatr Surg* 2013;48(1):228–32. [PubMed: 23331820]
529. Calkins KL, Dunn JC, Shew SB, Reyen L, Farmer DG, Devaskar SU, et al. Pediatric intestinal failure-associated liver disease is reversed with 6 months of intravenous fish oil. *JPEN J Parenter Enteral Nutr* 2014;38(6):682–92. [PubMed: 23894176]
530. Nandivada P, Chang MI, Potemkin AK, Carlson SJ, Cowan E, O'Loughlin A A, et al. The natural history of cirrhosis from parenteral nutrition-associated liver disease after resolution of cholestasis with parenteral fish oil therapy. *Ann Surg* 2015;261(1):172–9. [PubMed: 24374535]
531. Nehra D, Fallon EM, Potemkin AK, Voss SD, Mitchell PD, Valim C, et al. A comparison of 2 intravenous lipid emulsions: interim analysis of a randomized controlled trial. *JPEN J Parenter Enteral Nutr* 2014;38(6):693–701. [PubMed: 23770843]

532. Pichler J, Simchowit V, Macdonald S, Hill S. Comparison of liver function with two new/mixed intravenous lipid emulsions in children with intestinal failure. *Eur J Clin Nutr* 2014;68(10):1161–7. [PubMed: 24961544]
533. Angsten G, Finkel Y, Lucas S, Kassa AM, Paulsson M, Lilja HE. Improved outcome in neonatal short bowel syndrome using parenteral fish oil in combination with omega-6/9 lipid emulsions. *JPEN J Parenter Enteral Nutr* 2012;36(5):587–95. [PubMed: 22275330]
534. Goulet O, Antebi H, Wolf C, Talbotec C, Alcindor LG, Corriol O, et al. A new intravenous fat emulsion containing soybean oil, medium-chain triglycerides, olive oil, and fish oil: a single-center, double-blind randomized study on efficacy and safety in pediatric patients receiving home parenteral nutrition. *JPEN J Parenter Enteral Nutr* 2010;34(5):485–95. [PubMed: 20852176]
535. Muhammed R, Bremner R, Protheroe S, Johnson T, Holden C, Murphy MS. Resolution of parenteral nutrition-associated jaundice on changing from a soybean oil emulsion to a complex mixed-lipid emulsion. *J Pediatr Gastroenterol Nutr* 2012;54(6):797–802. [PubMed: 22157927]
536. Rayyan M, Devlieger H, Jochum F, Allegaert K. Short-term use of parenteral nutrition with a lipid emulsion containing a mixture of soybean oil, olive oil, medium-chain triglycerides, and fish oil: a randomized double-blind study in preterm infants. *JPEN J Parenter Enteral Nutr* 2012;36(1 Suppl):81s–94s. [PubMed: 22237883]
537. Skouroliaou M, Konstantinou D, Koutri K, Kakavelaki C, Stathopoulou M, Antoniadis M, et al. A double-blind, randomized clinical trial of the effect of omega-3 fatty acids on the oxidative stress of preterm neonates fed through parenteral nutrition. *Eur J Clin Nutr* 2010;64(9):940–7. [PubMed: 20551967]
538. Tomsits E, Pataki M, Tolgyesi A, Fekete G, Rischak K, Szollar L. Safety and efficacy of a lipid emulsion containing a mixture of soybean oil, medium-chain triglycerides, olive oil, and fish oil: a randomised, double-blind clinical trial in premature infants requiring parenteral nutrition. *J Pediatr Gastroenterol Nutr* 2010;51(4):514–21. [PubMed: 20531018]
539. Nasr A, Diamond IR, de Silva NT, Wales PW. Is the use of parenteral omega-3 lipid emulsions justified in surgical neonates with mild parenteral nutrition-associated liver dysfunction? *J Pediatr Surg* 2010;45(5):980–6. [PubMed: 20438939]
540. Burns DL, Gill BM. Reversal of parenteral nutrition-associated liver disease with a fish oil-based lipid emulsion (Omegaven) in an adult dependent on home parenteral nutrition. *JPEN J Parenter Enteral Nutr* 2013;37(2):274–80. [PubMed: 22683685]
541. Venecourt-Jackson E, Hill SJ, Walmsley RS. Successful treatment of parenteral nutrition-associated liver disease in an adult by use of a fish oil-based lipid source. *Nutrition* 2013;29(1):356–8. [PubMed: 23141119]
542. Xu Z, Li Y, Wang J, Wu B, Li J. Effect of omega-3 polyunsaturated fatty acids to reverse biopsy-proven parenteral nutrition-associated liver disease in adults. *Clin Nutr* 2012;31(2):217–23. [PubMed: 22035955]
543. Pironi L, Colecchia A, Guidetti M, Belluzzi A, D’Errico A. Fish oil-based emulsion for the treatment of parenteral nutrition associated liver disease in an adult patient. *European e-Journal of Clinical Nutrition and Metabolism* 2010;5(5):e243–e6.

Table 1:

Definition of levels of evidence

1++	High quality meta-analyses, systematic reviews of RCTs, or RCTs with a very low risk of bias
1+	Well-conducted meta-analyses, systematic reviews, or RCTs with a low risk of bias
1–	Meta-analyses, systematic reviews, or RCTs with a high risk of bias
2++	High quality systematic reviews of case control or cohort or studies. High quality case control or cohort studies with a very low risk of confounding or bias and a high probability that the relationship is causal
2+	Well-conducted case control or cohort studies with a low risk of confounding or bias and a moderate probability that the relationship is causal
2–	Case control or cohort studies with a high risk of confounding or bias and a significant risk that the relationship is not causal
3	Non-analytic studies, e.g. case reports, case series
4	Expert opinion

According to the Scottish Intercollegiate Guidelines Network (SIGN) grading system. Source: SIGN 50: A guideline developer's handbook. Quick reference guide October 2014 (8)

Table 2:

Definition of grades of recommendation (6)

A	At least one meta-analysis, systematic review, or RCT rated as 1++, and directly applicable to the target population; or A body of evidence consisting principally of studies rated as 1+, directly applicable to the target population, and demonstrating overall consistency of results
B	A body of evidence including studies rated as 2++, directly applicable to the target population; or A body of evidence including studies rated as 2+, directly applicable to the target population and demonstrating overall consistency of results; or and demonstrating overall consistency of results; or Extrapolated evidence from studies rated as 1++ or 1+
0	Evidence level 3 or 4; or Extrapolated evidence from studies rated as 2++ or 2+
GPP	Good practice points/expert consensus: Recommended best practice based on the clinical experience of the guideline development group

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

Table 3:

Outcome models used in clinical studies

Endpoints with implications for evaluating trials in clinical nutrition	Examples
Biomedical endpoint (BM)	e.g. improvement of body weight, body composition, morbidity, mortality
Patient-centered/-reported endpoint (PC)	e.g. validated quality-of-life score
Health economic endpoint (HE)	e.g. QALYs or budget savings
Decision-making endpoint (DM)	e.g. clinical parameters or biomarkers that allow to make a clinically relevant decision such as transfer from ICU to a normal ward or nutritional support yes/no
Integration of classical and patient-reported endpoint (IE)	The combination of BM and PC, e.g. complex scores such as the Frailty Index

Adapted from Koller et al. (9)

Table 4:

Classification of the strength of consensus

Strong consensus	Agreement of > 90% of the participants
Consensus	Agreement of > 75 – 90% of the participants
Majority agreement	Agreement of > 50 – 75% of the participants
No consensus	Agreement of < 50% of the participants

According to the AWMF methodology (10)

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

Table 5:

Criteria for systematic search for literature – databases, filters and keywords

Publication date	From 01-08-2011 – 22-11-2016
Language	English
Databases	Pubmed
Filters	Human
Publication type	controlled trial, systematic review
Keywords	(liver disease) AND nutrition

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript